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ABSTRACT
The E2F family of transcription factors appear to represent the primary cellular target of the
tumor suppressive properties of the retinoblastoma protein. E2F therefore functions in a pathway
which is a frequent target in human cancer, and the tumorigenicity of these mutations may be
mediated at the transcriptional level by E2F. E2F is also regulated by cell cycle-dependent
interactions with the pRB-related proteins p107 and p130. Unlike pRB, mutations in p107 or p130
are not associated with cancer. The different properties of the pRB family may result from the
manner in which each protein regulates E2F. To determine how individual E2Fs contribute to the
cell cycle regulatory properties of pRB, p107 and p1 30, we have examined the regulation of
individual members of the E2F family. Our data suggest that the induction of E2F responsive
genes is primarily due to the loss of nuclear repressor complexes at G1/S. This loss correlates
with the disappearance of nuclear forms of E2F-4 protein, which represents the majority of pRB-
bound nuclear E2F during G1. These data suggests that E2F-4, the most abundant E2F in vivo,
acts primarily as the DNA-binding component of a G1 transcriptional repressor complex. In
contrast, we find that E2F-1, -2 and -3 are present at low levels in vivo and localize to the nucleus
by virtue of a nuclear localization signal sequence in the N-terminal domain of these proteins.
Their constitutive nuclear localization suggests that these E2F family members will contribute to
the activation of responsive gene transcription during S-phase. Together, these data suggest that
induction of E2F-responsive genes at G1/S is triggered both by the loss of an abundant
transcriptional repressor, E2F-4*pRB, and by the presence of nuclear forms of E2F capable of
transcriptional activation. These functional differences among E2Fs may underlie the oncogenic
consequences specifically associated with pRB loss. Inactivation of pRB is predicted to both
abrogate repression of E2F-responsive genes, and relieve inhibition of nuclear, activatory E2Fs.
The combined effect of these forms of transcriptional deregulation of the E2F pathway may be
sufficient to promote transformation in vivo.
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CHAPTER 1
INTRODUCTION
A. The cell division cycle: an overview
Replication of genetic material in one cell and its proper segregation into each of two
daughter cells is the central function of the cell division cycle. Proper control of this cycle is of
fundamental importance to the viability of all organisms. It ensures the fidelity of DNA
duplication and is required for proper regulation of cell multiplication in both single-cell
populations and in complex multicellular organisms. Deregulation of cell division can lead to
lethality or, in the case of multicellular eukaryotes, loss of developmental control of growth and
differentiation. Consequently, cell division is a tightly controlled process subject to many forms of
regulation which ensure that daughter cells receive exact copies of the genome, and that the cell
division process only initiates under appropriate conditions.
The eukaryotic cell division cycle is divided into four discrete stages, termed Gap 1 (G 1),
DNA Synthesis (S), Gap2 (G2) and Mitosis (M), which follow in that order (reviewed in
Nasmyth, 1996). Each stage is marked by a distinct set of cellular processes and structures. Early
G 1 cells are comparatively small and have a low ratio of cytoplasmic-to-nuclear volume as a result
of partitioning during the previous mitosis. As cells progress through G , active synthesis of
cellular components necessary for completion of the next cycle results in expansion in cell size.
Eventually, the process of DNA replication is triggered and the cell enters S-phase, during which
the enzymatic process of DNA replication produces a copy of the entire genome. During the
following G2 phase, the cell prepares for mitosis by synthesizing components of the mitotic
apparatus. Chromosome condensation, formation of a mitotic spindle and pairing of homologs
along the metaphase plate mark entry into Mitosis (M), during which separation of homologs and
cytokinesis produces two daughter cells. This G1-S-G2-M cycle represents the various stages a
proliferating population of cells moves through. However, most cells in a developed organism are
actually in a state which corresponds to a cessation of division and entry into a quiescent state
called "GO". Cells in G1 which have either failed to receive the required growth factor stimulation
or have been signaled to cease division enter this GO state from G , and so GO is considered to be
an adjunct stage of G1. In some cell types, GO represents a state of transient arrest, exit from
which is dependent upon proper stimulation - in the case of resting B and T cells of the peripheral
immune system, GO exit is dependent upon antigen binding and cytokine signaling that normally
occur in the context of an immune response (Nourse et al., 1994). In other cell types, entry into
GO is thought to represent a irreversible withdrawal from the cell cycle necessary for terminal
differentiation.
Progression through the various stages of the cell cycle is subject to control by signals
from the extracellular environment as well as those emanating from within the cell. Eukaryotic
cells arrest the cell cycle in response to a variety of stimuli, including secreted inhibitors of cell
growth, nutrient starvation, loss of attachment to substratum, high cell density, and absence of
necessary growth factors in the extracellular environment (reviewed in Murray, 1993). Signals
which originate from within the cell are also capable of inducing pathways which result in cell
cycle arrest. DNA damage incurred during the process of replication, or caused by exposure to
genotoxic agents, results in the activation of cell-autonomous "checkpoint" pathways which
transiently arrest progression and allow the cell to mount a proper response (reviewed in Elledge,
1996). Checkpoint pathways monitor multiple components of the cell cycle and can likewise
arrest the cycle when the integrity of these components is compromised. The specific mechanisms
that underlie some checkpoint arrests remain unclear. However, studies of checkpoint
mechanisms in single-celled eukaryotes have begun to reveal a conserved mode of action which is
dependent upon the ability of checkpoint-specific molecules to target and modulate the activities of
more basic components of cell cycle control (eg. Furnari et al., 1997; Hwang et al., 1998; Sanchez
et al., 1997; Sidorova and Breeden, 1997).
Al. Molecular mechanisms of cell cycle control in yeast and frog
Current models of the molecular mechanisms of cell cycle control have their origins in
studies of the genetic requirements for cell cycle progression in the yeasts Sacchromyces cerevisiae
and Schizosacchromyces pombe, and in the biochemical analysis of the regulation of oocyte
maturation in the amphibian Xenopus laevis (reviewed in Nasmyth, 1996). Genes required for cell
cycle progression in budding and fission yeast were identified as temperature-sensitive mutations
that gave a uniform arrest at a particular cell cycle stage(s) when shifted to the restrictive
temperature (Hartwell et al., 1974; Nurse and Thuriaux, 1980). These mutations were designated
as cell-division cycle (CDC) genes due to their apparent roles in regulating the cell division
process.
One such CDC gene was identified as necessary for cell cycle progression in both budding
and fission yeast. This gene, termed cdc28 in S. cerevisiae and CDC2 in S. pombe, encodes a
serine/threonine protein-kinase that appears to play a fundamental role in cell cycle control as an S
and M phase "promoting factor" (Hindley and Phear, 1984; Lorincz and Reed, 1984; Reed et al.,
1985). This kinase represents the catalytic moiety of a multimer, and is only active when
complexed to a class of regulatory proteins called cyclins, so named because their levels oscillate
throughout the cell cycle (Evans et al., 1983). The abundance of these cyclins subunits is subject
to cell cycle-dependent control at both the transcriptional level and at the post-transcriptional level
of proteolytic degradation (Aerne et al., 1998; Cross et al., 1994; Walker et al., 1997; reviewed
King et al., 1996). Once assembled with catalytic cyclin-dependent kinase (CDK) subunits, the
activity of cyclin*cdk complexes is subject to a further level of regulation by both inhibitory and
activating phosphorylations on specific cdk residues mediated by yet other kinases and
phosphatases (reviewed in Elledge, 1996). Concurrent studies of the regulation of entry into
mitosis in Xenopus identified a biochemical activity capable of promoting entry in M-phase in
immature G2-arrested oocytes which was called Maturation Promoting Factor (MPF).
Identification of the components of MPF activity in Xenopus oocytes revealed that it contained a
CDK activity homologous to that identified in yeast CDC screens (Draetta et al., 1989; Dunphy et
al., 1988; Gautier et al., 1988). This concordance between yeast genetics and Xenopus
biochemistry revealed a conserved role for CDKs as regulators of the eukaryotic cell division cycle
and has significantly advanced understandings of how eukaryotic cells regulate progression
through specific stages of the cell cycle.
The cell cycle events catalyzed by cyclinocdk kinases represent irreversible changes in the
state of the cell, when it ceases performing tasks associated with one stage of the cell cycle and
begins to execute functions associated with the next stage. In vivo, different cyclin*cdk complexes
promote specific cell cycle stages. The cell cycle function of the single S. cerevisiae CDK, cdc28,
was first uncovered by temperature-sensitive arrest of a cdc28-ts allele at two points in the yeast
cell cycle: in Gi just prior to S-phase, and at G2/M (Piggott et al., 1982). The role of a single
yeast CDK in the regulation of multiple cell cycle transitions reflects the ability of Cdc28 to
associate successively with different cyclin subunits to promote different cell cycle events.
Activation of Cdc28 by the G1 cyclins (Clnl, Cln2 and Cln3) drives cells through G1 and into S,
while the Clb5 and Clb6 cyclins promote S-phase progression and the G2/M cyclins (Clbs 1, 2, 3,
& 4) drive cells into and through mitosis (reviewed in Nasmyth, 1996). The ability of different
cyclin subunits, in association with the same catalytic Cdc28 molecule, to promote different cell
cycle phases suggests that the functional specificity of the various different cyclin*Cdc28
complexes may largely lie with the cyclin molecule. This appears to be at least partially the case,
as the cyclin subunits have been shown to contribute to the target specificities of intact cyclin*cdk
complexes in vitro and in vivo (Huang et al., 1998; Levine et al., 1996; Peeper et al., 1993).
A2. Mammalian CDKs
Identification of CDK activities in a wide range of organisms has verified the fundamental
role these serine/threonine kinases play as basic elements of cell cycle control. Human homologs
of the yeast cyclins were cloned in part by virtue of their ability to functionally compensate for loss
of G1 cyclin (Cln) function in S. cerevisiae (Lew et al., 1991). This finding pointed towards a
degree of cyclin conservation extending to the level of functional cooperation with Cdc28 in the
promotion of G 1 in yeast, and suggested that human cyclins would likewise function to promote
specific cell cycle transitions. Subsequent work has demonstrated this to be the case. In
mammals, cyclins D and E promote G1 progression and entry into S, cyclin A is required
primarily for passage through S-phase and G2/M, and cyclins B 1 and B2 function during mitosis
(reviewed in Nasmyth, 1996). As in yeast, the periodic accumulation of these cyclins triggers the
activation of their catalytic cdk partners, which are a multigene family in higher eukaryotes
(Meyerson et al., 1992). The specificity of the cyclin-cdk interaction results in the formation of
active cyclin D*cdk4 (or cdk6) during G1, active cyclin E*cdk2 during late G1 and G1/S, active
cyclin A*cdk2 during S, and active cyclin A/Bocdkl(cdc2) during G2/M.
In higher eukaryotes, the activity of G1 cyclin*cdks is subject to a further level of control
by members of the CIP/KIP (cdc2/kinase inhibitory proteins) and INK4 (inhibitor of cdk4) gene
families . The protein products of these families, called cyclin-dependent kinase inhibitors (CKIs),
bind directly to cyclin*cdks and inhibit their enzymatic activity. The CIP/KIP family is comprised
of three separate CKI proteins called p21, p27 and p57 (reviewed in Hengst and Reed, 1998).
Each of these CKIs is capable of stable binding to and inhibition of G 1-phase cyclin*cdk
complexes, and overexpression of members of the CIP/KIP family produces a G1 arrest which
correlates with a decrease in the activity of G1 cyclin*cdks (Harper et al., 1995; Lee et al., 1995;
Matsuoka et al., 1995; Toyoshima and Hunter, 1994; Xiong et al., 1993). The upregulation of
CIP/KIP proteins in many differentiating tissues suggests that the primary role of these proteins
will be in cell cycle withdrawal at the onset of differentiation (reviewed in Zavitz and Zipursky,
1997). Genetic analysis of the function of the single Drosophila CIP/KIP, dacapo , reveals that it
is required for cell cycle exit during embryogenesis (de Nooij et al., 1996; Lane et al., 1996).
Similarly, targeted inactivation of p27 and p57 in the mouse results in proliferation defects in a
variety of developing tissues which appear to correlate with impaired ability to arrest at the onset of
differentiation (Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996; Yan et al., 1997;
Zhang et al., 1997). However, the role of each CIP/KIP in developmental control of proliferation
is likely to be tissue specific. The expression patterns of p21, p27, and p57 are different and in
some cases non-overlapping, (Lee et al., 1995; Nakayama et al., 1996; Parker et al., 1995; Yan et
al., 1997) and the consequences of homozygous deficiency for each of the CIP/KIPs in the mouse
are distinct. Thus, the role of the p21, p27 and p57 CKIs in cell cycle control is likely to vary
between different tissues and cell types.
Like the CIP/KIPs, the INK4 gene family consists of multiple CKIs and includes p15, p16,
p18 and p19 (reviewed in Carnero and Hannon, 1998). Each of these proteins is capable of
producing cell cycle arrest in Gl when overproduced, by virtue of their ability to bind cdk4 and
prevent the formation of active kinase (Chan et al., 1995; Guan et al., 1994; Guan et al., 1996;
Hirai et al., 1995; Koh et al., 1995). Evidence to date suggests that the INK4 proteins may play a
role more in proliferation control in the adult animal, rather than during development. Mice
homozygous for a targeted mutation of the murine p16INK4A develop normally, but show an
increased susceptibility to tumors (Chin et al., 1997; Serrano et al., 1996). In cultured cells,
accumulation of p16 is associated with cessation of cell division and entry into cellular senescence
(Alcorta et al., 1996; Hara et al., 1996; Serrano et al., 1997), suggesting that this INK4 member
may function in "homeostatic" cell cycle control in the adult, as opposed to a developmental role in
proliferation control. The tissue restricted patterns of expression of the different INK4 proteins
(Zindy et al., 1997) suggests that whereas they seem equally capable of cdk4 inhibition, each
member of the family fulfills a distinct role in the control of G1/S progression in the whole animal.
The combined effects of regulation by transcriptional and proteolytic control of cyclin
abundance, cdk phosphorylation state, and levels of enzymatic inhibitors, ensure that full activation
of individual cyclin-dependent kinases is restricted to discrete temporal intervals during the cell
cycle. These multiple mechanisms of regulation also provide numerous points at which
progression through the cell cycle is rendered responsive to signaling pathways which modulate
cdk activity. Whereas the activation of such pathways can be rate-limiting for cell cycle
progression, persistent cdk activation by deregulation of these pathways might then constitute the
loss of an important mechanism which normally limits cell division.
A3. Regulating transitions: the R point in eukaryotes
Many signaling pathways which are capable of regulating the rate of cell division do so by
altering the activity of cyclinocdks (reviewed in Elledge, 1996). By modulating the activity of these
kinases, these pathways are able to control the rate at which cells progress through the cell cycle
transitions which cyclin*cdks control. In higher eukaryotes, the most highly regulated transition is
that between a quiescent, resting cell to one which is actively engaged in the process of DNA
replication and is committed to completion of mitosis. This transition from a GO/G1 state to S-
phase (Gl/S) represents the point at which most extracellular signals converge to regulate
progression through the cell cycle and to control the overall rate of cell division.
Regulation of G 1/S progression occurs at a point termed the restriction point (R), which
was originally defined empirically as a discrete time point in mid-to-late G 1 at which cells commit
to entry into S-phase and completion of the remaining phases of the cell cycle (S, G2 and M)
(reviewed in Planas-Silva and Weinberg, 1997). Cells in the pre-R stages of Gl require the
continued action of mitogenic stimuli to prevent arrest in a GO-like state, while those that have
passed R are committed to completion of the cell division cycle and show a dramatically reduced
requirement for extracellular growth factors. Passage through R is accompanied by the induction
of a G1/S transcriptional program that readies the cell for completion of the division cycle. The
targets of this program include enzymatic activities required for DNA replication and regulatory
components that drive cell cycle progression. Thus, the R point represents a crucial regulatory
interval during which the cell integrates signals from the extracellular environment with the basic
cell cycle machinery to effect alterations in the transcriptional state of the cell.
Proper regulation of G1/S is required for execution of cell fate decisions such as continued
division, transient arrest, senescence and differentiation. Regulated progression through Gl/S
ensures that cell division does not occur in the absence of proper signals and that it remains
developmentally regulated in the context of the whole organism. Widespread deregulation of G1/S
entry during embryonic development often has lethal consequences, while clonal loss of GU/S
control later in development is thought to represent a fundamental step in the origin of
overproliferative disorders such as cancer.
B. Cancer & control of GI/S
The hallmark of cancer is uncontrolled cell proliferation leading to the formation of tumors.
Cellular phenotypes associated with cancer include mitogen-independent cell cycle progression and
a compromised ability to exit the cell cycle (reviewed in Sherr, 1996). In vivo, this inability to
withdrawal from cycle can preempt the execution of differentiative pathways; similarly, impaired
differentiation pathways can leave a cell in a state of incomplete cell cycle withdrawal in which it
remains sensitive to the mitogenic effects of growth factors which then drive inappropriate cell
division. As a result of these sorts of disruptions of normal cellular growth and differentiative
programs, tumors are often composed of rapidly dividing, poorly-differentiated cells.
The proliferative potential of primary cells in culture is normally limited by entry in a
period of growth arrest called "crisis". Entry into crisis occurs after a defined number of cell
divisions called the "Hayflick limit" (Hayflick, 1961; reviewed in Hayflick, 1997), and is marked
by a cessation of cell division in the G 1 phase and the acquisition of cellular phenotypes indicative
of replicative senescence (reviewed in Goldstein, 1990). Cell populations in crisis display elevated
levels of a number of CKI proteins known to act as inhibitors of Gi cyclinocdks (Alcorta et al.,
1996; Hara et al., 1996; Noda et al., 1994; Reznikoff et al., 1996; Tahara et al., 1995; Tsao et al.,
1995). This accumulation is causally linked to entry into senescence, as human fibroblasts
engineered to lack both copies of the p21CIP1 gene, or murine embryo fibroblasts (MEFs)
deficient for the p16INK4A gene, no longer encounter features of replicative senescence in culture
(Serrano et al., 1996; Brown et al., 1997). These findings suggest that entry into replicative
senescence represents a cell cycle regulatory mechanism which is normally enforced in vivo to
limit the growth potential of cells. At very low frequency, cells in culture appear capable of
escaping crisis and growing out into "immortal" clones. The appearance of this heritable,
immortal phenotype correlates with the acquisition of genetic alterations that permit the cell to
escape the controls that would normally enforce a crisis arrest (reviewed in Duncan and Reddel,
1997; Yeager et al., 1998). Further passage of immortal cells generally results in the outgrowth, at
very low frequency, of fully "transformed" cells that have become largely mitogen-independent
and capable of tumor formation when injected into immuno-compromised mice. The transition
from the immortal to the transformed phenotype is associated with the acquisition of further
mutations that activate mitogenic pathways and inactivate growth inhibitory mechanisms,
rendering the cell progressively more refractory to the action of anti-mitogenic factors and
increasingly more growth factor independent (reviewed in Sherr, 1996).
This model of progression in culture from a primary to a fully transformed state is thought
to in many ways recapitulate the genetic and phenotypic changes associated with the progression
from a normal cell to a cancerous one in the context of the whole organism. As cancer is in many
respects a disease of the cell cycle, the genetic alterations which underlie the acquisition of
tumorigenic phenotypes often occur in genes whose products regulate the cell division process.
The central role of cyclinocdk activity in promoting cell division suggests that mutations that
produce persistent cdk activation could lead to a cell-autonomous fate of continued cell division
and contribute to overproliferative phenotypes. The likely importance of R-point control in both
proliferation and differentiation programs in higher eukaryotic systems points to pathways
involving the G cyclinocdks as especially good candidates for harboring the sorts of mutations
that contribute to the process of tumorigenesis.
C. The RB-i gene
The heritable genetic changes associated with cancer have provided an excellent opportunity
to identify genes whose products represent crucial proliferation control elements. The study of the
molecular genetics of these mutations has revealed that they are broadly divisible into two classes:
those that promote cell division in the heterozygous state, and therefore act dominantly to disrupt
normal proliferation control pathways; and those for which homozygous mutation of both alleles
is required to reveal oncogenic phenotypes. The requirement for the homozygous inactivation of
the latter class of genes suggests that they normally act to inhibit tumorigenic processes, and that
only by the complete loss of cellular function are the relevant proliferation control pathways
deregulated sufficiently to promote transformation. It is now established that dominant, gain-of-
function mutations of the former class can also occur in genes which normally function to inhibit
tumorigenesis in vivo. Many of these tumor suppressors, and their counterpart oncogenes, are
known or predicted to contribute to the regulation of the G1/S cell cycle transition (reviewed in
Bartkova et al., 1997). There is considerable evidence to suggest that these cell cycle roles underlie
the link between mutations of these genes and promotion of tumorigenic processes. One of the
best studied tumor suppressors is the product of the human retinoblastoma susceptibility locus
(RB-1). The RB-I tumor suppressor gene was originally cloned by virtue of its absence in
retinoblastoma, a childhood cancer of the retina (Friend et al., 1986; Fung et al., 1987; Lee et al.,
1987). RB-1 encodes a 105kD nuclear phosphoprotein, pRB, which normally functions to restrain
S-phase entry by inhibiting the transcription of genes required for completion of G1 and entry into
S-phase (reviewed in Beijersbergen and Bernards, 1996). This function likely underlies its role in
tumor suppression, as expression of wildtype RB-1, but not tumor derived alleles, in cells that lack
functional pRB protein results in an arrest in the Gi phase of the cell cycle (Bookstein et al., 1990;
Goodrich et al., 1991; Huang et al., 1988).
Following its identification as the tumor suppressor involved in both familial and sporadic
retinoblastoma, it has become evident that RB-1 is mutated in a wide variety of other human
cancers (reviewed in Weinberg, 1992). Inactivation of the growth-suppressive function of pRB is
therefore likely a frequent event during the process of transformation of a broad spectrum of cell
types in vivo. The creation of mouse strains carrying only one wildtype copy of the murine
retinoblastoma gene, Rb, has confirmed this model of pRB tumor suppressor function (Clarke et
al., 1992; Jacks et al., 1992; Lee et al., 1992). Rb+/- mice are predisposed to tumors of the thyroid
and pituitary glands (60% and 100% penetrance respectively) and tumor formation correlates with
loss of the remaining wildtype Rb allele.
The phenotype of Rb+/- mice significantly does not include retinoblastoma, the human
cancer predisposition associated with germline transmission of a mutant RB-1 allele. However,
examination of the retina of Rb-/- embryos reveals inappropriate S-phase entry and increased
apoptosis in cells which are normally in a post-mitotic state (Morgcnbesser et al., 1994). These
observations suggest that loss of pRB may compromise the ability of differentiating cells to exit
the cell cycle, and that this aberrant proliferation can lead to the induction of cell death. A role for
pRB in differentiation control is further suggested by additional phenotypes associated with Rb
deficiency. These animals die in utero around day 14 of gestation, showing extensive apoptosis in
the developing nervous system and impaired hematopoesis in the fetal liver. pRB also seems to be
required for terminal cell cycle exit in certain myogenic lineages, as Rb-I- myoblasts are able to
form syncitial myotubes when cultured in low serum, but unlike wildtype cells, the nuclei in these
myotubes can be induced to undergo DNA replication by readdition of serum (Schneider et al.,
1994). The compromised ability of myogenic cells to fully commit to a differentiated state in the
absence of pRB is further indicated by the finding that homozygosity for a hypomorphic allele of
Rb results in a reduction in skeletal muscle mass in the limbs, which demonstrates a requirement
for complete pRB function in some aspect of myogenic development or maintenance
(Zacksenhaus et al., 1996).
The role of pRB as a key regulator of the mammalian cell cycle whose inactivation
contributes to the acquisition of a fully transformed phenotype is further highlighted by the finding
that pRB is a critical target of the small DNA tumor viruses (reviewed in Dyson and Harlow,
1992). The high-risk forms of adenovirus type 12, SV40, and human papilloma virus (HPV) each
encode oncogenic proteins (E1A, large Tag, E7 respectively) which are capable of collaborating
with other oncogenes in the transformation of cultured cells. In each case, cellular transformation
induced by these viral oncogenes overlaps with their ability to bind cellular pRB protein. These
viral proteins interact with pRB via a conserved "LxCxE" motif (amino acid designations in
single-letter code where "x" is any residue) common to most, but not all, pRB-interacting proteins
(Figge et al., 1988). Binding of these viral gene products to pRB is therefore thought to inactivate
the growth suppressive function of pRB and permit entry into S-phase. This ability to deregulate
G1/S via pRB-binding is crucial to the ability of these oncoproteins to contribute to transformation
in culture and tumorigenesis in vivo.
C1. Regulation of pRB by the cell cycle apparatus
The ability of overexpressed pRB to enforce a G 1 arrest in susceptible cell types suggests
that one function of this protein is to inhibit entry into the cell division cycle. As wildtype cells are
readily capable of Gl/S progression following appropriate stimuli, it is clear that cell cycle entry
can however occur in the context of wildtype pRB. This indicates the existence of cellular
pathways that function to inactivate the growth suppressive properties of pRB, and suggests that
these pathways act in the course of the normal cell cycle to permit transition through G1/S. Such
pathways could operate at transcriptional, and/or post-transcriptional levels to modulate pRB
function. The observation that pRB protein persists at all stages of the cell cycle suggests that such
a mechanism(s) is post-translational in nature, and that it likely involves modification of
preexisting pRB protein, rather than, for instance, its specific degradation in late G 1.
Examination of the state of pRB in synchronized cultures reveals that the protein is
expressed throughout the cell cycle, but that it undergoes a dramatic change in phosphorylation
state at or about the R point. During early and mid-G1 pRB is hypophosphorylated, but it
becomes highly phosphorylated in late G1 and G1/S (Buchkovich et al., 1989; Chen et al., 1989;
DeCaprio et al., 1989; Furukawa et al., 1990; Mihara et al., 1989). The temporal character of these
modifications suggests that they may serve to inactivate of the Gl/S-inhibitory function of pRB,
and that this event represents an important element of R-point control. The finding that the E7 and
Tag viral oncogenes bind specifically to the underphosphorylated forms of pRB also supports the
hypothesis that these species represent the active forms of pRB necessary for growth inhibition
(Imai et al., 1991; Ludlow et al., 1989).
The primary amino acid sequence of pRB contains a number of copies of the predicted
cdc2-family consensus phosphorylation site, minimally defined as S/T-P (Langan et al., 1989).
Phospho-peptide and phospho-amino analysis of 32p-labeled pRB confirms that the protein is
phosphorylated on multiple sites, and that it is highly enriched in phospho-serine and phospho-
threonine residues (DeCaprio et al., 1992; Lees et al., 1991). A direct assessment of the ability of
cdc2 to phosphorylate pRB reveals that cdc2 is able to efficiently and specifically recapitulate in
vitro a number of pRB phosphopeptides which occur in vivo (Lees et al., 1991). This suggests
that pRB represents a physiological substrate of cdc2-associated kinase activity. However, the G 1-
cell cycle timing of pRB modification in vivo (reviewed in Mittnacht, 1998) is not consistent with
a role for cdc2 in the initiation of this process, but supports a model in which cdc2 contributes to
the maintenance of pRB phosphorylation during G2/M (Hu et al., 1992). The cell cycle-regulated
phosphorylation of pRB is more consistent with a model in which the Gl-phase kinases, cdk2 and
cdk4, are responsible for the de novo phosphorylation of pRB during late G1.
A considerable amount of data now support a role for both G cyclinocdks, cyclin
D*cdk4/6 and cyclin E*cdk2, in the cell cycle-dependent phosphorylation of pRB (reviewed in
Mittnacht, 1998). In both cases, this activity underlies the ability of these kinases to overcome
pRB growth suppression (Hatakeyama et al., 1994; Hinds et al., 1992). The precise role of each of
these cell cycle kinases in the functional inactivation of the retinoblastoma protein remains unclear.
However, accumulating data suggests that these kinases are not completely functionally equivalent
(Hatakeyama et al., 1994; Resnitzky and Reed, 1995; Zarkowska and Mittnacht, 1997), and that
they collaborate to functionally inactivate pRB through a mechanism which involves sequential
phosphorylation, first by cyclin D*cdk4/6 in mid-G1, and then by cyclin Eecdk2 in late Gi and
GU/S (Connell-Crowley et al., 1997; Ezhevsky et al., 1997; Kitagawa et al., 1996; Lundberg and
Weinberg, 1998; see Chapter 5). This inactivation of pRB appears to be partially rate-limiting for
progression through G 1, as mouse embryo fibroblasts (MEFs) lacking both copies of the Rb gene
display a reduced dependence on extracellular growth factors for proliferation in culture, and have a
shortened G1 phase compared to wildtype cells (Brugarolas et al., 1998; Herrera et al., 1996).
The elucidation of this functional relationship between the activity of G 1 cdks and the
functional state of pRB has broad reaching implications. First, the many known growth
stimulatory and inhibitory pathways which converge to modulate the activity of G cdks are
predicted to alter the phosphorylation state, and thereby the growth suppression function, of pRB.
Second, the loss of pRB function during the course of tumorigenesis is predicted to deprive any
such growth inhibitory pathways of a potentially necessary downstream effector. Third, it is now
clear that pRB, as a target of cdk pathways, is itself a basic component of the cell cycle control
machinery, and that the tumor suppressive properties of this protein arise in large part as a
consequence of this role.
C2. Cellular regulators of pRB & tumorigenesis
The importance of the retinoblastoma protein as a tumor suppressor suggests that
deregulation of GU/S may also occur via mutation of other genes whose products are required for
proper functioning of the pRB pathway. In fact, work on cellular components of cell division
pathways has uncovered a number of genes that are frequently mutated in human cancers, and
whose primary function appears to be modulation of the tumor suppressive properties of pRB.
C2.1 Cyclin D
Cyclin D-associated kinase activity is predicted to play an important role in the inactivation
of the growth suppressive function of pRB during the G 1-phase of the cell cycle (reviewed in
Sherr, 1995). In mammals, cyclin D activity is the product of three highly related genes Cyclin
D1, D2, and D3. These proteins appear equally capable of directing the cdk4-catalyzed
phosphorylation of pRB (Dowdy et al., 1993; Ewen et al., 1993; Matsushime et al., 1994), and
may be to some degree functionally redundant. The members of the cyclin D family are expressed
in largely overlapping patterns during murine development (Bartkova et al., 1994; Inaba et al.,
1992). This suggests that in most tissues all three D-type cyclins participate in the inactivation of
pRB, and that loss of one would likely be compensated by the others. However, a few tissues
display expression of one particular D-type cyclin to the exclusion of the others. In these cases, it
is predicted that this D-type cyclin plays a required role in the inactivation of pRB and the
promotion of proliferation. This hypothesis is supported by studies of the biological consequences
associated with deficiency for the murine cyclin Dl and D2 genes. Cyclin D 1-deficient animals in
many respects develop normally, but show reduced body size, reduced viability and symptoms of
neurological impairment (Fantl et al., 1995; Sicinski et al., 1995). Dramatic hypoproliferative
defects are apparent in tissues which are normally the sites of highest cyclin Dl expression: the
developing retina, and the mammary epithelium during pregnancy. Similarly, animals deficient for
cyclin D2 display phenotypes consistent with underproliferation of tissues which normally express
high levels of cyclin D2 transcript (Sicinski et al., 1996).
The role of D-type cyclin-kinases in the inactivation of a negative regulator of G1/S with
tumor suppressive properties suggests that components of these biochemical activities could have
oncogenic potential. Indeed, cyclin Dl was originally cloned as PRADI, the product of a
translocation in parathyroid tumors between cyclin Dl coding sequences and the parathyroid
hormone locus (Motokura et al., 1991). It was subsequently found that cyclin Dl is also amplified
in human B-cell neoplasia as a result of a t(11:14) chromosomal translocation which juxtaposes
cyclin Dl with the immunoglobulin heavy chain enhancer Eg (Medeiros et al., 1990; Withers et
al., 1991). Further work has demonstrated that both cyclin Dl and cyclin D2 are overexpressed in
a number of human tumor types (reviewed in Hamel and Hanley-Hyde, 1997). The transforming
potential of cyclin D genes are demonstrated by their ability to cooperate with other oncogenes in
the transformation in cultured cells, and in the production of tumors in animal models (Hinds et
al., 1994; Jiang et al., 1993; Kerkhoff and Ziff, 1995; Lovec et al., 1994).
Among the G1 cyclins, cyclin D protein is unique in its ability to form a stable interaction
with pRB in vivo via an "LxCxE" motif present near the amino terminus of the protein (Dowdy et
al., 1993; Kato et al., 1993). This physical interaction may underlie target specificity of cyclin D-
kinases observed in vitro. Unlike other cyclinocdks, whose enzymatic activity is readily detected in
vitro using a variety of both physiological and non-physiological protein substrates, the activity of
cyclin D*cdk4/6 kinases are most apparent when the retinoblastoma protein is used as substrate
(Matsushime et al., 1992; Matsushime et al., 1994; Meyerson et al., 1994). Together, these data
suggest that the retinoblastoma protein is a specific substrate of cyclin D-kinases, and that such
specificity may arise in part due to a direct interaction between cyclin D and the retinoblastoma
protein. Additional data implies that pRB represents the primary target of the growth promoting
activity of D-type kinases in vivo. Injection of o-cyclin D1 neutralizing antibodies produces a G1
arrest in cells with intact pRB, but has no affect upon cells which lack functional pRB protein
(Lukas et al., 1995), strongly suggesting that cyclin D 1-associated kinase activity is dispensable in
cells in which pRB is already functionally inactivated. Thus, evidence supports a model in which
phosphorylation of the retinoblastoma protein is the only function of the cyclin Dl proto-oncogene
which is absolutely required for cell cycle progression, and that pRB is the critical cell cycle target
through which oncogenic forms of cyclin Dl mediate their tumorigenic effect.
Accumulating data suggest that cyclin D-kinase activity represents the component of the
pRB pathway which is directly inducible by growth factor signaling in pre-R cells. D-type cyclin
transcript levels are induced rapidly upon restimulation of GO/G 1 cells with serum or with specific
growth factors (Surmacz et al., 1992; Winston and Pledger, 1993; Won et al., 1992). This
transcriptional induction seems to represent a required element of cell cycle reentry, as cyclin D-
associated kinase activity is required by multiple receptor-mediated mitogenic signal transduction
pathways for induction of S-phase (Lukas et al., 1996). The molecular basis of this dependence is
likely to involve the Ras/Raf signaling pathway, which activates G1 kinases via induction of cyclin
Dl transcription and degradation of p27KIP1 (Agrawal et al., 1996; Aktas et al., 1997; Filmus et
al., 1994; Liu et al., 1995; Takuwa et al., 1997; Weber et al., 1997). In fact, recent work has
demonstrated a direct link between p21 ras-dependent mitogenic signaling and the pRB cell cycle
control pathway (Mittnacht et al., 1997; Peeper et al., 1997; Serrano et al., 1995; Stacey et al.,
1994). Anti-pan-Ras antibodies block Ras signaling and produce a G arrest in wildtype MEFs.
However, blocking Ras function in Rb-/- MEFs does not result in a discernible cell cycle
phenotype. This result implies that the primary function of the Ras pathway in cell cycle control is
to promote GU/S through a pRB-dependent mechanism, and that inactivation of pRB renders this
aspect of Ras function dispensable. Together, these data have established a causal link between
growth factor-receptor activation, cyclin Dl transcription and formation of cyclin D-cdk species
capable of contributing to the phosphorylation-mediated inactivation of pRB.
C2.2 Thepl6INK4A/MTS1 locus
Analysis of the genetic basis of human cancer predisposition has provided another tumor
suppressor that regulates cell cycle progression through the pRB pathway. The pl6INK4A/MTS1
(inhibitor of cdk4/multiple tumor suppressor-1) gene was originally cloned as a cDNA which
encoded a protein capable of interacting with the cdk4 catalytic subunit of the G 1 kinase cyclin
D*cdk4 (Serrano et al., 1993). Soon thereafter, p16 was found to lie within the 9p21 genomic
region commonly deleted in gliomas, lung cancers, leukemias and both sporadic and familial
forms of melanoma (Kamb et al., 1994). The p16 gene has been found mutated in a wide range of
human tumors and transformed cell lines (Nobori et al., 1994; reviewed in Carnero and Hannon,
1998). Modeling the function of p16 in mice confirms the tumor suppressive properties of this
locus: mice homozygous for a targeted deletion of the second exon of the p16 gene are highly
predisposed to fibrosarcomas and lymphomas by -30 weeks of age, and administration of
carcinogenic agents accelerates this process (Serrano et al., 1996). MEFs derived from p16-/-
embryos show growth properties consistent with progression towards the transformed state.
Wild-type diploid MEFs normally enter crisis after about -20 population doublings. However,
p16-/- cells do not enter a growth crisis period during culture and appear to have become
immortalized by loss of p16. The increased susceptibility of immortal p16-/- cells to neoplastic
transformation is demonstrated by the finding that introduction of Ha-rasvall2 alone into p16-/-
MEFs is sufficient to induce anchorage-independence and formation of tumors in
immunocompromised mice (Serrano et al., 1996). These data are consistent with a model in
which loss of both alleles of pl6INK4A/MTS1 represents a growth deregulatory event that
accelerates the process of oncogenesis in vivo .
The p16 gene encodes a small molecular weight cyclin-dependent kinase inhibitor (CKI).
Expression of pl6 produces a G1 arrest in some cell lines, which correlates with the ability of p16
protein to block the formation of active cyclin D*cdk4 kinase by binding and sequestering cdk4
(Serrano et al., 1993). Importantly, tumor derived alleles of pl6 are deficient in their ability to bind
cdk4 and to produce cell cycle arrest (Koh et al., 1995; Ranade et al., 1995), and enforced
expression of wildtype p16 in pRB-deficient cell lines also fails to arrest proliferation (Lukas et al.,
1995; Medema et al., 1995). These data demonstrate that p16 anti-proliferative activity is entirely
dependent upon both its ability to bind cdk4 and the presence of intact retinoblastoma protein.
Significantly, there are instances of germline mutations within cdk4 exons that cosegregate with
melanoma susceptibility within a kindred (Wolfel et al., 1995; Zuo et al., 1996). These mutations
render cdk4 refractory to inhibition by INK4 proteins. These data demonstrate that like cyclin D,
the catalytic subunit of the cyclin D*cdk4 G 1 kinase also has oncogenic potential, and that this
potential is revealed by escape from regulation by the p16 tumor suppressor protein.
Participation of pRB and p16 in a common G1/S growth regulatory pathway is likely to
underlie the observation that concurrent loss of both tumor suppressors in the same clonal line is a
rare event (reviewed in Elledge and Harper, 1994; and in Sherr and Roberts, 1995), as it would
predict no growth advantage for a compound mutant cell. Loss of the p16 CKI during the course
of tumorigenesis consequently deprives the cell of a critical negative regulator of G1/S that
normally acts in a post-translational manner to regulate the activity of the proto-oncogenic cyclin
Docdk4(or cdk6) kinase and modulate the phosphorylation-dependent growth suppressive
properties of pRB. The frequency of mutations in components of this pathway suggests that it
may be among the most commonly disrupted pathways in human cancer (reviewed in Sherr,
1996). In fact, accumulating data regarding genetic lesions in various cell lines and cancers
suggest that this p l6cyclin D*pRB G1/S regulatory pathway may even be a required mutational
target during human tumorigenesis.
Since the generation of genetic models of the phenotypic consequences of pl6 loss, it has
become evident that a second important tumor suppressor gene lies within the p16 locus (reviewed
in Haber, 1997). This gene, called pl 9ARF (alternative reading frame), has its own unique 5' exon
(exon-lcl) distinct from the first exon of p]6 (exon -1P), but shares its second exon (exon-2) with
p16. Translation of pl9ARF in a different frame produces a polypeptide which is capable of
producing cell cycle arrest in both the G and G2 phases, but with no homology to the INK4
family or to any other cellular protein (Quelle et al., 1995).
While some of the mutations described in the p16 region in human cancers specifically
target coding sequences unique to p16, most of the lesions of this region are predicted to disrupt
the coding sequences of both pl6INK4A and pl9 ARF. In a number of these cases, it has been
demonstrated that these mutations specifically disrupt the ability of p 16, but not p19, to arrest the
cell division cycle (Quelle et al., 1997). However, the p19 product of the INK4a locus does appear
to fulfill an important growth regulatory function. Recent work has demonstrated that pl9ARF
functions as a tumor suppressor in mice (Kamijo et al., 1997). This property is likely due to the
ability of p 9 ARF to promote the degradation of the mdm2 oncoprotein (murine double minute-2)
(Pomerantz et al., 1998; Zhang et al., 1998). Mdm2 is in turn a negative regulator of the p53
tumor suppressor, which is involved in both checkpoint control and induction of apoptosis
(reviewed in Levine, 1997). As the targeted disruption of murine pl 6INK4A removed exon-2
sequences shared with p19ARF (Serrano et al., 1996), it is now clear that the organismal and cell
culture phenotypes associated with "pl6-deficiency" represent the consequence of deficiency for
both these tumor suppressors. These data reveal an unexpected level of complexity in the biology
of the INK4a locus, and support the emerging concept that it encodes growth inhibitory proteins
that individually act upstream of either pRB or p53. Given that p53 mutation is thought to be the
most frequent genetic alteration in human cancers (Hollstien et al., 1991; Levine et al., 1991), this
model raises important questions regarding which of these gene products, p16 or p19, plays a
more important role in tumor suppression. However, a clear role for the p16 protein in G1/S
regulation suggests that the tumor suppressive properties of the INK4a locus are in part attributable
to the cell cycle-regulatory effects of the p16 via a pRB-dependent pathway of growth control.
C2.3 CyclinE
Evidence to date suggests that cyclin Eocdk2 kinase activity fulfills a required role in the
promotion of S-phase entry. Constitutive expression of cyclin E shortens the duration of G1,
decreases cell size, and diminishes the serum requirement for the transition from G 1 to S phase
(Ohtsubo and Roberts, 1993). Inhibition of endogenous cyclin.cdk2 kinase by overexpression of
either the p21 CKI or a dominant-negative form of cdk2, results in G -phase cell cycle arrest
(Harper et al., 1995; Lundberg and Weinberg, 1998; van den Heuvel and Harlow, 1993; Xiong et
al., 1993). Specific inhibition of cyclin E-associated kinase by microinjection of x-cyclin E
antibodies inhibits S-phase entry (Ohtsubo et al., 1995). Genetic analysis of function in
Drosophila melanogaster demonstrates a strict requirement for cyclin E in S-phase entry during
development (Knoblich et al., 1994). Fly embryos homozygous for a mutation in cyclin E
encounter cell cycle arrest at cycle 17 of embryogenesis. Inhibition of cyclin E-kinase in the
developing eye by ectopic dacapo expression delays S-phase entry; DmcycE is likely to represent a
critical target of the cell cycle inhibitory effects of dacapo, as the phenotype of ectopic dacapo
expression is enhanced by heterozygosity for DmcycE but not for DmcycA or B (deNooij et al.,
1996). This proliferative potential of cyclin E is apparently incompatible with developmentally
programmed arrest, as ectopic expression of DmcycE in cells of the dorsal epidermis prevents cell
cycle exit and stimulates additional cell division (Lane et al., 1996). These observations show that
cyclin E activity can be rate-limiting for S-phase entry in eukaryotic cells, and suggest that cyclin E
targets a molecule(s) with an important and conserved G1/S regulatory role.
It is likely that cell cycle phenotypes associated with alterations in cyclin E activity arise in
part due to the role of cyclin E-associated kinase in the phosphorylation-mediated inactivation of
pRB. In vivo, the inactivation of pRB by G 1 cyclin.cdks is accomplished by both cyclin D- and
cyclin E-associated kinase activity (reviewed in Mittnacht, 1998). The staggered cell cycle-
dependent accumulation of active cyclin D- and cyclin E-associated kinase activities suggests that
cyclin D*cdk4 initiates this process in mid-G1 and cyclin E*cdk2 completes it in late G1 and G1/S.
However, overexpression and in vitro-kinase systems have failed to effectively demonstrate
significant differences in the manner in which these two kinases regulate pRB. Given this apparent
functional overlap between cyclin Eocdk2 and cyclin D*cdk4 in the inactivation of pRB, it is of
note that alterations in the cyclin E locus have not been found associated with any human cancer
syndromes. The prevalence of amplifications and translocations involving the cyclin D loci
suggests that amplification of cyclin E might facilitate constitutive inactivation of pRB and
deregulation of G1/S via a similar pathway. However, the absence of such mutations strongly
suggests that cyclin E- and cyclin D-associated kinase activities are not completely functionally
equivalent with respect to the mechanisms through which they regulate cell cycle progression.
It is clear from multiple eukaryotic systems that one target of cyclin E*cdk2 activity is the
retinoblastoma protein (Du et al., 1996a; Hatakeyama et al., 1994; Hinds et al., 1992). However,
unlike cyclin D, cyclin E plays a role in both pRB-dependent and pRB-independent cell cycle
regulatory pathways (Alevizopoulos et al., 1997; Leng et al., 1997; Lukas et al., 1997). This is
best illustrated by the finding that injection of neutralizing a-cyclin E antibodies arrests both pRB-
wildtype and pRB-deficient cells in GI (Ohtsubo et al., 1995). Therefore, in addition to pRB,
cyclin E*cdk2 kinase is required for phosphorylation of other unknown target(s) that regulate
G1/S. This additional role would seem to suggest that cyclin E has the potential to be even more
oncogenic than cyclin D, as its activity is predicted to regulate both pRB-dependent and
-independent G1/S control pathways.
This prediction is in direct contrast to the lack of cyclin E mutations in human cancer.
There are a number of possible explanations of this apparent incongruity. It is possible that
deregulation of this second, undetermined cyclin E-dependent pathway is not compatible with
continued cellular viability; alternatively, the combined deregulation of pRB-dependent and
-independent GU/S control pathways may produce a shortening of GI so pronounced that affected
cells eventually succumb to minimum size limitations. The lack of cyclin E-mediated oncogenicity
may also be a direct reflection of the manner in which it regulates pRB function. Recent work
from a number of sources has begun to suggest that cyclin D and cyclin E phosphorylate different
sites within the pRB sequence (Kitagawa et al., 1996). Although not a confirmed property of the
endogenous kinases, such site-specificity may underlie the apparent cooperativity between cyclins
D and E in the functional inactivation of pRB in vivo. Confirmation of such cooperativity by the
sequential activation of these kinases would strongly suggest that, in the absence of prior cyclin D-
mediated phosphorylation of pRB, cyclin E*cdk2 is insufficient to independently inactivate the
growth suppressive properties of pRB. This hypothesis is supported by the finding that specific
inhibition of cdk4-, but not cdk2-kinase activity, results in the accumulation of
hypophosphorylated pRB which does not appear to be phosphorylated by cyclin E*cdk2
(Lundberg and Weinberg, 1998; Resnitzky and Reed, 1995). In this regard, each kinase may be
individually required, but not sufficient, for phosphorylation-mediated inactivation of pRB. In the
absence of growth factor-stimulation of cyclin D transcription in vivo, increased levels of cyclin E-
kinase may be unable to promote cell cycle progression because a necessary upstream event - the
cyclin D-mediated phosphorylation of pRB - has not occurred. Thus, amplification of cyclin E
would not relieve the growth factor-dependence of pRB inactivation and R-point control. In
contrast, proliferative signals generated by amplification of cyclin D would be propagated by the
mitogen-independent accumulation of cyclin E-kinase.
C3. Targets of pRB: transcriptional control of cell cycle & differentiation
Analysis of the post-translational regulators of pRB function has uncovered proteins with
oncogenic and tumor suppressive activities that correlate with their roles in cell cycle control. The
pRB-dependence of the cell cycle phenotypes associated with each of these proteins suggests that
pathways downstream of pRB include proteins with central roles in tumorigenesis and cell cycle
control. The identification of these pRB targets is necessary to understand fully the molecular
mechanisms of carcinogenesis, and to permit the development of models of the true physiological
function of the pRB gene product.
C3.1 The A*B pocket
Analysis of pRB mutations found in human tumors suggests that the function of a region
within the RB-1 gene called the "A*B pocket" is required for pRB growth suppression (Hiebert,
1993; Qin et al., 1992). The "pocket" is composed of the A and B domains separated by a region
known as the "spacer". This region of pRB is an important mutational target in the process of
tumorigenesis (reviewed in Dyson and Harlow, 1992). In retinoblastoma, inactivation of the
remaining of RB-i wildtype allele normally occurs by small-scale deletion or point mutation
which results in disruption of either the A or B domain, or in some cases the loss of the entire A*B
pocket (reviewed in Sellers and Kaelin, 1996). The importance of the A*B pocket for pRB
function is further emphasized by the finding that this region falls within the domain recognized by
the E1A, Tag, and E7 oncoproteins, suggesting that the oncogenic and cell cycle phenotypes
induced by these viral proteins may depend upon their ability perturb the normal function of this
domain.
Extensive work has resulted in a lengthy list of cellular and viral proteins capable of
interacting with pRB in vitro via sequences in the A*B pocket (reviewed in Mulligan and Jacks,
1998). For only a subset of these has an in vivo interaction been demonstrated which represents a
biologically significant property of the endogenous proteins. From these, it has become clear that
the biological properties of pRB are likely a result of its ability to modulate the transcriptional state
of certain cellular promoters. This function of pRB is directly linked to its ability to interact
physically with transcription factors in nuclear complexes bound to DNA. This connection
between transcription control and regulation of G 1 progression provides a link between the activity
of G1 cyclin-cdks and modulation of transcriptional programs required for cell cycle progression.
As the commitment to Gl/S progression is at one level a transcriptional decision whether or not to
synthesize the enzymatic, structural and regulatory components necessary for entry into and
completion of S phase, the G1/S regulatory role of pRB may reflect its ability to interfere with
induction of this program. By extension, the transformation and differentiation phenotypes
associated with pRB-deficiency are likely to correlate with deregulation of transcriptional programs
normally regulated by the retinoblastoma protein.
C3.2 Differentiation control
Deletion analysis of the pRB cDNA has demonstrated that the AeB pocket is required for
the Gi arrest which results from overexpression of pRB in the SAOS-2 human osteosarcoma cell
line (Qian, 1992 ; Qin, 1992). Interestingly, in addition to this cell-cycle phenotype, the integrity of
the A*B pocket is also required for a "differentiation" function of pRB seen in these cells.
Reintroduction of pRB in SAOS-2 cells is associated with the induction of a distinctive phenotype
in which cells flatten out and grow quite large (Hinds et al., 1992; Qin et al., 1992; Templeton et
al., 1991). These large cells are no longer cycling, yet they appear to remain metabolically active
and display signs of osteoblast differentiation as measured by induction of bone-alkaline
phosphatase activity and mineral deposition (Sellers et al., 1998). Certain tumor-derived alleles of
RB-1 associated with high-penetrance retinoblastoma are deficient in this differentiation-promotion
activity (Sellers et al., 1998). The ability of pRB to drive under-differentiated SAOS-2
osteosarcoma cells towards a bone-differentiation fate may reflect the ability of pRB to interact
with one or more endogenous transcription factors involved in bone differentiation. That tumor-
derived alleles may be deficient in this function(s) imply that tumorigenicity as a result of pRB loss
may involve both deregulation of G1/S cell cycle control and impairment of differentiation
pathways.
One cellular factor that interacts with pRB via the B-domain of the pocket region and has
an established role in cellular differentiation is the fate determining transcription factor MyoD (Gu
et al., 1993). Expression of MyoD during development is linked to the activation of muscle-
specific genes and the execution myogenic differentiation programs (reviewed in Molkentin and
Olson, 1996). Stable expression of MyoD in human fibroblasts is sufficient to trigger the
expression of muscle markers, such as myogenin, and the formation of myotube-like syncitia in
culture. The inability of cultured Rb-/- murine myotubes to commit to terminal cell cycle exit
correlates with reduced expression of MyoD-responsive genes (Gu et al., 1993; Novitch et al.,
1996), suggesting that pRB is required for MyoD function. Recent experiments show that pRB is
required for MyoD-mediated transactivation of the muscle creatine kinase (MCK) promoter
(Sellers et al., 1998). While a reporter driven by the MCK promoter is normally induced
dramatically by coexpression of MyoD, expression of MyoD in Rb-/- MEFs has little or no effect
on the activity of the this promoter. Consistent with a physical and functional interaction between
pRB and MyoD, the lack of MyoD-mediated activation of the MCK reporter in RB-1-I- cells is
rescued by co-expression of a wildtype, but not a tumor-derived, allele of RB-1 carrying an
internal deletion in the A*B pocket. In addition to activation of genes associated with
differentiation programs, expression of MyoD is also associated with the induction of a G 1 arrest
(Crescenzi et al., 1990). This arrest correlates with the ability of MyoD to induce the CIP/KIP
family member p21 (Halevy et al., 1995) and suggests that MyoD may induce cell cycle exit
during skeletal muscle differentiation by upregulation of the p2 1 CKI.
It is likely that the involvement of pRB in the execution of GO differentiation programs by
virtue of its ability to interact with fate determining transcription factors like MyoD contributes to
tumorigenesis in the absence of pRB. However, it is clear that these interactions are insufficient to
fully explain the tumorigenic consequences of pRB loss and are unlikely to play a role in a more
generalized function of pRB as a G 1 regulator. Firstly, whereas all tumor-derived alleles of RB-1
tested to date are deficient in the induction of a G1 arrest in primary cells, certain tumor-derived
alleles are unaffected in their ability to functionally interact with MyoD (Sellers et al., 1998),
suggesting that tumor suppression is to some degree dissociable from differentiation control.
Secondly, the ability of pRB and components of the pRB pathway to either inhibit or promote the
progression of human and mouse primary cells through the G1 phase of the cell cycle occurs in a
cellular context lacking detectable levels of differentiation-specific factors like MyoD, and
production of these cell cycle phenotypes does not correlate with the induction of such activities.
Lastly, the generation of chimeric mice reveals that Rb-/- cells are capable of contributing to most
fully differentiated tissues and cell types in these animals (Maandag et al., 1994; Williams et al.,
1994). As the juxtaposition of wildtype and pRB-deficient cells in this system more closely
recapitulates the clonal loss of pRB function during tumorigenesis, the absence of a differentiation
deficit in these Rb-I- cells suggests this function may not underlie tumorigenic phenotypes
associated with pRB loss in human tumors. Together, these observations indicate that interactions
with transcriptional activities associated with differentiation do not account for the central role of
pRB as a regulator of G1/S. Clearly, the critical target(s) of pRB-mediated GI/S control is likely
to have a more generalized role in cell cycle control which is directly linked to the basic machinery
regulating cell division.
C3.3 Cell cycle control: E2F
Considerable evidence now suggests that a class of pRB-binding proteins called
E2F/DRTF (Early-2 Factor/ Differentiation Regulated Transcription Factor; henceforth referred to
as E2F) represent the target of pRB-mediated growth suppression in vivo (reviewed in Bernards,
1997). These DNA-binding transcription factors interact with pRB via the A*B pocket and
normally function to regulate the expression of genes required for GO/G 1 exit and S-phase
progression. The role of E2F as an important transcriptional effector of the p16*cyclin DepRB
suggests that the growth regulatory properties of this pathway will in large part be determined by
the transcriptional properties of E2F.
E2F displays many of the expected characteristics of a major target of pRB growth
suppression. E2F is reported to bind specifically to the unphosphorylated, growth-suppressive
form of pRB during G1 (Bagchi et al., 1991; Bandara and La Thangue, 1991; Cao et al., 1992;
Chellappan et al., 1991; Mudryj et al., 1991; Bandara, 1991; Bagchi, 1991; Chellappan, 1991 ;
Cao, 1992 ; Kaelin, 1992). This association does not prevent E2F from binding DNA but results
in repression of E2F transactivation activity (Helin et al., 1993a; Hiebert et al., 1992). Moreover,
the resulting pRB*E2F complex can act as an active repressor of E2F responsive promoters
(Adnane et al., 1995; Bremner et al., 1995; Chow and Dean, 1996; Weintraub et al., 1995;
Weintraub et al., 1992). Consistent with an important role in proliferation control, the pRB*E2F
interaction is disrupted during the course of tumorigenesis, as all tumor-derived alleles of pRB
tested to date are deficient in E2F binding (Sellers et al., 1998). In vivo the pRB*E2F interaction is
regulated by the cell cycle-dependent kinases. Phosphorylation of pRB by G 1 cyclinecdks
dissociates pRB from DNA-bound E2F complexes, simultaneously relieving pRB-mediated
repression, and permitting "free" E2F that remains at the promoter to transactivate target genes at
G1/S. Expression of the adenovirus E1A transforming protein activates E2F-dependent
transcription by binding pRB and disrupting the pRB*E2F complex (Bandara and La Thangue,
1991; Chellappan et al., 1992; Chellappan et al., 1991; Raychaudhuri et al., 1991).
As would be expected of a critical transcriptional regulator of Gl/S, a list of E2F-
responsive genes includes many whose products are implicated in or directly linked to the process
of cell proliferation. These genes can be grouped into two classes: those whose products are
involved in cell cycle regulation (eg. RB-1, p107, cdc2, cyclin A2, cyclin E, E2F-1, b-myb) or
those that encode activities directly linked to the enzymatic process of DNA replication (eg.
dihydrofolate reductase [DHFR], mcm3, cdc6, ribonucleotide reductase subunits 1 and 2
[RNR1/2], DNA ligase, thymidine kinase [TK], and the large subunit of DNA polymerase a
[Polx]) (reviewed in Bernards, 1997). Together, these data suggest that pRB functions to inhibit
E2F activity and that inactivation of pRB, either by mutation, viral proteins or phosphorylation,
activates E2F and the transcriptional program(s) it controls.
D. The E2F and DP family proteins: heterodimerization and structure
In vivo, E2F activity is composed of a heterodimer of two distantly related polypeptides
called E2F and DP (DRTF protein) (Wu et al., 1995). Heterodimerization is absolutely required
for high affinity binding to E2F-site DNA sequences and for transactivation (Bandara et al., 1993;
Helin et al., 1993b; Krek et al., 1993). Once bound to DNA, the transactivation and regulatory
properties of E2F*DP complexes are primarily determined by the E2F subunit. There are
currently six members of the E2F family in human and mouse (E2F-1 through E2F-6) (Trimarchi
et al., 1998; reviewed in Bernards, 1997), which are grouped together based upon high homology
throughout their DNA, heterodimerization, transactivation and pRB-binding domains.
Mammalian DP activity is also represented by a family of genes, of which there are currently two
known members (DP-1 and DP-2) (Girling et al., 1993; Wu et al., 1995; Bandara, 1994). It
appears that any member of the E2F family of polypeptides can complex with any member of the
DP family to give rise to functional E2F activity.
The E2F family of polypeptides can be divided into three subclasses based upon domain
structure. E2F-1, -2 and -3 all contain an extended amino-terminal domain which is absent in the
other E2Fs. This N-terminus is rather divergent at the amino acid level, although there appears to
be some conserved function within this domain, as it is responsible for the cyclin A-binding and
nuclear localization properties (see Chapter 4) of E2F-1, -2 and -3 (Adams et al., 1996; Krek et al.,
1994). E2F-4 and -5 represent the second subclass of E2F proteins; these E2Fs lack the N-
terminus present in E2F-1, -2 and -3. Further, at a few amino positions within the DNA binding
domain that are identical between the first E2F subclass (E2F-1,- 2 & -3), E2F-4 and -5 encode
residues that are divergent with respect to the first group, but conserved between each other. To
date, the biological consequences of some of these sequence differences remain unclear.
E2F-6 is currently the only representative of the third structural group. Human and mouse
E2F-6 encode a protein containing consensus E2F DNA binding and dimerization domains, but
lacking the entire C-terminal domain present in the other E2Fs that encodes the pRB-binding and
transactivation functions (Morkel et al., 1997; Trimarchi et al., 1998). Further, E2F-6 protein
contains an N-terminal domain of intermediate length between the other two E2F subgroups.
These structural differences suggest that while E2F-6 protein may be competent to heterodimerize
with DP proteins and bind DNA, it does not interact with the pRB tumor suppressor protein or
participate in transcriptional regulation of responsive genes in a manner strictly analogous to the
other members of the E2F family.
Like the E2F family, the DP-1 and DP-2 proteins are fairly well conserved throughout
their entire length. The regions of highest DP homology are the DNA binding and
heterodimerization domains, which are required for E2F-binding and contribute to the DNA
binding affinity of the intact E2F*DP complex. Both DP proteins contain a highly acidic C-
terminal stretch of approximately 20 residues which makes a small contribution to the
transactivation potential of the heterodimer (Bandara et al., 1994). Alternative splicing of the DP-2
transcript produces a number of different DP-2 polypeptides in vivo (Ormondroyd et al., 1995;
Rogers et al., 1996). The functional roles of the coding regions whose inclusion is regulated by
alternative splicing remain unclear, although the relative expression levels of the DP-2 isoforms
appears to vary between different cell lines and tissues (Rogers et al., 1996). There are no apparent
differences between these isoforms in their ability to interact with E2F proteins and produce a
heterodimer competent to bind DNA.
E. The pRB-related proteins p107 and p130
The physical and functional interactions between E2F*DP heterodimers and the tumor
suppressor pRB suggest that E2F activity plays a critical role in the regulation of cell cycle
progression. As a result, this transcription factor family is predicted to represent an important
target of proliferation control pathways that regulate the G1/S transition. Elucidation of the
molecular mechanisms of pRB regulation suggests that cell cycle regulatory pathways stimulate
E2F activity through the inactivation of proteins which normally function to repress E2F. It is
now clear that pRB does not represent the only cellular protein that potentially falls into this E2F-
repressive class. Examination of the properties of endogenous proteins has revealed that E2F
activity is subject to cell cycle-dependent control by two other proteins called p107 and p1 30.
(Cobrinik et al., 1993; Ewen et al., 1991; Hannon et al., 1993; Li et al., 1993; Mayol et al., 1993).
Both p107 and p130 contain an "A*B pocket" domain and are capable of interacting with E2F
proteins in DNA-bound complexes; like pRB, this interaction results in a repression of E2F
transactivation activity (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995;
Sardet et al., 1995; Vairo et al., 1995). Consistent with the high degree of homology between the
pRB family members, experiments suggest that E2Fp 107 and E2F*p 130 complexes can also
function as active repressors of E2F-responsive promoters in a manner similar to pRB (Chow et
al., 1996; Starostik et al., 1996).
Foremost, these observations suggest that the transcriptional role of mammalian E2F
proteins is unlikely to be restricted exclusively to the pRB growth regulatory pathway. They imply
that E2F is also the target of p 107/pl30-dependent pathways of transcriptional regulation, and that
E2F will play an important role in mediating the biological properties of these pathways.
Understanding the roles of p 107/p 130 in proliferation control, and characterizing the cellular
pathways that regulate p107/p130 function therefore become necessary for the development of
models of E2F function in cell cycle control and tumorigenesis.
The p107 and p130 proteins are highly homologous to pRB throughout portions of their
coding regions. This conservation indicates that these three genes are evolved from a common
ancestral locus, and has led to the collective designation of pRB, p107 and p130 as the "pocket
proteins". This evolution has apparently also produced some degree of divergence, as the p107
and p130 proteins are more highly homologous to each other than they are to pRB, particularly
with the spacer region. A region of p107/p 130 homology within the spacer region is predicted to
harbor an important functional domain. This region contains a motif, which is homologous to
regions within the CIP/KIP family proteins, through which p107/p 130 interact stably with cyclin
A*cdk2 and cyclin E*cdk2 (Adams et al., 1996; Cobrinik et al., 1993; Li et al., 1993). This
interaction, which does not prevent p107 and p130 from interacting with E2F, or E2F from
binding DNA, results in an inhibition of the activity of these kinases (De Luca et al., 1997; Woo et
al., 1997; Zhu et al., 1995).
The regions of conservation between members of the pRB family also include a number of
the consensus cdc2 family-phosphorylation sites that are known to be modified in the
retinoblastoma polypeptide in vivo. This conservation suggests that p 107/p 130 activity may be
regulated through cell cycle-dependent phosphorylation in a manner similar to pRB. Consistent
with this hypothesis, both p107 and p130 are phosphoproteins in vivo and can serve as efficient
substrates for cdc2-type kinases in vitro and in vivo (Beijersbergen et al., 1995; Li et al., 1993;
Xiao et al., 1996). Studies of the relevance of these phosphorylation events to pl07/p130 function
have lagged behind those of pRB. However, recent work has begun to suggest that cyclin D-
dependent phosphorylation of p130 during GO exit represents an important transcriptional
regulatory event in cell cycle reentry (Dong et al., 1998; Mayol et al., 1996).
The shared structural and E2F-binding properties of the pocket protein family indicate that
p107 and p130 are capable of growth suppression through a mechanism similar to pRB.
Consistent with such a role as negative regulators of cell proliferation, overexpression of p107 and
p130 in certain cell lines produces a Gl-phase arrest (Beijersbergen et al., 1995; Vairo et al., 1995;
Zhu et al., 1993). Like pRB, this growth suppression activity appears to be subject to negative
regulation by components of the cell cycle machinery, as co-expression of D-type cyclins is
capable of blocking p107-mediated cell cycle arrest (Beijersbergen et al., 1995). Unlike pRB,
mapping of the regions in p107 which are required for this activity has revealed that two distinct
domains of this protein can function independently in growth suppression (Zhu et al., 1995). The
first is the conserved A*B pocket, which presumably enforces arrest by binding and inhibiting
E2Fs. The other p107 growth suppression-domain corresponds to the cyclinocdk interaction motif
within the "spacer" region, and likely functions via sequestration and/or inactivation of cell cycle
kinases. These molecular genetic data demonstrate that p107 and p130 can regulate cell cycle
progression via inhibition of both E2F and cyclinocdk activities.
The finding that all three members of the pRB family are sequestered by viral oncoproteins
such as large T antigen and E1A (reviewed in Dyson and Harlow, 1992), implies that inactivation
of the growth suppression functions of p107/p130 contributes to virally-induced cellular
transformation. Indeed, the ability of SV40 large T antigen to transform primary murine cells is
dependent upon the pocket-protein binding domain even in Rb-/- cells (Christensen and Imperiale,
1995; Zalvide and DeCaprio, 1995). This strongly suggests that inactivation of p107 and p130 is
necessary for full disruption of growth control pathways. In the case of SV40 large T, this
inactivation appears to be dependent both on direct binding, and on induction of post-translational
changes in phosphorylation state and protein stability (Sheng et al., 1997; Stubdal et al., 1997;
Zalvide et al., 1998). As with pRB, these forms of regulation result in the disruption of E2Fpl07
and E2F*p 130 complexes, and are therefore predicted to have deregulatory effects upon E2F-
responsive gene transcription. Because the regions of viral oncoproteins required to bind
p 107/p130 overlap with those that bind pRB, it has been difficult to establish by standard
molecular techniques whether, or to what extent, these pathways differ from those deregulated by
disruption of E2F*pRB complexes.
F. The unique tumor suppressive properties of pRB
The apparent functional conservation of pRB, p107 and p130 as regulators of E2F, and as
targets of viral oncogenes whose inactivation is necessary for the production of transformed
phenotypes, suggests that these proteins play similar roles in negatively regulating the cell division
cycle. These similarities suggest that p107 and p130 may also function to inhibit tumorigenesis in
the context of the whole organism. However, genetic evidence from both human tumors and
mouse strains carrying targeted disruptions of the genomic loci of pRB-family members argues
against functional equivalence between pRB, p107 and p130.
The different biological properties of pRB and p107/p130 are apparent at both the
tumorigenic and developmental levels. While RB-i clearly functions as a tumor suppressor in the
human, neither pl07 or p130 has been found mutated in any type of cancer (reviewed in
Weinberg, 1995). This finding suggests that in humans, pRB fulfills a proliferation control
function which is not redundant with, or compensated by, the p107 and p130 gene products. This
result is reiterated in the mouse, which carries a complement of E2F and pRB family genes highly
homologous to their human counterparts: while Rb-/+ animals are highly predisposed to thyroid
and pituitary tumors, heterozygosity for disruption of pl07 or p130 in the mouse is without
tumorigenic consequence in the 129/Sv mouse strain (Cobrinik et al., 1996; Lee et al., 1996).
Significantly, nullizygous p107 or p130 129/Sv mice are completely viable and do not
display any developmental or tumorigenic phenotypes (Cobrinik et al., 1996; Lee et al., 1996). As
is the case with tumor suppression, this result demonstrates that pRB plays a required role during
murine development that is not shared with p107/p 130. The apparent lack of required individual
developmental roles for p107 and p130 may actually occur as a result of functional overlap at the
molecular level between these two E2F regulatory proteins. The p107 and p130 proteins bind
largely overlapping subsets of E2F proteins in vivo (reviewed in Bernards, 1997), and cells
deficient for p130 display elevated levels of p107 with increased contribution to E2F DNA-
binding complexes (Hurford et al., 1997; Mulligan et al., 1998). This molecular phenotype
apparently reflects functional compensation at the transcriptional level, as compound deficiency for
both p107 and p130 results in the deregulation of known E2F-responsive genes (Hurford et al.,
1997). This p107/p130 pathway of transcriptional control appears to be required for proper
regulation of proliferation in some developing tissues: compound 107-/-;pl30-/- mice die
neonataly and show long-bone developmental defects that appear to correlate at the cellular level
with chondrocyte overproliferation (Cobrinik et al., 1996). This phenotype is similar to that seen
in mice deficient for the p57 KIP2 cdk inhibitor, suggesting that this protein may function together
with p 107/p130 to regulate E2F activity in these cells (Yan et al., 1997). However, p107 and p130
do not appear to be completely functionally equivalent within this pathway. The presence of a
single copy of the p107 gene in pl07+/-; p130-/- animals restores development to near wildtype; in
contrast, pl07-/-;p130+/- animals are dramatically runted and show increased perinatal lethality
(Cobrinik et al., 1996). This runted phenotype is similar to that observed in pl07-/-;Rb+/- mice
(Lee et al., 1996). While this correlation is clearly not a demonstration of equivalence, it may
reflect the involvement of pRB, p107 and p130 in a shared developmental pathway(s). However,
the lack of an increased rate of oncogenesis in (pl07-/-;p130+/-), (p107+/-; p130-/-) and (p107-/-
;Rb+/-) animals suggests that the functional redundancy of these pocket protein family members
may not extend to a collaborative suppression of tumorigenesis.
A recent report suggests that phenotypes associated with deficiency for murine pRB family
members are highly strain dependent. In contrast to the 129/Sv phenotypes described above,
homozygous inactivation of the p107 and p130 loci in a BALB/c genotypic background produces
severe developmental defects which appear to correlate at the transcriptional level with deregulation
of E2F-responsive transcription (LeCouter et al., 1997). The origins of this phenotypic variabilty
remain unclear. It may reflect strain differences in the developmental expression patterns of p107
and p130, or it may arise as a direct consequence of the presence of modifier genes in specific
murine strains. Clearly, the identification of the molecular origins of this phenotypic variability is
now a paramount concern, and will likely broaden our understanding of the molecular
mechanisms through which p107 and p130 function to restrain cellular proliferation.
G. E2F as cell cycle regulator
The different biological properties of pRB and p 107/p 130 contrast significantly with the
apparently shared role of these proteins as negative regulators of E2F activity. The apparent lack
of critical GI/S regulatory or tumor suppressive roles for p 107/p130 indicates that E2F may not
represent the critical target of pRB, and that the growth regulatory properties of pRB may be
mediated through E2F-independent pathways. However, the number of important cell cycle
regulatory proteins and DNA replication enzymes whose promoters are E2F-inducible suggests
that E2F-mediated activation of target promoters may be sufficient for entry into S-phase. Such
sufficiency would imply that E2F is endowed with significant oncogenic potential, and that the
tumor suppressive properties of pRB derive in large part from its ability to inhibit this potential.
While this model is attractive in its simplicity, it fails to explain why p107 and p1 30, two other
proteins that also inhibit E2F activity, are not tumor suppressors themselves. Resolution of this
issue is significantly dependent upon the characterization of the cell cycle regulatory properties of
the E2F family proteins. If experiments demonstrate that E2Fs are insufficient to override R-point
control, it would then be likely that this class of transcription factors is not the critical target of
pRB's growth regulatory properties. However, if E2F proteins prove sufficient to drive the G1/S
transition, the lack of p107/p130-mediated tumor suppression suggests an important level of
functional specificity in the pocket protein*E2F pathway.
G1. Mammalian E2F overexpression
The structural differences between the multiple members of the mammalian E2F family
suggests that functional distinctions may exist between E2Fs in their ability to promote
proliferation. However, the precise roles of individual E2Fs in the pl6*cyclin D'pRB growth
regulatory pathway remains unclear. At one extreme, it is possible that a property exclusive to a
single E2F (for instance a unique target gene) renders it more important to G1/S control in certain
tissues than its fellow E2Fs, and that it is therefore the critical E2F through which pRB mediates
growth suppression. At the other extreme, it is not the deregulation of a single E2F, but the
combined effect of deregulating the transcriptional potential of multiple E2Fs, which represents the
crucial event in deregulation of growth.
The absence of cancer-associated oncogenic mutations in E2F loci suggest that
deregulation of individual E2Fs is not sufficient for the oncogenic processes promoted by pRB
loss in humans. This suggests that it may be the combined effects of deregulating multiple E2Fs
which causes loss of G1/S control. In order to determine how individual E2Fs might contribute to
phenotypes associated with pRB deficiency, it is therefore necessary to establish the ability of
individual mammalian E2F proteins to regulate progression through G/S .
To study the ability of human E2Fs to contribute to oncogenic processes, many groups
have characterized phenotypes associated with overexpression of E2F family members in cultured
cells. In these systems, E2F displays the expected characteristics of a positive regulator of GU/S
with oncogenic potential. Enforced expression of E2F-1, -2 or -3 will drive quiescent cells back
into the cell cycle (Johnson et al., 1993; Qin et al., 1994; Shan and Lee, 1994). E2F-4 and -5 are
also capable of inducing S-phase when expressed in cells, although to a lesser extent than E2F-1,
-2 and -3 (Beijersbergen et al., 1994; DeGregori et al., 1997; Lukas et al., 1996). Consistent with
the proposed role for E2Fs as the primary transcriptional effectors of the p l6*cyclin D*pRB
pathway, the expression of E2F- 1 ,-2 or -3 is sufficient to overcome G 1-phase cell cycle blocks
associated with overexpression of pRB, or of inhibition of G phase kinases (DeGregori et al.,
1995; Lukas et al., 1996; Mann and Jones, 1996; Qin et al., 1995). As in the experiments above,
E2F-4 and E2F-5 are less efficient than E2F-1, -2 and -3 in overriding cell cycle blocks imposed
through the pRB pathway: E2F-4 or -5 efficiently bypass a pl6-mediated G1 block only when
coexpressed with DP-1 (Lukas et al., 1996). In some circumstances, overexpressed E2F-1 is
capable of inducing transformed phenotypes in primary cells (Johnson et al., 1994; Singh et al.,
1994; Xu et al., 1995), and can cooperate with E6 and a pRB-binding-deficient form of E7 in the
transformation of normal human foreskin keratinocytes (Melillo et al., 1994). These mitogenic
effects of E2F can apparently be reproduced in the context of the whole organism: transgenic
overexpression of one E2F family member, E2F-1, under the control of the skin-specific keratin-
5 promoter, promotes epidermal hyperplasia and can cooperate with an v-Ha-ras transgene to
induce skin tumors in mice (Pierce et al., 1998).
In certain settings, overexpression of oncogenes, such as myc and adenoviral E1A , is
associated with an increased sensitivity to apoptotic stimuli (reviewed in Evan, 1997). While
overexpression of E2F-1 in serum-starved cells drives S-phase entry, the ultimate fate of these
cells is also programmed cell death (Hiebert et al., 1995; Kowalik et al., 1995; Qin et al., 1994;
Shan and Lee, 1994; Wu and Levine, 1994). This apoptotic response can be explained by a
"conflicting signals" model in which the simultaneous activation of mitogenic pathways by E2F,
and growth arrest pathways by a second stimulus (eg. serum/growth factor deprivation), produce
antagonistic and incompatible signals that are resolved by the induction of cellular suicide.
However, in some cases E2F-1 overexpression induces actively dividing cells to undergo
apoptotic death even in the presence of abundant growth factors (Hsieh et al., 1997; Krek et al,
1995; Phillips et al., 1997). This response to overexpression of E2F-1 is reminiscent of the
apoptotic cell death seen in Rb -/- mice and raises the possibility that apoptosis is a physiologically
relevant response to deregulation of cellular E2F- 1. This hypothesis is supported by the finding
that cell death induced by ectopic E2F-1 expression is largely dependent upon p53 status (Hiebert
et al., 1995; Qin et al., 1994; Wu and Levine, 1994), and that some of the cell death observed in
Rb-/- embryos is rescued by crossing into a p53-/- background (Macleod et al., 1996;
Morgenbesser et al., 1994).
Genetic analysis of the regions of E2F necessary for the induction of cellular
transformation and apoptosis suggests that the DNA binding and transactivation domains are
required for the production of these cell biological phenotypes (Hsieh et al., 1997; Johnson et al.,
1993; Krek et al., 1995; Melillo et al., 1994; Phillips et al., 1997; Shan and Lee, 1994; Singh et al.,
1994; Xu et al., 1995). This requirement strongly implies that the biological effects of E2F
overexpression occur mainly as a consequence of the induction of E2F target genes. These same
targets are predicted to become deregulated by the loss of pRB in a manner sufficient to trigger
premature entry into S-phase in the absence of upstream signals.
While the experiments described in this section provide compelling evidence in favor of the
"sufficiency" of overexpressed E2Fs for S-phase entry, the important issue of the extent to which
individual E2Fs are "necessary" for cell cycle progression has not been as well addressed. The
abilities of dominant-negative versions of E2F- 1 and DP- 1 to block S-phase entry when
overexpressed in certain cultured cell lines (Dobrowolski et al., 1994; Wu et al., 1996) suggest that
transcriptional activation by E2Fs is necessary for S-phase entry. However, these data contrast
with results obtained by microinjection experiments in a different cell type that suggest that S-
phase entry can be triggered by cyclin E*cdk2 in the absence of E2F activation (Lukas et al., 1997).
This difference may reflect the observation that activation of cyclin E-kinase is a downstream
consequence of E2F transcription (see below, section G3) and may therefore bypass a requirement
for E2F in cell cycle progression; alternatively, it may simply be indicative of cell type-specific
requirements for S-phase entry. Regardless, these experiments have not significantly clarified the
extent to which E2F-driven transcription is required for G /S progression in wildtype cells.
Proper resolution of this question is clearly dependent upon the ability to assess the requirement(s)
for endogenous E2F function in cell cycle regulation from a genetic perspective.
G2. Drosophila E2F function
The conservation of components of the pRBeE2F pathway in other eukaryotic organisms,
such as Drosophila melanogaster, has provided the opportunity to conduct genetic analysis of the
requirement for E2Fs in cell cycle control. While these model systems do not permit a direct
assessment of E2F function in mammalian tumorigenesis, they have confirmed a requirement for
E2F in developmental control of S-phase entry and progression in flies.
Drosophila E2F and DP (dE2F and dDP) were originally identified by low-stringency
screening of a Drosophila imaginal disc cDNA library with a fragment of the human E2F-1
cDNA corresponding to the highly conserved C-terminal portion of the DNA binding domain
(Dynlacht et al., 1994; Ohtani and Nevins, 1994). Drosophila E2F and DP are structurally and
functionally highly analogous to their mammalian homologs. dE2F bears most resemblance to
the E2F- 1,-2 and -3 subgroup at the amino acid level and is capable of DNA binding and
transactivation from a heterologous reporter. dE2F also retains the pRB-binding domain and
physically and functionally interacts with the Drosophila melanogaster pRB homolog RBF (Du et
al., 1996a).
Genetic analysis of the function of E2F in Drosophila has provided evidence that dE2F
and dDP promote cell cycle progression during development. Flies homozygous for mutations in
dE2F or dDP encounter lethality in the late larval or early pupal stages of development (Royzman
et al., 1997). In dE2F animals, this lethality is apparently the result of dramatic developmental
delay that arises due to a prolongation of S-phase and a slowed overall rate of cell cycling. This
effect is apparently directly linked to transcriptional deficiency at E2F-responsive promoters, as the
G 1/S pulse of expression normally associated with two E2F responsive genes, RNR2 and PCNA,
is absent in these cells. These phenotypes demonstrate a requirement for dE2F and dDP in timely
progression through S-phase and confirm a cell cycle regulatory role for E2F activity which is
linked to the transcriptional induction of target genes. Significantly, cells in dE2F null larvae are
capable of S-phase entry, as measured by BRDU-incorporation (Royzman et al., 1997). This
result suggests that the induction of E2F-responsive genes at G1/S is not absolutely required for
cell cycle progression. However, it is possible that other E2F-like activities persist in these
animals, or that loss of dE2F is sufficient to relieve the repression of certain promoters during G1
whose products are minimally sufficient for S-phase entry.
G3. CyclinE as a critical E2F target
Similar to human E2F, ectopic expression of dE2F*dDP during Drosophila development
drives S-phase entry and apoptosis (Du et al., 1996b). Analysis of the genetic requirements of S-
phase induction by ectopic dE2F expression reveals that, in some tissues, cyclin E is a necessary
downstream target of dE2F activity (Duronio et al., 1996; Duronio and O'Farrell, 1995). The role
of mammalian cyclin E*cdk2 in the functional inactivation of pRB suggests that cyclin E*cdk2 is
functionally upstream of E2F, however, the inability of overexpressed dE2F to drive S-phase in
the absence of cyclin E suggests that this target gene directly couples E2F activity to G1/S control
in some Drosophila tissues. The discovery of multiple E2F binding sites in the promoters of both
human and mouse cyclin E suggest that E2F is responsible for regulating the periodic expression
of cyclin E in mammals as well (Botz et al., 1996; Geng et al., 1996; Ohtani et al., 1995). The link
between E2F activity and the periodic transcription of a G1 cyclinocdk subunit which is necessary
for cell cycle progression places E2F within a basic cell division control pathway and suggests that
the role of E2F in this pathway includes participation in a positive feedback loop through cyclin E
to enhance the phosphorylation-driven inactivation of pRB during late G1.
The connection between E2F and cyclin E transcription may represent an important
mechanism which contributes to the loss of proper G1/S control in RB-1-- cells. While it is clear
that one target of cyclin Eocdk2 activity is the retinoblastoma protein, experiments in cultured cells
demonstrate cyclin Eocdk2 functions in both pRB-dependent and pRB-independent Gl/S control.
This demonstrates that in addition to pRB, cyclin E*cdk2 kinase targets an unknown protein(s)
whose phosphorylation is likely required for entry into S-phase. The finding that exogenous E2F-
1 is capable of activating the transcription of the endogenous human cyclin E gene (Ohtani et al.,
1995) suggests that loss of pRB renders one G1 cyclin, cyclin D, dispensable and transcriptionally
activates cyclin E, the other. This model is further supported by the finding that cyclin E
expression is specifically deregulated in Rb-/- MEFs, but not in either 107-/- or p130-/- cells
(Herrera et al., 1996; Hurford et al., 1997; Mulligan et al., 1998). Where such a mechanism
operates, E2F-driven activation of cyclin E transcription as a result of pRB inactivation may
facilitate the functional inactivation of as yet unknown proteins whose normal function, as targets
of cyclin E*cdk2, is to restrain G1/S progression. In such a manner, deregulation of Gl/S as a
result of pRB loss may also involve deregulation of "pRB-independent" pathways of G1/S control
by virtue of the ability of E2F to induce cyclin E.
H. E2F regulation in vivo
Studies such as those discussed above confirm the ability of E2F proteins to promote cell
cycle progression, and tend to indicate that E2F activity is likely to be the critical target of pRB
growth suppression. However, while overexpression studies have made important contributions
to models of the mitogenic effects of E2F activity, they have not been able to fully address the
important questions of: (1) how E2F in general, and the transcriptional activity of individual E2F
proteins in particular, contribute to cell cycle progression; and (2) what are the precise regulatory
mechanisms that function to restrict the activity of E2F proteins to specific stages of the cell
division cycle.
It is well established that direct, inhibitory interactions with members of the pRB family
represent a critical E2F regulatory mechanism. However, the timing and extent to which
individual E2F proteins are subject to this inhibition remains unclear. In contrast, the cell cycle-
dependent E2F-binding properties of each pRB family protein are well characterized, and have
provided important clues regarding the regulation of E2F activity in vivo. These studies of the cell
cycle-dependent patterns of E2F DNA binding complexes and have found that pRB, p107 and
p130 interact with E2F at distinct stages of the cell cycle (Chittenden et al., 1993; Schwarz et al.,
1993; Shirodkar et al., 1992). This demonstrates that one level at which the pRB proteins differ in
their E2F regulatory properties is the timing of these inhibitory interactions, and suggests that this
difference may in part underlie the differences in the biological properties of pRB, p107 and p130.
The most abundant form of E2F activity in GO cells is a kinase-deficient E2Fop 130
complex (Chittenden et al., 1993; Cobrinik et al., 1993; Vairo et al., 1995). In contrast, pRB and
p107 do associate with E2F until the cells have reached the G1/S transition, and during S-phase the
E2F*p 107 complex also contains stably bound cyclin A*cdk2 kinase (Schwarz et al., 1993;
Shirodkar et al., 1992). Patterns of E2F*pocket protein binding in actively dividing cells differ
somewhat from those observed in cells reentering the cell cycle from GO. In these cells, the
E2FpRB complex is most abundant prior to S-phase, supporting the model of pRB-mediated
repression of E2F activity during G1 (Chellappan et al., 1991; Shirodkar et al., 1992). E2F
complexes containing p130 and p107 are present in late G1 and S-phase respectively, and include
stably bound forms of cyclin E*cdk2 or cyclin A*cdk2 (Bandara et al., 1991; Devoto et al., 1992;
Lees et al., 1992; Mudryj et al., 1991; Pagano et al., 1992). Considered together, the data regarding
cell cycle-dependent interactions between E2F and pocket proteins, in both actively dividing cells
and those reentering the cell cycle, suggest that pRB, p107 and p130 act in concert to restrict the
activity of E2F, and therefore E2F-responsive genes, to precise stages of the cell cycle. The role of
pRB, as the only tumor suppressor in this group of highly related E2F-regulatory proteins, would
suggest that the retinoblastoma plays a critical role in this pathway by virtue of an important level
of functional specificity.
A number of recent studies suggest that E2F-1, -2 and -3 interact specifically with pRB,
and not with p107/p130, in vivo, and that E2F-4 and E2F-5 proteins participate in complexes with
pl07/pl30 (Beijersbergen et al., 1994; Dyson et al., 1993; Ginsberg et al., 1994; Hijmans et al.,
1995; Lees et al., 1993; Sardet et al., 1995). This suggests that the unique biological properties of
pRB versus p 107/p 130 may arise as a consequence of their ability to regulate distinct subsets of
cellular E2F. This hypothesis has not been tested by a comprehensive characterization of E2F
complexes found in vivo. In fact, comparatively little is known regarding extent to which specific
members of the E2F family participate in the various "free" E2F and E2F*pocket-protein
complexes which display cell cycle-dependent patterns of regulation. As a result, it has been
difficult to assign specific cell cycle functions to individual E2F gene products. In this regard,
overexpression studies have made important contributions to models of mammalian E2F function.
However, it is clear that cellular phenotypes associated with these experiments are to some degree
the result of non-physiological levels of E2F expression which may escape normal regulatory
mechanisms and overcome functional specificity. This concern makes uncertain the link between
ectopic expression and the cell cycle regulatory roles of individual E2Fs in vivo. Similarly, it is
unclear the extent to which genetic analysis of a single Drosophila E2F reveals specific cell cycle
functions of the multiple mammalian E2Fs, some of which are more structurally related to dE2F
than others, particularly since the expansion of the E2F family in higher eukaryotes may represent
a division, or even diversification, of the function(s) of dE2F. These concerns do not detract from
the contributions such data make towards the construction of basic models of E2F function.
However, together they emphasize the need for analysis of endogenous mammalian E2F species
in order understand the role of individual E2Fs play in mediating the growth regulatory properties
of the pocket protein family in general, and of pRB in particular.
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A. Abstract
The E2F transcription factor couples the coordinate expression of cell cycle proteins to their
appropriate transition points. Its activity is controlled by the cell cycle regulators pRB, p107 and
p1 30. These bind to E2F at defined but distinct stages of the cell cycle. Using specific antisera,
we have identified the DP and E2F components of each of these species. Although present at very
different levels, DP-1 and DP-2 are evenly distributed amongst each of these complexes. In
contrast, the individual E2Fs have distinctly different binding profiles. Consistent with previous
studies, E2F-1, -2 and -3 bind specifically to the retinoblastoma protein. In each case, their
expression and DNA binding activity is restricted to post GI/S fractions. Surprisingly, E2F-1 and
E2F-3 make unequal contributions to the pRB-associated and free E2F activity, suggesting that
these proteins perform different cell cycle functions. Most significantly, this study showed that
E2F-4 accounts for the vast majority of the endogenous E2F activity. In arrested cells, E2F-4 is
sequestered by the p130 protein. However, as the cells pass the G1/S transition, the levels of pRB
and p107 increase and E2F-4 now associates with both of these regulators. In spite of this, a
considerable amount of E2F-4 exists as free E2F. In G1 cells, this accounts for almost all of the
free activity. Once the cells enter S-phase, free E2F is comprised of an equal mixture of both
E2F-4 and E2F-1.
B. Introduction
E2F is a cellular transcription factor that plays a pivotal role in the regulation of cell
division. Its responsive genes are either strongly implicated in or directly linked to the induction of
cellular proliferation. E2F appears to act to tether the expression of these genes to the point in the
cell cycle at which their products are known to act. E2F activity is tightly regulated by the physical
association of key components of the cell cycle machinery. The best characterized of these is a
known tumor suppressor, the retinoblastoma protein (pRB). The retinoblastoma gene (RB-1)
was originally identified and subsequently cloned by virtue of its absence in retinoblastomas
(Friend et al., 1986; Fung et al., 1987; Lee et al., 1987). However, further studies have identified
RB-1 gene mutations in 30% of all human tumors and, in each case, these result in either loss or
functional inactivation of the retinoblastoma protein (reviewed in Weinberg, 1992). Moreover, the
transforming potential of the small DNA tumor viruses correlates closely with their ability to bind,
and presumably sequester, pRB (reviewed in Dyson and Harlow, 1992).
In normal cells, the growth-inhibitory properties of pRB are inactivated by phosphorylation
(Dynlacht et al., 1994; Hinds et al., 1992). This modification appears to be mediated by one or
more of the cell cycle dependent kinases, cyclin D/cdk4 or 6 (mid-G 1 specific), cyclin E/cdk2
(G1/S specific) or cyclin A/cdk2 (S-phase specific) (Ewen et al., 1993; Hinds et al., 1992; Hu et
al., 1992; Lees et al., 1991; Matsushime et al., 1994; Meyerson et al., 1994). This provides a
simple mechanism to ensure that the growth inhibitory properties of pRB become inactivated once
cells are triggered to re-enter the cell cycle.
In 1991, a number of laboratories demonstrated that the retinoblastoma protein binds to
E2F in vivo (Bagchi et al., 1991; Bandara and La Thangue, 1991; Chellappan et al., 1991).
Although many other pRB-binding proteins have been reported, E2F has all of the predicted
characteristics of a major pRB-target. It binds specifically to the un-phosphorylated form of pRB
(Chellappan et al.,1991; Mudryj et al., 1991). This association does not effect its DNA binding
activity but is sufficient to inhibit its transcriptional properties in a manner that can be specifically
relieved by pRB phosphorylation (Dynlacht et al., 1994; Helin et al., 1993a; Hiebert et al., 1992;
Lees et al., 1993). In addition, E2F is capable of acting as an oncoprotein. E2F overexpression
will drive quiescent cells to re-enter the cell cycle (Johnson et al., 1993) and, in some situations, is
sufficient to bring about transformation (Singh et al., 1994; Xu et al., 1995). More often, E2F
expression induces cells to undergo apoptosis suggesting that E2F is sufficient to induce cell cycle
re-entry even in the presence of conflicting growth signals (Melillo et al., 1994; Qin et al., 1994;
Shan et al., 1994; Wu and Levine, 1994). In each case, genetic analyses suggest that these effects
are directly dependent upon the inappropriate activation of one or more target genes.
E2F is also regulated by two other proteins called p107 and p130 (Cao et al., 1992;
Cobrinik et al., 1993; Devoto et al., 1992; Shirodkar et al., 1992). These were originally identified
and cloned by virtue of their association with the adenovirus E1A protein and both share
considerable sequence homology with the retinoblastoma protein (Ewen et al., 1991; Hannon et
al., 1993; Li et al., 1993; Mayol et al., 1993). Unlike pRB, these proteins also associate stably with
the cell cycle dependent kinases, cyclin A/cdk2 and cyclin E/cdk2, and this association does not
prevent them from binding to E2F (Cao et al., 1992; Cobrinik et al., 1993; Devoto et al., 1992;
Ewen et al., 1992; Faha et al., 1992; Lees et al., 1992; Mudryj et al., 1991). Several studies have
shown that pRB, p107 and p130 each bind to E2F at defined but different stages of the cell cycle
(Chittenden et al., 1993; Schwarz et al., 1993; Shirodkar et al., 1992). In arrested cells, the
predominant E2F species appears to be a kinase deficient form of the p 130/E2F complex
(Chittenden et al., 1993; Cobrinik et al., 1993). In contrast, pRB and p107 do not associate with
E2F until the cells reach the G1/S-transition (Lees et al., 1992; Schwarz et al., 1993). In each case,
formation of the p 130/E2F/kinase or p 107/E2F/kinase complexes coincides exactly with the
timing of appearance of either cyclin E/cdk2 at the GI/S transition or cyclin A/cdk2 during S-phase
(Lees et al., 1992; Shirodkar et al., 1992). Although p107 and p130 are not tumor suppressor
proteins, they appear to repress E2F in a similar manner to pRB (Hijmans et al., 1995; Zhu et al.,
1993), and are also targeted by the small DNA tumor viruses (reviewed in Dyson and Harlow,
1992). These data therefore suggest that pRB, p130 and p107 act in concert to confine the
activation of E2F, and therefore E2F-responsive genes, to precise stages of the cell cycle.
In the last three years, we and others have cloned at least seven genes that encode
components of E2F (Ginsberg et al., 1994; Girling et al., 1993; Helin et al., 1992; Ivey-Hoyle et
al., 1993; Kaelin et al., 1992; Lees et al., 1993; Sardet et al., 1995; Wu et al., 1995). These genes
fall into two distinct classes, termed E2F and DP, that share little or no sequence homology. E2F
and DP proteins heterodimerize in vivo and this association appears to be essential for both high
affinity DNA binding and transcriptional activation (Bandara et al., 1993; Helin et al., 1993b; Krek
et al., 1993; Wu et al., 1995). Several groups have shown that the individual E2F/DP
heterodimers differ in their regulatory protein binding properties. Although both subunits are
required for high affinity binding, this specificity appears to be determined by the E2F moiety.
We have shown that complexes containing E2F-1, -2 or -3 bind specifically to pRB and not p107
in vivo (Dyson et al., 1993). In contrast, E2F-4 and -5 complexes have been reported to bind
specifically to p107 and/or p130 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al.,
1995; Vairo et al., 1995). Since the regulatory proteins bind to E2F at defined but different stages
of the cell cycle, this specificity is likely to play an essential role in determining both the timing and
length of activation of the individual E2F/DP heterodimers. It has also been suggested that
differences in either the intrinsic properties of the E2F/DP heterodimers and/or the modulating
effects of the associated regulatory protein might cause the pRB- and p107-/p103-specific E2Fs to
activate different classes of responsive genes. Despite this speculation, we actually know very little
about the cell cycle regulation of the individual E2F/DP complexes. To help address this issue, we
have used specific antisera to analyze the temporal expression patterns and binding properties of
the individual family members. These studies have revealed striking differences in the cell cycle
regulation of E2F- 1, -2, -3 and -4.
C. Results
C1. Generating anti-E2F antibodies
In the last three years it has become clear that the endogenous E2F activity arises from the
concerted action of multiple E2F/DP heterodimers. Although there is considerable information
about the basic properties of the E2F and DP proteins, we have yet to understand whether the
individual E2F/DP complexes are required to mediate distinct functions in vivo or whether they
are functionally redundant. In order to address this question, we need to be able to identify and
follow each of these complexes in vivo. To this end, BALB/c mice were immunized with
purified, bacterially-expressed proteins in which a tag of six histidines is fused to either full-length
E2F-2, amino acids 1-244 of E2F-3 or amino acids 147-413 of E2F-4. The response of these
mice was monitored by assaying successive bleeds for their ability to detect E2F/DP complexes in
either gel shift or immunoprecipitation assays. For these experiments, C33-A cells were
transiently transfected with pCMV-E2F-1, -2, -3, -4 or -5 expression vectors in combination with
pCMV-HA-DP-1. These cells were either labeled with 3 5 S-methionine for immunoprecipitation
experiments or used to generate whole cell lysates for gel retardation assays. The polyclonal
antisera were tested for their ability to either supershift E2F/DP/DNA bound complexes or co-
precipitate both the labeled E2F and its associated DP protein. In each case, these antisera
specifically recognized the relevant E2F-2, E2F-3 (data not shown) or E2F-4 (Figure la)
containing complexes in both gel retardation and immunoprecipitation assays.
In the case of E2F-2 and -3, the polyclonal antisera were of sufficiently high titer (a strong
positive reaction with a 1tl1 of a 1/100 dilution) to conduct hybridoma fusions. The resultant lines
were initially screened by enzyme-linked immunosorbent assay (ELISA) for their ability to secrete
antibodies that recognized the relevant E2F immunogen. These primary screens identified
multiple wells that produced either anti-E2F-2 or -3 antibodies. Subsequently, these ELISA-
positive tissue culture supernatants were tested for their ability to specifically recognize the relevant
E2F/DP complexes in either gel shift or immunoprecipitation assays. Exactly as described above,
these experiments were conducted using extracts from C33-A cells transiently transfected with
E2F and DP expression vectors. Most of the ELISA positive E2F-2 and -3 antisera specifically
recognized either E2F-2 or E2F-3 in immunoprecipitation and/or gel retardation assays (data not
shown). Figure 1 confirms that the monoclonal antibodies utilized in this manuscript [KH20 (anti-
E2F- 1), LLF2-1 (anti-E2F-2) and LLF3-1 (anti-E2F-3)] specifically recognize their respective
E2Fs in both gel retardation assays (Figure la) and western blots (Figure lb) . In the former case,
neither the binding capacity or specificity of these antibodies was affected when DP- 1 was replaced
by DP-2 or when the regulatory proteins, pRB or p107, were individually included in the DNA-
bound complexes (data not shown).
C2. E2F-4 associates with pRB in vivo
To date, five distinct members of the E2F gene family have been identified (Beijersbergen
et al., 1994; Ginsberg et al., 1994; Helin et al., 1992; Ivey-Hoyle et al., 1993; Kaelin et al., 1992;
Lees et al., 1993; Sardet et al., 1995). Although these proteins share similar DNA binding and
transcriptional properties, numerous studies have reported distinct differences in their specificity of
regulatory protein binding. E2F-1, -2 and -3 each bind specifically to the retinoblastoma protein in
vivo (Dyson et al., 1993; Lees et al., 1993). In contrast, E2F-4 interacts in vivo with both p107 and
p130 while E2F-5 associates specifically with the Go-regulatory protein, p130 (Beijersbergen et
al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995; Vairo et al., 1995). Since there is extensive
evidence that pRB, but not p10 7 and p130, is a tumor suppressor, it is essential that we understand
the functional significance of the different binding specificities of the individual E2F/DP
complexes.
Initially, we tested our antibodies for their ability to detect the individual E2F/DP
complexes in vivo. For these experiments pRB or p107 were immunoprecipiated from
asynchronous ML-1 cells, associated E2F activity was released by treating the precipitates with
deoxycholate (DOC) and then detected in E2F gel shift assays in the absence or presence of our
anti-E2F antibodies (Figure 2a). While the control (anti-large T antigen) monoclonal antibody
failed to bring down any proteins capable of binding the E2F probe (lane 1), a considerable
amount of E2F activity was recovered from both the pRB- and p107-immunoprecipitates (lanes 2
and 10 respectively). In both cases, we were able to resolve this E2F DNA binding activity into a
series of bands, all of which can be specifically competed by a 50-fold molar excess of wild-type
but not mutant unlabeled E2F probe (data not shown). Consistent with our previous findings, the
monoclonal antibodies against E2F-1 (KH20 ; lanes 4 & 12), E2F-2 (LLF2-1; lanes 5 & 13) and
E2F-3 (LLF3-1; lanes 6 & 14) supershifted E2F-DNA binding activity from DOC-treated pRB-
but not pl07-immunoprecipitates. Both E2F-1 and E2F-3 were easily detectable in these assays
and seemed to be present at roughly similar levels. In contrast, the anti-E2F-2 supershift was
extremely weak (Figure 2a, lane 5), although clearly detectable when the input level of pRB-
associated E2F activity is increased (Figure 2b). Since several other E2F-2 monoclonal antibodies
detected similarly low levels (data not shown), these data suggest that E2F-2 comprises a small
proportion of the pRB-associated E2F activity.
To date, E2F-1, -2 and -3 are the only known pRB-associated E2Fs. To determine
whether these three proteins comprise all of the pRB-associated E2F activity, we tested how a
mixture of these three antibodies affected the pRB-associated E2F activity. Surprisingly, the
antibody cocktail supershifted less than half of the pRB-associated E2F activity (Figure 2a, lane 7).
Moreover, this supershift had no detectable effect upon the most abundant, upper species of E2F
activity. Since control experiments (using transfected E2F/DP complexes) were able to confirm
that all three antibodies were present in at least 10 fold excess (data not shown), these data indicate
that pRB must associate with one or more additional E2F species in vivo.
In an effort to identify this additional activity, we tested the effect of the E2F-4 polyclonal
antisera in this assay. Consistent with previous studies, the anti-E2F-4 sera supershifted a
significant proportion of the p107-associated E2F activity (lane 16), confirming that we can detect
the association between E2F-4 and p107 in vivo. In addition, this antisera also specifically
supershifted a large proportion of the E2F activity released from the pRB-immunoprecipitates
(Figure 2a, lane 8). In this case, the presence of this antibody selectively depleted the prominent
upper complex that had been unaffected by the E2F-1, -2 and -3 specific monoclonal antibodies
(Figure 2a, lane 7). To determine whether E2F-1, -2 , -3 and -4 were sufficient to account for all
of the pRB-associated E2F, we included a mixture of all four antibodies in the DNA binding
reaction (Figure 2a, lanes 9 & 17). Together, these reagents recognized all of the upper complex as
well as a portion of the lower complexes. However, a significant fraction of the lower species was
not supershifted by the antibodies, suggesting that they represented novel E2F species. Since
forms of equal mobility also persisted when the p107-associated E2F preparation was treated with
the E2F-1, -2 , -3 and -4 antibody cocktail, these novel E2Fs appeared to associate with both pRB
and p107 in a manner similar to E2F-4. Obviously, E2F-5 is a good candidate to be one or both
of these species and we are currently raising E2F-5 specific antisera to determine whether this
accounts for the remaining E2F activity or whether the cell contains other, as yet unidentified E2F
species.
Although E2F-4 is generally considered to be a p107/p 30-associated protein, these data
suggest that it also comprises a significant proportion of the pRB-associated E2F activity.
Consistent with this finding, Vairo et al. have previously reported that their anti-E2F-4 polyclonal
antisera also disrupts a portion of the pRB-associated E2F activity (Vairo et al., 1995). However,
both of these studies have been conducted using polyclonal antisera. We therefore wished to
confirm that our E2F-4 antisera was unable to supershift the endogenous E2F-1, -2 or -3 species.
Exactly as above, we tested the different combinations of E2F antisera for their ability to supershift
E2F activity that had been released from pRB-immunoprecipitates. However, in this experiment,
we increased the levels of pRB-released E2F activity by over 5 fold (Figure 2b). Although this
reduced our ability to detect discrete E2F complexes, we were now able to supershift significant
levels of E2F-1 (lane 3), E2F-2 (lane 5) or E2F-3 (lane 7) from the pRB precipitates. Co-addition
of the E2F-4 antisera had no effect upon these E2F-1 , E2F-2 or E2F-3 supershifts (Figure 2b,
lanes 4, 6 and 8), confirming that our E2F-4 polyclonal antibody did not crossreact with any of
these pRB-specific E2Fs. On the basis of this and other studies, we therefore conclude that E2F-4
comprises a significant proportion of the pRB-associated E2F activity.
C3. Differential cell-cycle expression of E2F proteins
Previous studies have shown that pRB, p107 and p130 bind to E2F at defined but distinct
stages of the cell cycle. Having confirmed that our antisera effectively recognize endogenous E2F
activity, we were able to compare the cell cycle regulation of the individual E2F/DP complexes
with that of the regulatory proteins. Human T cells were selected for these experiments for three
reasons. Firstly, these cells re-enter the cell cycle in a highly synchronous manner and the staging
is maintained throughout the first round of division. Secondly, the timing of pRB-, p107- and
pl30-complex formation has already been well documented in this system (Chittenden et al.,
1993). Finally, because these are primary cells, their cell cycle regulation should most closely
parallel that found in vivo.
Human T cells were isolated from peripheral blood and stimulated to proliferate by the
addition of phytohemagglutinin (PHA). At each time point the level of DNA replication was
monitored by assessing the uptake of tritiated thymidine (Figure 3a). In this experiment
[3H]thymidine incorporation peaked 36 hours-post stimulation and declined to near basal levels by
the 66 hr time point. The sharp increase between the 30 hr and 36 hr time points indicates the
majority of cells traversed the G1/S transition in this time interval; the narrowness of the peak and
the rapid decline to near basal levels suggested that the cells responded to the proliferative signal in
a synchronous manner.
Expression of the E2F proteins was assessed by Western blot analysis of whole cell
extracts from each of the time points (Figure 3b). In a similar manner to the ML-1 cells, E2F-2
was expressed at extremely low levels in the T cells (see the gel shift assays below) and was
undetectable in the Western blot experiments. In contrast, E2F-1, -3 and -4 were all present at
reasonable levels in the T-cell fractions. E2F-1 was first detected at 30 hours, coincident with the
beginning of S-phase. At this time point, it existed as a clear doublet. The level of the more
prominent, upper species reached a maximum at 42 hours and then declined to a moderate level
that was maintained throughout the remainder of the cell cycle. In contrast, the smaller species
was only detected in fractions undergoing DNA replication. Both the timing and the rapid rate
induction of E2F-1 protein synthesis were consistent with the known E2F-dependent, GI/S-
specific transcriptional activation of this gene (Hsiao et al., 1994; Johnson et al., 1994; Neuman et
al., 1994).
In contrast to E2F-1, our studies show that the E2F-3 mRNA is present in both the
arrested and PHA-stimulated T cell fractions at similar, low levels (data not shown). We were
therefore surprised to find that expression of the E2F-3 protein required cell cycle re-entry. In fact,
E2F-3 was not detected until 24 hours after PHA stimulation, just 6 hours prior to the initiation of
DNA synthesis and the induction of E2F-1 expression. Following its appearance, the level of
E2F-3 rose quickly to reach a maximum at 36 hours that was maintained throughout the
remainder of the cell cycle. Although the profile of E2F-3 expression closely mirrored that of
E2F-1, this protein was detected as a single species throughout the time course of the experiment.
Consistent with previous studies (Vairo et al., 1995), the E2F-4 protein was detected at
significant levels in all of the time points. In Go cells, E2F-4 was present as a single species
whose levels increased steadily as the cells progressed through G 1 and S phase and then returned
to the Go levels towards the end of the cell cycle. At 30 hours, we first detected two additional
E2F-4 species, the presence of which appeared to be specific to fractions that were undergoing
DNA synthesis. In fact, the appearance of these species was entirely coincident with the
appearance of the minor form of E2F-1.
For comparison, we also screened the T-cell fractions for the presence of the regulatory
proteins, pRB and p107. As previously described, pRB was detected as a single species in Go
cells that corresponds to the underphosphorylated form (Figure 3b). Once the cells re-entered the
cell cycle the overall level of pRB increased and slower migrating species were also detected.
These first appeared 24 hours after PHA-addition and persisted through the remainder of the cell
cycle and are entirely consistent with the cell cycle dependent phosphorylation of pRB that is
initiated at the G 1/S transition.
The p107 protein was first detected 24 hours after PHA addition. From this time on, its
levels continued to rise to reach a peak at 42 hours and then dropped to undetectable levels at 66
hours. Since the level of this species was only just within the detection limits of the experiments,
we cannot conclude that p107 was absent from the early and late time points. However, these
experiments clearly show that expression of the p107 protein is induced upon cell cycle re-entry.
The concomitant increase in the levels of the E2Fs and their regulatory proteins, was consistent
with recent reports that the RB-1 and p107 genes both contain E2F-responsive elements within
their promoters (Shan et al., 1994; Zhu et al, 1995).
C4. Cell cycle-dependent E2F DNA-binding activities
The western blotting data indicated that E2F-1, -3 and -4 were each expressed at defined
but different points of the cell cycle. However, since monomeric E2Fs are unable to bind to DNA
in the absence of an associated DP protein, it was important to determine when each of the E2F
proteins became competent to bind to DNA. In order to abolish any possible influence of the
regulatory proteins, the T cell extracts were treated with deoxycholate (DOC) to dissociate the
higher order complexes and the total "free" E2F activity was assayed by gel shift (Figure 4). E2F
activity was detected in all of the time points, but the levels increased significantly as the cells re-
entered the cell cycle to reach a maximum in the S-phase fractions. Wild-type but not mutant E2F
oligonucleotides competed all of the upper species (labeled as free E2F in Figure 4) but failed to
alter the strong lower band indicating that this corresponds to a non-specific binding activity (data
not shown).
As expected, addition of a control monoclonal antibody (PAb419), had no effect on the
DNA binding properties of any of these bands. In contrast, the E2F- 1, -2, -3 or -4 specific
antibodies were all capable of supershifting a proportion of the free E2F activity from one or more
of the T-cell fractions. The three pRB-specific E2Fs, E2F-1, -2 and -3, were each detected in a cell
cycle dependent manner. E2F-1 activity was first supershifted in the 30 hr extract, its levels
peaked in the 36 and 42 hr samples and then declined to a low level in the remainder of the time
points. E2F-2 DNA binding activity was also detected in this assay but at extremely low levels,
beginning at the 36 hour time point and declining to almost undetectable levels in the later time
points. Finally, an-LLF3-1 specific supershift was first identified 24 hours after PHA addition.
Although this activity did increase during S-phase, E2F-3 remained clearly detectable in all
subsequent fractions.
In each case, the timing and level of these DNA-bound complexes were nearly identical to
the timing and level of the individual E2Fs detected in our western blotting experiments. [The
apparent discrepancy in our ability to detect E2F-2 in the DNA binding assay and not the western
blot simply reflects the greater sensitivity of the gel shift assay and the extremely low levels of this
protein and is entirely consistent with our analysis of other cell lines, including ML-1 and C33-A
(data not shown).] In light of these findings, these experiments strongly suggest that there is little
delay between the synthesis of the individual E2Fs and their ability to associate with a DP to form
competent DNA binding complexes.
Consistent with its expression pattern, E2F-4 dependent DNA binding activity was
detected in all of the time points (Figure 4). In the early stages of the cell cycle, E2F-4 comprised
almost all of the total E2F activity. However, as the cells progressed through the cell cycle,
significant levels of non-supershifted bands appeared in those time points in which E2F- 1, -2
and/or -3 activity had previously been detected. As with our analysis of ML-1 cells (see Figure 2),
E2F-4 seemed to correspond to the major, higher mobility species while E2F-1, -2 and -3
corresponded to the collection of bands migrating immediately below.
Our preliminary experiments in ML-1 cells indicated that E2F-1, -2, -3 and -4 were not
sufficient to account for all of the endogenous E2F activity (Figure 2). We were therefore
interested to determine whether the unidentified E2Fs are present at all stages of the cell cycle, like
E2F-4 or whether their presence is also cell cycle regulated in a similar manner to the pRB-specific
E2Fs. To this end, the gel shift reactions were performed in the presence of a cocktail of all three
monoclonal reagents and the polyclonal sera (Figure 4). Consistent with the results in ML-1 cells,
supershifting E2F-1, -2, -3 and -4 revealed the presence of two distinct bands that were unaffected
by the presence of these antisera. One of these novel T cell E2F activities is present in all of the
time points, suggesting that its expression is regulated in a similar manner to E2F-4, and may
therefore correspond to the recently described p130-specific E2F, E2F-5. The second, slower
migrating activity is completely absent in Go/GI extracts, appears strongest in the S-phase extracts
(30 hr through 54 hr) and declines to low levels in the remainder of the time points in a similar to
the three pRB-specific E2Fs.
C5. E2F-1, -3 and -4 associate with regulatory proteins in a cell cycle-dependent manner
Having determined the timing of synthesis and DNA binding activity of the individual
E2Fs, it was important to establish whether these DNA binding complexes were free to activate
transcription or whether their activity was blocked by the association of regulatory protein(s). We
therefore used gel shift assays to examine the pattern of complexes arising from each of the T-cell
time points (Figure 5a). For clarity, we have labeled each of these complexes in order of their
appearance. In Go cells, E2F activity was detected as two discrete complexes, labeled A and B
respectively (Figure 5a, lane 1). During the first twelve hours the level of the A and B complexes
declined steadily. At the same time, we began to detect a third novel species, labeled C, whose
levels increased steadily (Figure 5a, lane 3). At the G1/S transition (between 30-36 hours after
PHA addition) this pattern altered considerably (compare lanes 6 and 7). Firstly, we detected the
formation of two novel complexes that migrated with increased mobility. The larger complex
(labeled D) was present at reasonably high levels while the smallest complex (labeled E) was
barely detectable. At the same time we detected significant changes in both the A and the B
complex. Despite the previous steady decline, the levels of the upper A complex appeared to
increase dramatically between 30 and 36 hours. In fact, the antibody experiments described below
indicate that the increase in the level of this band was actually caused by the appearance of a novel,
similarly sized species (labeled F) that replaced the Go-A complex. In a similar manner, the levels
of the B complex declined and disappeared between 30 and 36 hours to be replaced by another
novel species (labeled G) that has increased mobility. These five complexes (C through G)
persisted in all of the fractions (36, 42, 48 and 54 hr) containing S-phase cells (Figure 5a, lanes 7-
10). However, as the cells exited S-phase (between 54 and 60 hours) the pattern of these
complexes altered once more. The S-phase specific G complex disappeared rapidly and was
replaced by an additional species, labeled H, that migrates with the same mobility as the original
Go-B complex. At the same time the level of other complexes declined. Although this reduction
affected all four of these species, the E and F complexes appeared to be lost preferentially. The
strong peak of E2F activity in S-phase coincided exactly with the increased levels of E2F detected
in both the western blotting (Figure 3b) and DOC-release gel shift (Figure 4) assays.
To determine the identity of each of these complexes, the T-cell extracts were analyzed in
gel shift assays in the presence of antibodies against the regulatory proteins. The most interesting
time points are shown in Figure 5b. Consistent with previous studies, a p130 polyclonal antisera
specifically supershifted both the A and the B complexes (data not shown), confirming that p130
is contained within both of the Go complexes and free E2F is absent at this time (Chittenden et al.,
1993; Cobrinik et al., 1993). As the cells re-entered the cell cycle, the level of these p130
complexes declined steadily and disappeared between 30 and 36 hours after PHA addition. Low
levels of p107 and pRB-specific supershifts were first detected at 30 hours. These supershifts
caused a partial reduction in the upper two bands, indicating that they both contain a mixture of two
species, A (p130) + F (p107) and B (p130) + G (pRB). By the time DNA replication had reached
maximum levels (42 hours), the p107- and pRB-specific antibodies were able to supershift all of
the upper two bands (lanes 10 -12) indicating that the p130 complexes (A and B) have been
completely replaced by p107 (complex F) and pRB (complex G). By 54 hours the majority of the
cells had completed DNA replication (Figure 3a). Although the pRB specific antibodies continued
to supershift a significant amount of E2F activity from this later time point, they only shifted the
lower half of the second band (Figure 5b, compare lanes 13 and 14) indicating that once again it
derived from two distinct species, G (pRB) and H. Consistent with this observation, antibodies
against p107 suddenly generated two distinct supershifted species; one abolishing the F complex
and the other affecting the upper half of this G (pRB) + H (p107) band. Throughout the
experiment, antibodies against either pRB, p107 or p130 failed to alter the C and D complexes,
indicating that they comprise the free, transcriptionally active E2F.
Having determined the regulatory protein component of each of the T cell complexes, we
wished to establish the identity of their associated E2Fs. The fractions were therefore treated with
antisera specific to either the DP (Figure 5c) or E2F proteins (Figure 5d). We have previously
investigated the relative levels of DP-1 and DP-2 in asynchronous ML-1 cell extracts (Wu et al.,
1995). This study showed that DP-1 is the major species within these cells and together with DP-
2 is sufficient to account for all of the endogenous E2F DNA binding activity. Our analysis of the
T cell fractions was highly consistent with these data (Figure 5c). In fact, DP-1 seemed to
comprise at least 80% of the B, C, D, E, G and H complexes. Although the DP-1 supershift co-
migrates with the higher mobility complexes (A and F), two distinct supershifted species were
detected in Go time point (compare lanes 1 and 2) suggesting that the A complex also contained a
large amount of this protein. These data therefore suggest that the DP-1 was equally distributed
among all of the complexes and not limited to particular species. Because it is a polyclonal
antisera, the DP-2 antibody do not give rise to a discrete supershifted band(s). However, we did
detect a reduction in the level of some early complexes (for example B and C in lanes 4 and 6) as
well as a minor supershift in the later time points (compare lanes 16 and 18; 19 and 21), indicating
that DP-2 makes some contribution to many of these species. Together these data suggest that
DP-1 and DP-2 do not participate preferentially in any specific complex(es).
In contrast to the DP data, we detected clear differences in the identity of the E2F
component of these complexes. In the early time points (prior to 30 hours), we failed to detect any
evidence of the pRB-specific E2Fs. In contrast, E2F-4 was present at high levels. In Go, the
E2F-4 polyclonal antisera specifically supershifted all of the B complex (Figure 5s, lane 5),
indicating that this corresponds to p130/E2F-4. In addition, this antisera also recognized the
complex that first appeared in mid G 1. This C-complex persisted in all subsequent time points,
and in each case was fully supershifted by the E2F-4 antisera. Since this complex did not contain
an associated regulatory protein, these experiments suggest that E2F-4 is transcriptionally active
from mid-G 1 to late S-phase. In addition to E2F-4, our analysis of DOC-treated cell extracts
detected a second Go/GI-specific E2F of unknown identity. Consistent with this observation, the
Go/Gl-specific p130-A complex was unaffected by the E2F-1, -2 -3 or -4 antisera. In light of
recent observations that E2F-5 binds specifically to p130 (Hijmans et al., 1995) it seems likely that
the A complex corresponds to p 130/E2F-5.
At the G1/S-transition (30 hours after PHA addition), we detected major changes in the
binding properties of both the regulatory proteins (as described above) and the E2Fs. Consistent
with both the western blotting and DOC-release data, E2F-1 and E2F-3 specific supershifts were
first detected at this time (see Figure 5d, lanes 12 and 14). Although the initial supershifts were
weak, the levels of E2F- 1 and E2F-3 continued to rise as the proportion of S-phase cells increased.
By 42 hours it was clear that the E2F- 1 antisera specifically supershifted almost all of the D
complex (Figure 5d, compare lanes 16 and 17). This finding is consistent with previous data
(Chittenden et al., 1993) and suggests that E2F- I1 is a significant component of the free E2F and is
likely to play an important role in activating G1/S and S-phase specific transcription. Although
E2F-1 and E2F-3 seem to be present at similar levels, it was almost impossible to identify the
origin of the E2F-3 supershift. Even in the peak S-phase fractions, the presence of the E2F-3
antisera did not significantly alter the intensity of any of the original complexes (Figure 5d,
compare lanes 16 and 19) suggesting that E2F-3 is a minor component of one or more of these
species. Consistent with its low level of expression (see Figure 3b and 4), we were also unable to
detect any E2F-2 supershift in the presence of the undissociated complexes.
Although our previous experiments had shown that E2F-4 also bound pRB in vivo, we
were extremely surprised by the extent to which E2F-4 continued to dominate the latter E2F
activity. In both the G1/S and S-phase fractions (30 and 42 hours), E2F-4 was detected as the
predominant component of both the p107 (complex F) and pRB (complex G) species (Figure 5d,
lanes 15 and 20). At the same time, the level of the free E2F-4 complex (C) also continued to rise
as the proportion S-phase cells increased. Together, these data indicate that the E2F-4 protein
exists in excess of the pRB-specific E2Fs at all stages of the cell cycle. These high levels may help
to explain why E2F-4 binds pRB in the presence of E2F- 1, -2 and -3.
C6. pRB does not bind E2F activity during GO/Gi
Our cell cycle experiments clearly demonstrate that the G1 T cell fractions contain both
pRB (as judged by western blotting) and free E2F-4 (as judged by gel retardation assay). In light
of these findings, we might expect pRB and E2F-4 to associate during the early cell cycle stages.
However, our gel retardation assays failed to detect any pRB-containing complexes until after the
cells have traversed the GI/S transition. We therefore used the immunoprecipitation-DOC release
assay to screen the early T cell fractions for any evidence of pRB-E2F complexes. To ensure that
we would detect rare complexes, a second batch of PHA-activated T cells was prepared
specifically for this experiment. In this instance, the profile of E2F complexes was almost
identical to the previous batch of T cells (data not shown) with maximum DNA synthesis being
detected approximately 48 hours after PHA addition (Figure 6a). A significant proportion of each
time point was then immunoprecipitated with either a control (PAb419) or an anti-pRB (XZ55)
monoclonal antibody. Any associated E2F activity was released by treating the precipitates with
deoxycholate (DOC) and detected in E2F gel shift assays (Figure 6b). While the control (anti-
large T antigen) monoclonal antibody failed to bring down any proteins capable of binding the E2F
probe (lanes 1-11), we were able to detect E2F activity within some of the pRB-
immunoprecipitates. However, consistent with our gel shift assays, this activity was specifically
detected in post G1/S fractions (lanes 19-22) and was most abundant in late S-phase cells. The
appearance of these S-phase specific pRB/E2F complexes is highly consistent with apparent
increase in the rate of pRB synthesis that occurs at this point in the cell cycle. Although we cannot
rule out that pRB/E2F complexes are present at low levels, these data suggest that the pRB species
that are present in G0/GI cells are unable to associate with any E2F DNA binding activity.
C7. E2F-1 and -3 display different pRB-binding properties
Our cell cycle experiments suggest that the pRB-specific E2Fs also act after the cells have
traversed the GI/S boundary (Figures 3b, 4 and 5d). However, there is some indication that these
proteins participate in different complexes. The E2F-1 specific monoclonal antibody produces a
clear supershift that arises at the expense of the S-phase specific, free E2F complex (Figure 5d,
lane 17). Since this antibody had little detectable effect upon the pRB/E2F complexes, these data
suggest that E2F-1 is present in the predominantly free form. In the same experiment, the E2F-3
specific monoclonal antibody also produced a clear supershifted species. However, in this case,
we were unable to detect a significant reduction in any of the E2F complexes. We have therefore
used two distinct assays to try and identify the nature of the E2F-3 complex. Initially, we tested
whether the pRB-specific monoclonal antibody, XZ55, was able to alter the mobility of the
individual E2F supershifts. In this experiment, the T cell fractions were tested in a gel shift assay
with a mix of E2F and pRB specific antibodies. Since similar results were obtained at each time
point, only data from the peak S-phase fraction is shown (Figure 7a). As before, the E2F-1 and
E2F-3 specific antibodies both gave rise to a discrete supershifted band (lanes 2 and 8). However,
these bands were differentially affected by the addition of the anti-pRB monoclonal. Inclusion of
both KH20 and XZ55 (lanes 4) gave rise to two discrete supershifted species that comigrated with
the single E2F-1 (lane 2) and pRB (lanes 2) shifts respectively. This therefore supports our
previous conclusion that pRB is not a component of the E2F-1 complex. In contrast, a mixture of
LLF3-1 and XZ55 gave rise to a novel complex (lane 10) that migrated with reduced mobility
relative to the individual E2F-3 (lane 8) or pRB (lane 9) supershifted species. The formation of
this band suggests that, unlike E2F-1, the majority of the E2F-3 protein is associated with pRB.
Moreover, this partitioning was apparent at every stage of the cell cycle at which the E2F-1 and
E2F-3 DNA bound complexes were detected (data not shown).
To confirm this difference, we have used the immunoprecipitation-DOC release assay to
examine the E2F content of the pRB associated T-cell E2F activity. For this experiment, we
pooled the two T-cell fractions (54 and 60 hrs) that were previously shown to contain the majority
of the pRB-associated E2F activity (Figure 6b) and immunoprecipitated either pRB or p107
complexes. The associated E2F activity was then released by DOC-treatment and detected in gel
shift assays in the presence of the E2F antisera (Figure 7b). Consistent with our previous
experiments, antibodies against E2F-1 (lanes 2 and 7) or E2F-2 (lanes 3 and 8) failed to supershift
any of the pRB- or pl07-associated E2F activity. In contrast, LLF3-1 specifically detected a
significant amount of E2F-3 in the pRB- (lane 4) but not the p107- (lane 9) immunoprecipitate.
Not surprisingly, the E2F-4 polyclonal antisera recognized the majority of both the pRB- (lane 5)
and p107- (lane 10) associated E2F activity, giving rise to a large smear of supershifted bands.
Although the apparent lack of association between pRB and either E2F-1 or E2F-2 may be due to
the detection limits of this assay, these experiments reveal a major difference in the binding profile
of E2F- I1 and E2F-3. Despite the fact that these two proteins are present at similar levels, E2F-1
remains predominantly free in all fractions in which it was detected, while the majority of E2F-3
seems to remain bound to the retinoblastoma protein.
D. Discussion
E2F is known to play a pivotal role in coupling the coordinate expression of cell cycle
proteins to their appropriate transition points. Although the field has made considerable progress
in establishing both the properties and regulation of the individual E2F/DP heterodimers, we do
not understand how these complexes bring about the differential activation of different target
genes. Several groups have reported that the individual E2F/DP heterodimers bind specifically to
either pRB (E2F-1, -2 and -3) or p107/p130 (E2F-4 and -5) in vivo (Biejersbergen et al., 1994;
Dyson et al., 1993; Ginsberg et al., 1994; Hijmans et al., 1995; Lees et al., 1993; Sardet et al.,
1995Vairo et al., 1995). It is generally accepted that this specificity will play a major role in
determining both the timing and length of activation of these E2F complexes. It has also been
suggested that differences in either the intrinsic properties of the E2F/DP heterodimers and/or the
modulating effect of the associated regulatory protein(s), would be sufficient to somehow ensure
that these different E2F subclasses target different E2F responsive genes. Differences in E2F
target gene specificity could also explain why pRB and not p107 or p130 is a tumor suppressor.
In this study, we document the cell cycle regulation of the individual E2F/DP heterodimers
and their associated regulatory proteins. Both the components of the complexes and the timing of
their appearance is summarized in Figure 8. These findings considerably alter our interpretation of
the relative roles of the individual E2Fs. Most surprising, our data indicate that a single E2F/DP
complex, E2F-4/DP-1, is responsible for the majority of the endogenous E2F DNA binding
activity. Moreover, this complex interacts in turn with each of the known E2F regulatory proteins,
including the retinoblastoma protein. In Go cells, E2F-4 and an unidentified E2F that has
properties similar to those described for E2F-5, were sufficient to account for all of the
endogenous E2F activity. In both cases, these complexes were associated with p130 and
presumably transcriptionally inactive. Once the cells re-entered the cell cycle the unidentified E2F
complex disappeared rapidly while the levels of E2F-4 increased continually. By mid-GI, we
were able to detect significant quantities of free, presumably transcriptionally active E2F-4/DP- 1.
Although the levels of the p 130/E2F-4 complex were in decline, this was insufficient to account
for the rise in levels of free E2F-4/DP-1. The mid-G 1 "free" E2F must therefore be composed of
a combination of p 30-released and newly synthesized protein. Most known E2F responsive
genes are first transcribed at the G1/S-transition (reviewed in Nevins, 1992), considerably later
than the appearance of the free E2F-4. In fact, northern analysis confirms that the transcription of
at least one known E2F-responsive gene, E2F-1, is not detected until 12 hours after the appearance
of the free E2F-4 (our unpublished data). This suggests that this initial free E2F-4 does not
activate the transcription of the known G1/S-responsive genes. Obviously, it will be important to
determine whether this E2F-4 complex activates a different set of responsive genes or whether it
requires an additional modification (for example phosphorylation) to give rise to a transcriptionally
active complex.
Once cells reach the G 1/S boundary, we detected a significant increase in the total level of
E2F activity that continues throughout S-phase. Consistent with the induction of p107 and pRB
expression, this increase arises largely from the appearance of p1 07- and pRB-containing
complexes. Surprisingly, both of these complexes are almost entirely composed of E2F-4/DP- I1
and this occurs without any apparent reduction in the level of free E2F-4 species. This suggests
that the increased synthesis of this protein is sufficient to match the increasing demand for E2F-4.
Our data have suggested that the mid-G 1, free E2F-4 (consisting of p 30-released and newly
synthesized protein) does not activate the "GI/S" class of E2F responsive genes. This raises
questions about the target specificity of the S-phase free E2F-4 complex. At this time, we assume
that the free E2F-4 may include forms that have been released from association with either p107
and/or pRB. If the regulatory proteins influence the target specificity of their associated E2Fs, this
S-phase E2F-4/DP-1 activity could activate the transcription of responsive genes that the mid-G 1
complex was unable to target.
The S-phase activity is further complicated by the appearance of E2F-1 -2 and -3 as well as
an additional E2F that is clearly detectable in DOC-release experiments. Unlike the Go complex,
there are no good candidates for this novel species suggesting that it may correspond to an as yet
unidentified, sixth E2F. The E2F-1, -2 and -3 proteins are absent in arrested cells and are not
expressed until the G 1/S-transition. Once synthesized, these proteins are quickly detected in DNA-
dependent assays suggesting that DP association is not a rate limiting step in the formation of
active E2F/DP complexes. In all cell types examined (ML-1, C33-A and human thymocytes),
E2F-2 seems to be a very minor component of the endogenous E2F activity and we were unable
to determine the relative levels of the bound and free forms of this protein. In contrast, E2F- 1 and
E2F-3 were both clearly detectable. Strikingly, although these proteins were present at roughly
similar levels (as judged by both westerns and DOC-release assays) they appear to be present in
very different forms. Through S-phase, G2 and M, the majority of E2F-3 remains associated with
the retinoblastoma protein in a presumably inactive form. In contrast, E2F-1 is predominately
detected within a free E2F complex in agreement with previous studies (Chittenden et al., 1993).
In fact, although the total S-phase levels of E2F-4 vastly exceed those of E2F-1, these proteins
seem to contribute almost equally to the amount of free E2F that is present at this stage of the cell
cycle.
These observations raise important questions as to the underlying mechanism(s) that
determines whether or not a particular E2F is free. At this time, it is not clear how the p 130/E2F
and pl07/E2F complexes are regulated. In contrast, it is generally accepted that dissociation of the
pRB/E2F is induced by the cell cycle dependent phosphorylation of the retinoblastoma protein.
Since our data show that pRB is being continually synthesized throughout S-phase, the presence of
these late pRB/E2F complexes does not challenge the model. However, it does not help to address
why we detect major differences in the bound:free ratio of E2F-1, -3 and -4 or why pRB does not
bind to E2F during G 1. It is possible that the level of these E2Fs exceeds that of the unbound
retinoblastoma protein and these differences reflect differences in its affinity/avidity for the three
E2Fs. Although we cannot rule this out, both the levels of pRB and the in vitro binding properties
of the individual E2F/DP species are inconsistent with this model. Alternatively, one has to argue
that these complexes are modified in different ways. It has recently been reported that
phosphorylation of E2F can increase its affinity for pRB (Peeper et al., 1995). If this is true in
vivo, differential phosphorylation of the individual E2F/DPs would significantly influence their
relative pRB-binding properties. Finally, one could imagine that the E2F/pRB complexes are
formed with equal efficiency but dissociated at different rates because the cdks somehow recognize
the individual E2F/pRB complexes with varying degrees of efficiency. Understanding what
determines the bound:free ratio of the individual E2F/DPs will become increasingly important if
these complexes are found to activate different target genes.
In light of the models discussed above, it is of note that additional forms of E2F-1 and
E2F-4 appeared in the western blots in the S-phase fractions. At the same time, E2F-3 was
consistently detected as a single species. It is interesting to speculate that these differences reflect
changes in the phosphorylation of these proteins that specifically effect the free E2F species. This
would be consistent with the recent finding that the free E2F-1/DP complex is specifically
phosphorylated by the S-phase kinase, cyclin A/cdk2, and that this is sufficient to inhibit its DNA
binding and transcriptional activity (Dynlacht et al., 1994; Krek et al., 1994). Obviously, further
studies are required to determine both the nature and the functional consequences of these in vivo
modifications.
A long term goal of the field has been to understand why pRB, but not p107 or p130, is a
tumor suppressor. This is particularly confusing because these proteins display many of the same
characteristics: all three contribute to the regulation of E2F and all are targeted by the transforming
proteins of the small DNA tumor viruses. The finding that the individual E2Fs bound with high
specificity to either pRB or p107/p 130 offered a possible explanation for pRB's unique properties.
This model proposes that the pRB- and p107/p130-specific E2Fs activate different E2F responsive
genes and the pRB-E2F targets are the ones that confer a growth advantage. The observation that
E2F-4 is also regulated by the retinoblastoma protein suggests that pRB may be the tumor
suppressor because only its loss is sufficient to mobilize the vast majority of the endogenous
E2F/DP species.
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Figure 1. Specificity of the E2F antisera. (A) Anti-E2F antibodies were tested in gel shift assays
using whole cell extracts (5 tg per lane) of C33-A cells that were transiently transfected with the
indicated CMV-E2F and CMV-DP expression vectors. Where noted, gel shift reactions contained
1k1 of monoclonal antibody supernatant specific for E2F-1 (KH20), E2F-2 (LLF2-1) or E2F-3
(LLF3-1). The anti-E2F-4 lanes contain lg1 of a 1:10 dilution of mouse polyclonal sera. (B)
Anti-E2F antibodies were tested in western assay using whole cell extract (20gg per lane) derived
from C33-A cells transiently transfected with the indicated CMV-E2F and CMV-DP expression
vectors. Blots were probed with antisera specific to E2F-1 (KH20), E2F-2 (LLF2-1), E2F-3
(LLF3-1) or E2F-4 (Santa Cruz #sc-512x) as indicated.
Figure 2. E2F-1, -2, -3 and -4 associate with pRB in vivo. (A) Asynchronous ML-1 whole cell
extract (800 gg per lane) was immunoprecipitated by either PAb419 (anti-T antigen), XZ55 (anti-
pRB) or SD6 (anti-p107) and the immune complexes treated with 0.72% sodium deoxycholate
(DOC) to release associated E2F activity. The supernatants were then analyzed in E2F gel shift
assays in the presence of l gl of the anti-E2F-1 (KH20), anti-E2F-2 (LLF2-1) or anti-E2F-3
(LLF3-1) tissue culture supernatant or ll of the diluted anti-E2F-4 polyclonal sera. Binding
reactions containing multiple antibodies included 11 of each of the indicated antibodies.
(B) Asynchronous ML-1 whole cell extract (5000 jgg per lane) was immunoprecipitated with
XZ55 (anti-pRB) and the immune complexes released as described above. Supernatants were
analyzed in E2F gel shift assays in the presence of 1 jtl of anti-E2F-1 (KH20), anti-E2F-2 (LLF2-
1), anti-E2F-3 (LLF3-1) or lI of the diluted anti-E2F-4 polyclonal sera. Reactions containing
multiple antibodies included I l of each of the indicated antibodies.
Figure 3. Cell cycle expression of the E2F proteins. (A) [3H] thymidine incorporation into T
cells at the indicated times following addition of PHA. (B) The levels of E2F-1, -3, -4, pRB and
p107 in each of the T cell fractions was assessed by western blotting. Each lane contained 15jtg of
whole cell extract. The filters were probed with a 1/5 dilution of the E2F-1 (KH20), E2F-3
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(LLF3-1), pRB (cocktail of XZ77 and XZ91) or p 107 (cocktail of SD2, SD6, SD9 and SD15)
tissue culture supernatant or a 1:1000 dilution of the anti-E2F-4 mouse polyclonal antisera, #sc-
512x.
Figure 4. Cell cycle dependent E2F DNA binding activity. The T cell whole cell extracts (6gtg per
lane) were preincubated with 0.6% sodium deoxycholate in order to dissociate higher order
complexes. These samples were then analyzed in E2F gel shift assays in the presence of 2 l of
tissue culture supernatant [PAb419 (anti-Tag), KH20 (anti-E2F-1), LLF2-1 (anti-E2F-2), LLF3-1
(anti-E2F-3)] and/or lgl of the diluted polyclonal anti-E2F-4 as indicated. The bracket denotes the
position of the "free" E2F, as determined by competition with unlabeled wildtype E2F binding
site. The non-competable activity is also indicated. In each case, the position of the supershifted
complex(es) is marked with an arrow. All gels were exposed for 4 days, except the anti-E2F-2 gel
which was exposed for 8 days.
Figure 5. Cell cycle regulation of the individual E2F complexes. The T-cell whole cell extracts
(8gg per lane) were analyzed in the E2F gel shift assay in either the absence (A) or the presence of
the following antisera: (B) 2gtl of the anti-pRB (XZ55) or anti-pl07 (SD6) tissue culture
supernatant; (C) 2 l of the anti-DP-1 (WTH 1) tissue culture supernatant or 1 gl of the anti-DP-2
(Santa Cruz #sc-829x) polyclonal antisera; (D) 2tl of the anti- E2F-1 (KH20), anti- E2F-2 (LLF2-
1) or anti- E2F-3 (LLF3-1) tissue culture supernatant or 1k1 of the diluted polyclonal anti-E2F-4.
In each case, complexes are labeled as described in the text.
Figure 6. Cell cycle regulation of the pRB-associated E2F activity. (A) Time course of [3H]
thymidine incorporation into human T cells at the indicated times following addition of PHA.
(B) T cell whole cell extract (500 gg) from each of the indicated time points was subject to
immunoprecipitation with anti-pRB (XZ55) tissue culture supernatant. Associated E2F activity
was released by incubation of the precipitates in 0.72% sodium deoxycholate and the supernatant
was analyzed by E2F gel shift assay.
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Figure 7. Identification of the pRB-associated E2F activity. (A) Whole cell extracts (8gg per
lane) from the 54 hr time point of the first batch of T cells were analyzed in E2F gel shift assays in
the presence of 2 l of the indicated anti-E2F monoclonal antibody and/or the pRB-specific XZ55.
(B) Whole cell extracts containing the peak pRB-associated E2F activity of the second batch of T
cells (54 hr and 60 hr) were pooled and 500 gg total protein was subject to immunoprecipitation
with either the anti-pRB (XZ55) or the anti-pl07 (SD6) tissue culture supernatant. Associated
E2F activity was released by incubation in the presence of 0.72% sodium deoxycholate and the
supernatant was analyzed in E2F gel shift assays in the absence or presence of either 1 tl of the
anti- E2F-1 (KH20), anti- E2F-2 (LLF2-1) or anti- E2F-3 (LLF3-1) tissue culture supernatant or
iRl of the diluted polyclonal anti-E2F-4.
Figure 8. Diagrammatic representation of the cell cycle dependence and identity of the various
E2F complexes. Complexes are labeled A-H according to the nomenclature used in the text; their
constituent E2F and pocket-protein moieties are indicated.
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F. Materials and Methods
Plasmid construction.
The cDNA clones encoding E2F-1, -2, -3, and -5 and DP-1 and -2 have been described previously
(Helin et al., 1992; Hijmans et al., 1995; Lees et al., 1993; Sardet et al., 1995; Wu et al., 1995).
The E2F-4 cDNA clone was isolated by screening a Nalm-6 human pre-B cell library with a
degenerate probe derived from sequences encoding the C-terminal 15 amino acids of the minimal
DNA binding domains of E2F-1, -2 and -3 (our unpublished data). The sequence of this clone is
identical to those described previously (Beijersbergen et al., 1994; Ginsberg et al., 1994).
Plasmids encoding the 6x His-tagged E2F proteins were each constructed using the vector pQE8
(Qiagen). pQE8-E2F-2 (1-437) was generated by subcloning a BglII fragment encompassing the
complete E2F-2 open reading frame from pCMV-E2F-2 into the BamHI site of pQE8.
Sequences encoding amino acids 1-244 of E2F-3 and 147-413 of E2F-4 were amplified by
polymerase chain reaction with Vent polymerase (NEB) using the following primers: 31.6
[GATCGGATCCATGGTGAGAAAGGGAATCCAGCCC] & 31.3 [GATCGGATCCT
CAGCCCATCCATTGGACGTTG] (E2F-3) and TPF4 [GATCGGATCCAGATGCTTTGCT
GGAGATAC] & 4.15 [GATCGGATCCTCAGAGGTTGAGAACAGGCAGATC] (E2F-4).
The resulting products were digested with BamHI and subcloned into pQE8 to generate pQE8-
E2F-3 (1-244) and pQE8-E2F-4 (147-413) respectively. The eukaryotic expression vectors were
constructed in pCMV-Neo-Bam (Baker et al., 1990). pCMV-E2F-1 (1-437), pCMV-E2F-2 (1-
437) and pCMV-HA-hDP-1 (1-410) have been described previously (Helin et al., 1992; Lees et
al., 1993; Wu et al., 1995). The E2F-5 eukaryotic expression vector pcDNA3-E2F5 has been
described previously (Sardet et al., 1995) and was a kind gift of C. Sardet. Sequences
encompassing the complete E2F-3 open reading frame (425 amino acids) were prepared by
polymerase chain reaction with Vent polymerase (NEB) using the primers 31.6 (as above) &
31.15 [CTAGGATCCGGATCGAAGGAGAGTTCACACGAAGC]. The amplified fragment
was digested with BamHI and subcloned into pCMV-Neo-Bam to generate pCMV-E2F-3 (1-
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425). The complete E2F-4 open reading frame was excised from pBKS-E2F-4 as a EcoRV-
BamHI fragment and transferred to pCMV-Neo-Bam using BamHI linkers (NEB).
Polyclonal and monoclonal antibody production
6x His-tagged E2F-2 (amino acids 1-437), E2F-3 (amino acids 1-244) or E2F-4 (amino acids
147-413) polypeptides were expressed in bacteria, purified over Ni2+-NTA-Agarose resin
(Qiagen) and used to immunize female BALB/c mice. The resultant polyclonal antisera was
monitored by testing its ability to specifically supershift transfected E2F-2, -3 or -4/DP-1
complexes in gel shift assays or recover transfected E2F-2, -3 or -4/DP-1 complexes in
immunoprecipitation assays.
In the case of both E2F-2 and E2F-3, as little as 1 p1 of a 1:100 dilution of the polyclonal
antisera was sufficient to detect the correct E2F/DP complex. These mice were sacrificed and the
spleens removed. Hybribomas were generated by PEG-mediated fusion of the recovered
splenocytes to the SP2/O cell line. Eight days post fusion the tissue culture supernatants were
screened for their ability to detect the relevant 6xHis-tagged purified proteins by ELISA. These
positive supernatants were then screened for their ability to specifically supershift transfected E2F-
2 or -3/DP-1 complexes in gel shift assays, recover transfected E2F-2 or -3/DP-1 complexes in
immunoprecipitation assays or western blot assays. The positive hybridoma cell lines were
separated from other hybridomas using limiting dilution and then single cell cloning.
The monoclonal antibodies KH20 (anti-E2F-1), WTH 1 (anti-DP-1), XZ55, XZ77 and
XZ91 (anti-pRB), and SD2, SD6, SD9 and SD15 (anti-pl07) (Dyson et al., 1993) were a gift of
Nick Dyson and Ed Harlow.
Tissue culture
The human lines ML-1 (premyeloid leukemia) and C33-A (cervical carcinoma) were grown under
standard conditions in Dulbecco's modified Eagle medium supplemented with 10% fetal calf
serum. Transient transfections into C33-A cells were carried out by standard CaPO4 precipitation
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methods (Ausubel et al., 1988). Ten cm dishes of C33-A cells at 50% confluence were transfected
with O1gg of each of the E2F and DP expression plasmids plus 10gg of carrier DNA. Cells were
washed 16 hours post-transfection and re-fed with fresh media. Cells were harvested 24 hours
later and whole cell extracts prepared as described below.
For T cell preparations, buffy coats from human blood were obtained from the
Massachusetts General Hospital Blood Bank. The mononuclear cell layer was isolated by
centrifugation on a Ficoll-Paque cushion (Pharmacia) and then washed twice with phosphate
buffered saline. Mononuclear cells were then resuspended at 2.0 X 106 cells per ml in RPMI
supplemented with 10% heat-inactivated fetal calf serum and 1 gg of phytohemagglutinin (PHA,
Murex UK) per ml to stimulate T-cell proliferation. Cells were harvested at the indicted times and
the majority were used to prepare whole cell extracts as described below. At each time point,
thymidine incorporation was also assayed by incubating 1ml of cultured T cells for 30 min in the
presence of 10 gCi of [3H]thymidine. After washing, these cells were lysed in 0.3N NaOH,
spotted onto GF/C glass filters (Whatman), TCA precipitated and counted.
Gel shift assays
Whole cell extracts were prepared from ML-1, C33-A and T cells using standard procedures.
Briefly, cells were lysed at 5 x 106/0.1 ml in 0.5 M KC1, 35% glycerol, 100 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES; pH 7.4], 5 mM MgCl2, 0.5 mM
ethylenedinitrilo-tetraacetic acid [EDTA; pH 8.0], 5 mM NaF, 1 mM phenylmethylsulfonyl
fluoride, 1 mM dithiothreitol [DTT], 5 gg/ml aprotinin, 5 gg/ml leupeptin and then spun at 40 C
for 45 min at 40,000rpm in a TLA45 rotor (Beckman) to remove cell debris. Supernatants were
removed and protein concentrations determined (Protein Assay Reagent, BioRad). Gel shift
reactions were performed as follows. The initial DNA binding mixtures contained 1 gg of
sonicated salmon sperm DNA and 5-8 gg of whole cell extract (as indicated in the figure legends)
in 20 gl of 50 mM KC1, 20 mM HEPES, pH 7.4, 1 mM MgC12 , 8.5% glycerol, 1 mM EDTA,
pH8.0. For experiments involving T cell extracts, 75 ng of double-stranded mutant E2F
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oligonucleotide (ATTTAAGTTTCGatCCCTTTCTCAA) was also included in the binding reaction
to inhibit the formation of non-specific DNA complexes. Samples were incubated 10 min on ice
prior to the addition of 1 ng of 32P-end-labeled, double-stranded, wildtype E2F oligonucleotide
(ATTTAAGTTTCGCGCCCTTTCCAA). Binding reactions were incubated a further 10 min on
ice followed by 15 min at room temperature. The samples were then analyzed by electrophoresis
at 180V at 40 C in 4% polyacrylamide gels buffered with 0.25X TBE (22 mM Tris, 22 mM
borate, 0.5 mM EDTA).
Deoxycholate (DOC)-treated gel shift reactions were performed in an identical manner
except for the presence of 0.6% sodium deoxycholate (SIGMA) in the initial binding mixture and
the addition of Nonidet P-40 to 1% at the beginning of the room temperature incubation step. In
both standard and DOC-treated gel shift reactions, competitions were carried out by the addition of
100 ng of unlabeled double-stranded wildtype or mutant E2F oligonucleotide prior to the addition
of cell extract. Where indicated, hybridoma supernatant or diluted polyclonal antisera was also
added to the DNA binding reactions prior to the addition of cell extract.
Immunoprecipitation-DOC release assays
Immunoprecipitation-deoxycholate-released proteins were generated from the standard ML-1 or T-
cell whole cell extracts. 500-5000 jtg extracts were incubated on a rocking platform for 60 min at
40 C with 200 jtl of the indicated hybridoma supernatants in lX IP-DOC buffer (20 mM HEPES,
pH 7.4, 40 mM KC1, 1 mM MgCl2, 0.1 mM EDTA, pH 8.0) containing 3 mg bovine serum
albumin (BSA) per ml. Immune complexes were recovered on Protein A-Sepharose beads
(Pharmacia) and then washed three times in 1X IP-DOC buffer. The associated proteins were
released by the addition of 10 gtl of 0.72% sodium deoxycholate in IX IP-DOC buffer. Nonidet
P-40 was added to a final concentration of 1.5% and the supernatants assayed in the gel shift
protocol described above.
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Western blots
Whole cell extract was prepared from T cells as described above. The indicated amounts of
cellular protein were separated by 8% SDS-PAGE and transferred onto Immobilon-P membranes
(Millipore) by electrophoresis for 16 h at 20V in 390mM glycine, 50mM Tris, 20% methanol.
The membranes were blocked in IX TBST (10mM Tris pH 8.0, 150mM NaC1, 0.2% Tween-20)
containing 5% dry milk for 2 h at room temperature and then immunoblotted with the indicated
antibodies. Horseradish peroxidase-linked sheep anti-mouse Ig or HRP-linked donkey anti-rabbit
Ig (Amersham) were used as secondary antibodies and the blots developed using the ECL system
(Amersham).
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A. Abstract
E2F directs the cell-cycle dependent expression of genes that induce or regulate the cell
division process. In mammalian cells, this transcriptional activity arises from the combined
properties of multiple E2F*DP heterodimers. In this study, we show that the transcriptional
potential of individual E2F species is dependent upon their nuclear localization. This is a
constitutive property of E2F-1, -2 and -3, whereas the nuclear localization of E2F-4 is dependent
upon its association with other nuclear factors. We have previously shown that E2F-4 accounts
for the majority of endogenous E2F species. We now show that the subcellular localization of
E2F-4 is regulated in a cell-cycle-dependent manner that results in the differential
compartmentalization of the various E2F complexes. Consequently, in cycling cells, the majority
of the p107*E2F, p130*E2F and free E2F complexes remain in the cytoplasm. In contrast, almost
all of the nuclear E2F activity is generated by pRB*E2F. This complex is present at high levels
during G1 but disappears once the cells have passed the restriction point. Surprisingly,
dissociation of this complex causes little increase in the levels of nuclear, free E2F activity. This
observation suggests that the repressive properties of the pRB*E2F complex will play a critical role
in establishing the temporal regulation of E2F responsive genes. How the differential subcellular
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localization of pRB, p107 and p130 contributes to their different biological properties is also
discussed.
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B. Introduction
E2F is a transcriptional regulator that plays a pivotal role in the regulation of cellular
proliferation (reviewed in Nevins, 1992 and Beijersbergen and Bernards, 1996). Many E2F-
responsive genes have been identified and their products are components of either the cell cycle
control (e.g. cyclin E, cyclin A and cdc2) or DNA synthesis (e.g. dihydrofolate reductase,
thymidine kinase or DNA polymerase a) machinery. In each case, E2F is thought to restrict the
expression of these genes to the point of the cell cycle at which their products act (Hsiao et al.,
1994).
E2F is regulated by the retinoblastoma protein (Bagchi et al., 1991; Bandara and La
Thangue, 1991; Chellappan et al., 1991), a tumor suppressor that is functionally inactivated in a
large proportion of all human tumors (reviewed in Weinberg, 1992). Consistent with its anti-
proliferative role, the retinoblastoma protein (pRB) blocks the ability of E2F to activate
transcription (Hiebert et al., 1992; Helin et al., 1993b). In addition, over-expression studies
indicate that the resultant pRB*E2F complex can act as a transcriptional repressor, in which E2F
provides the sequence specific DNA binding activity and pRB inhibits transcription by
sequestrating adjacent transcription factors (Adnane et al., 1995; Bremner et al., 1995; Sellers et al.,
Weintraub et al., 1992; Weintraub et al., 1995). This suggests that E2F participates in both the
activation and inhibition of cellular proliferation. Consistent with this hypothesis, homozygous
deletion of the murine E2F-1 gene causes atrophy in some tissues and tumors in others (Field et
al., 1996; Yamasaki et al., 1996).
The growth inhibitory properties of pRB are regulated by its cell cycle dependent
phosphorylation (reviewed in Bartek et al., 1996). Phosphorylation is catalyzed by one or more of
the cell cycle dependent kinases (Ewen et al., 1993; Hinds et al., 1992; Hu et al., 1992; Lees et al.,
1991; Matsushime et al., 1994; Meyerson et al., 1994) and over-expression studies indicate that
this modification is essential for S-phase entry (Hinds et al., 1992). In vivo studies confirm that
the phosphorylation of pRB is sufficient to induce the release of free, presumably transcriptionally
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active E2F (Chellappan et al., 1991). Because of the dual role of the E2F complex,
phosphorylation of the retinoblastoma protein provides a simple mechanism to switch E2F-
responsive genes from the fully repressed to the fully induced state. Consistent with this model,
the timing of transcriptional activation of E2F responsive genes correlates closely with the
induction of pRB phosphorylation at the GI/S transition.
Our understanding of E2F is complicated by the finding that this activity is regulated by
two other proteins, p107 and p130 (Cao et al., 1992; Cobrinik et al., 1993; Devoto et al., 1992;
Shirodkar et al., 1992). These two proteins share significant sequence similarity with the
retinoblastoma protein (Ewen et al., 1991; Hannon et al., 1993; Li et al., 1993; Mayol et al., 1993)
and over-expression studies confirm that they can regulate E2F in a similar manner (Starostik et
al., 1996; Zhu et al., 1993). Despite these similarities, pRB, p107 and p130 interact with E2F at
different stages of the cell cycle (Cao et al., 1992; Chittenden et al., 1993; Cobrinik et al., 1993;
Lees et al., 1992; Mudryj et al., 1991; Shirodkar et al., 1992). Moreover, unlike the pRB*E2F
complex, the timing of appearance or disappearance of the p130eE2F and p107*E2F species does
not correlate with the timing of repression or activation of known E2F responsive genes. These
findings suggest that pRB, p107 and p130 do not regulate E2F in the same way in vivo and
genetic analyses confirm that these proteins have different biological consequences. While pRB is
mutated in 30% of all human tumors, neither p107 or p130 is a tumor suppressor (Weinberg,
1995). Similarly, the mutation of pRB, p107 or p 130 within otherwise isogenic mouse strains
gives rise to very different phenotypes (Clarke et al., 1992; Cobrinik et al., 1996; Jacks et al., 1992;
Lee et al., 1992; Lee et al., 1996). Clearly, the different biological consequences of pRB, p107 and
p130 action could reflect differences in their regulation of E2F or of non-E2F targets.
To date, at least seven human genes have been identified that encode components of the
E2F transcriptional activity (reviewed in Beijersbergen and Bernards, 1996). These can be divided
into two distinct groups, termed E2F (1 through 5) and DP (1 and 2), that share little sequence
similarity. E2F and DP proteins heterodimerize and this association is essential for high affinity
DNA binding, transcriptional activity and interaction with pRB, p107 or p130 (Bandara et al.,
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1993; Helin et al., 1993a; Krek et al., 1993; Sardet et al., 1995; Wu et al., 1995). In vivo studies
have confirmed that the endogenous E2F activity arises from the concerted action of multiple
E2F*DP complexes (Moberg et al., 1996; Wu et al., 1995). These individual E2FoDP complexes
have different pRB, p107 and p130 binding properties. Complexes containing E2F-1, -2 or -3
associate with pRB, but not p107 or p130 in vivo (Dyson et al., 1993; Lees et al., 1993). In
contrast, E2F-4 and -5 complexes have been reported to bind preferentially to p107 and p130
(Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995; Vairo et al., 1995).
Consistent with these findings, sequence comparisons indicate that E2F-1, -2 and -3 are more
closely related to each other than they are to E2F-4 and -5. Taken together, these observations
suggest that the two E2F subsets (E2F-1, -2 and -3 versus E2F-4, and -5) will play distinct roles
in vivo that will at least partially account for the different biological consequences of pRB, p107
and p130 action. Overexpression assays have revealed some differences in the properties of the
individual E2F*DP complexes (DeGregori et al., 1995; Hofmann et al., 1996; Lukas et al., 1996)
but the mechanistic distinction(s) between these species remains unclear.
We have previously characterized the cell cycle regulation of the individual E2FoDP
complexes (Moberg et al., 1996). This study revealed clear differences in the relative contribution
and potential activity of these species. E2F- 1, -2, -3 and -5 exist at low levels in vivo and together
comprise less than a third of the endogenous E2F species. In contrast, E2F-4 accounts for the
majority of E2F complexes at every stage of the cell cycle. Moreover, in addition to binding p107
and p130, E2F-4 was found to be the major component of the pRB-associated E2F activity.
These findings suggest that E2F-4 plays a pivotal role in establishing the biological properties of
the cellular E2F activity. Nevertheless, we also found that the appearance of free E2F-4*DP,
which occurs early in G1, is insufficient to induce the activation of known E2F-responsive genes.
This observation can be explained in two distinct ways; (i) the transcriptional activity of free E2F-4
is regulated by an unknown mechanism and/or (ii) it is directed at an unknown set of target genes.
Since E2F-4 accounts for most of the endogenous E2F species, either mechanism will have a
profound effect upon the biological consequences of E2F action.
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In this study, we have used a combination of in vitro and in vivo assays to investigate these
two hypotheses. These experiments did not allow us to examine whether E2F-4 has a different
target specificity from the other E2Fs. However, our data indicate that, unlike E2F-1, -2 and -3,
the transcriptional activity of E2F-4 is regulated at the level of subcellular localization. In vivo, the
nuclear localization of E2F-4 is restricted to certain stages of the cell cycle and is limited to a
specific subset of the E2F-4 complexes. This novel mode of E2F-4 regulation provides new
insight into the molecular mechanism(s) that establish the different biological properties of the
individual E2F family members and may offer important insight into the in vivo roles of the E2F
regulators, pRB, p107 and p130.
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C. Results
C1. In vivo expression of E2F-4 inhibits its transcriptional activity
Our previous studies indicate that the appearance of free E2F-4 complexes is not sufficient
to trigger the activation of known E2F-responsive genes (Moberg et al., 1996). This observation
suggests two potential models of E2F-4 action; either its transcriptional activity is regulated by an
unknown mechanism or it is directed at an unknown set of target genes. To distinguish between
these two models, we generated stable cell lines that express the individual E2F proteins in an
inducible manner. In this system, the expression of a given transgene is controlled by a
transcriptional regulator, the hybrid VP16 -tetracycline repressor, whose activity is inhibited in the
presence of tetracycline (Gossen and Bujard, 1992). Using this approach, we selected two cell
lines (called U2F2 and U2F4) that expressed either E2F-2 or E2F-4 in a strictly regulated manner
(Figure 1 a). When cultured in the presence of tetracycline, the levels of E2F-2 or E2F-4 in the
U2F2 or U2F4 cell lines were similar to those detected in the parental cell line. In contrast,
tetracycline withdrawal produced a modest increase in E2F-2 (between 3 and 8 fold) in the U2F2
cells and a dramatic increase in E2F-4 (greater than 40 fold) in the U2F4 cells.
To establish the biological properties of the induced E2F proteins, we compared the level
of E2F DNA binding activity and transcriptional activity present in the U2tTA10, U2F2 or U2F4
cells after culture in either the absence or presence of tetracycline. DNA binding was assessed by
screening whole cell lysates for their ability to bind to the consensus E2F site in a gel retardation
assay (Figure lb). Consistent with our expression data, the uninduced cells contained similar
levels of E2F DNA binding activity. In contrast, induction of the U2F2 and U2F4 cell lines
increased the levels of a single E2F complexes, the fastest migrating, free E2F species. Supershift
experiments confirmed that this was caused by a direct increase in the level of either free E2F-
2*DP (U2F2) or E2F-4*DP (U2F4, Figure lb). These data indicate that the induction of E2F-2 or
E2F-4 resulted in an increase in the level of free E2F-2 or E2F-4 complexes without altering the
other, endogenous E2F species. The transcriptional activity of these induced E2F complexes was
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tested by transiently transfecting these cells with an artificial E2F-responsive reporter, called E2F4-
CAT, in which the expression of the chloramphenicol acetyl transferase (CAT) gene is controlled
by a minimal promoter containing the E1B TATA box and four consensus E2F sites (Helin et al.,
1993a). This reporter was selected because it has been shown to respond with similar efficiency to
free E2F-2*DP and E2F-4*DP complexes in in vitro transcription assays (Dynlacht et al., 1997).
Although induction of the U2F2 cell line produced a relatively small increase in the levels of E2F-
2*DP complexes (Figure lb), the E2F transcriptional activity increased by more than 11 fold
(Figure Ic). In contrast, tetracycline withdrawal caused little change in the transcriptional activity
of the U2F4 cells, despite the much greater increase in the level of free E2F-4*DP complex
(Figures lb and c). Since this complex can efficiently activate this reporter in vitro, we conclude
that there are additional factors in vivo that prevent activation of transcription by the free E2F-4.
Although this finding does not rule out the possibility that the individual E2F proteins activate
different target genes in vivo, it suggests the existence of an unidentified regulatory mechanism that
controls the activity of E2F-4 differently from that of E2F-2.
C2. The transcriptional activity of E2F-4 is inhibited by its cytoplasmic localization.
To determine the mechanism responsible for the inhibition of E2F-4 transcriptional
activity, we investigated whether there were any obvious differences in the regulation of the
individual E2F proteins. As part of this study, we examined the localization properties of E2F
proteins that have been expressed in micro-injection assays (Figure 2a). Consistent with their role
as transcriptional regulators, the three pRB-specific E2Fs, E2F-1, -2 and -3, were all detected in
the nucleus. In contrast, the vast majority of the E2F-4 protein localized to the cytoplasm.
Although we could not rule out the possibility that the localization of this protein was an artifact of
its over-expression and presumably monomeric state, this finding strongly suggested that the
differential localization of E2F-2 and E2F-4 might account for the differences in their
transcriptional activity revealed in the inducible cell lines. To test this hypothesis, we used indirect
immunofluorescence to examine the localization of E2F-2 or E2F-4 that had been induced in the
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U2F2 or U2F4 cells (Figure 2b). These proteins are expressed at considerably lower levels than
those produced in the micro-injection assays and therefore a much greater proportion form
productive E2F*DP heterodimers. However, their localization was identical to that observed by
micro-injection; E2F-2 was detected in the nucleus while E2F-4 was predominantly cytoplasmic
(Figure 2b). These findings suggest that the transcriptional activity of exogenously expressed
E2F-4 is inhibited in vivo by its cytoplasmic localization.
C3. Localization of the endogenous E2F-4 protein is regulated in a cell cycle dependent
manner.
We have previously shown that the appearance of endogenous free E2F-4 complexes does
not induce the transcription of known E2F responsive genes (Moberg et al., 1996). Our data now
suggest that the transcriptional activity of these complexes could be blocked by their sequestration
in the cytoplasmic compartment. To test this hypothesis, we compared the subcellular localization
of the endogenous E2F proteins. Initially, we used standard methods to prepare nuclear and
cytoplasmic extracts for a wide variety of human cell lines. These fractions were then screened by
western blotting for the presence of either E2F- 1 or E2F-4 (Figure 3a). Regardless of the cell line,
E2F-1 was consistently detected in the nuclear fraction. Similar results were also observed with
E2F-2 and E2F-3 (data not shown). In contrast, the majority of the endogenous E2F-4 protein
was contained within the cytoplasm. These findings confirm that the endogenous E2F proteins
localize to different subcellular compartments in a similar manner to the overexpressed E2Fs. To
reinforce these data, we also examined the localization of the endogenous E2F-4 by indirect
immunofluorescence. Initially, we screened for E2F-4 in an asynchronous population of U20S
cells (Figure 3b). Within this population, the individual cells had one of two distinct staining
patterns; the E2F-4 was either predominantly cytoplasmic or it was present in both the cytoplasm
and the nucleus. This dual staining pattern was observed with multiple E2F-4 monoclonal
antibodies in several different cell types (data not shown).
122
The presence of two distinct E2F-4 staining patterns within asynchronous cells suggested
that the localization of E2F-4 might change through the cell cycle. To test this idea, we compared
the pattern of E2F-4 staining at different cell cycle stages. Initially, U20S cells were released from
a drug induced G2/M arrest and harvested at 6 hour intervals for both FACS analysis and E2F
immunofluorescence (Figure 3b). Consistent with our hypothesis, E2F-4 was detected in both
the nucleus and the cytoplasm in the enriched G1 population but was predominantly cytoplasmic in
cells that had entered S-phase. Since the pRB pathway is known to be disrupted in most if not all
tissue culture cell lines, we also examined the localization of E2F-4 in a primary human diploid
fibroblast cell line, WI-38 cells. In this case, the cells were arrested in Go/G1 by contact inhibition
and serum starvation and then stimulated to re-enter the cell cycle. The localization of E2F-4 was
then examined in the peak Go/G 1 and S-phase fractions (as judged by FACS analysis) using
immunofluorescence (Figure 3c). In this primary cell line, the cell cycle dependent change in
subcellular localization E2F-4 was even more pronounced. Almost all of the E2F-4 protein was
retained in the nucleus in the Go/G 1 population. However, by the time that the cells had entered S-
phase, the vast majority of E2F-4 was detected in the cytoplasm.
These experiments yield several important findings. First, our data suggest that E2F-4, but
not E2F-1, -2 or -3, is regulated at the level of subcellular localization. Second, these changes
appear to be linked to the state of cell cycle progression. In either GO or G1 cells, a significant
proportion of the endogenous E2F-4 is retained in the nucleus but this protein is almost entirely
cytoplasmic by S-phase. The dramatic alteration in the relative levels of nuclear to cytoplasmic
E2F-4 could be caused by either the translocation of preexisting E2F-4 or the combined effect of
the degradation of nuclear E2F-4 and appearance of newly synthesized cytoplasmic protein.
Finally, our analysis of the E2F inducible cell lines suggests that the cytoplasmic form(s) of E2F-4
are unable to activate transcription. By extension of this logic, our data suggest that the
transcriptional effects of the endogenous E2F-4 are primarily exerted during Go and G 1.
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C4. The subcellular localization of the endogenous E2F complexes changes through the cell
cycle.
The identity and regulation of the endogenous E2F complexes has been analyzed in a wide
variety of cell types and growth conditions (Cao et al., 1992; Chittenden et al., 1993; Devoto et al.,
1992; Moberg et al., 1996; Shirodkar et al., 1992). However, all of these studies have been
conducted using whole cell rather than nuclear extracts. We have previously shown that E2F-4
comprises more than 80% of the endogenous E2F species and makes a major contribution to each
of the pRB*E2F, pl07*E2F and pl30*E2F complexes (Moberg et al., 1996). The localization
properties of this protein suggested that a significant proportion of the endogenous E2F complexes
exist in the cytoplasm at certain stages of the cell cycle. To address this issue, we used
counterflow centrifugal elutriation to generate populations of a human lymphoma cell line, HL60,
that were highly enriched in either G1 (94%), S (78%) or G2/M (81%) cells. These cells were then
fractionated to yield nuclear and cytoplasmic extracts. Initially, we used western blotting to
compare the subcellular localization of the E2F- 1 and E2F-4 proteins (see Figure 4a). Regardless
of the cell cycle staging, the vast majority of the endogenous E2F- I1 protein was detected in the
nuclear fraction. In contrast, this experiment confirmed that the localization of E2F-4 changed
through the cell cycle; this protein was present in both the nucleus and cytoplasm during G 1 but
became increasingly cytoplasmic as the proportion of G1 cells declined. These changes strictly
mirrored those detected in our immunofluorescence studies.
To determine the localization of the E2F*DP complexes, we used gel retardation assays to
compare the level of E2F DNA binding activity in the cytoplasmic and nuclear fraction of each cell
cycle population (Figure 4b). These experiments demonstrated that localization has a profound
effect upon the profile of E2F complexes. In the first cell cycle fraction, comprised of 94% GI
cells, the nucleus contained considerably more E2F activity than the cytoplasm. However, the
ratio of cytoplasmic to nuclear E2F activity increased dramatically as the HL60s progressed
through the cell cycle. This change arose from two distinct effects: a steady increase in the levels
of cytoplasmic E2F activity and a dramatic reduction in the levels of the nuclear E2F complexes.
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By the last three elutriation fractions (which were almost free of contaminating G 1 cells) less than
10% of the E2F DNA binding activity was retained in the nucleus. Consistent with our finding
that E2F-4 accounts for the majority of the endogenous E2F activity (Moberg et al., 1996), the
change in the relative levels of the nuclear and cytoplasmic E2F complexes closely mirrored the
changes in the localization of the E2F-4 protein detected by either western blotting or
immunofluorescence. This experiment yielded one other critical finding: the cytoplasmic and
nuclear E2F complexes migrated with different mobilities. Of the three major E2F complexes,
two (labeled A and C) were predominantly cytoplasmic while the third (labeled B) accounted for
almost all of the nuclear E2F activity. This strongly suggested that the cytoplasmic and nuclear
E2F activities were generated by different E2F species.
C5. The pRB*E2F, p107*E2F and p130*E2F complexes localize preferentially to either the
cytoplasm or the nucleus.
The retinoblastoma protein, a known tumor suppressor, and its related proteins, p107 and
p130, are thought to play a pivotal role in determining the biological properties of the endogenous
E2F complexes (reviewed in Beijersbergen and Bernards, 1996). Although it is widely accepted
that these three proteins must regulate E2F in different ways in vivo, over-expression assays have
failed to reveal any obvious differences in the properties of the pRB*E2F, p107*E2F and
p130*E2F complexes. The experiments described above raised the possibility that these
complexes are preferentially sequestered in different subcellular compartments in vivo. To address
this hypothesis, we used specific monoclonal antibodies to identify the components of the nuclear
and cytoplasmic complexes in each cell cycle fraction. Our analysis of the peak G1 and S-phase
fractions is shown in Figure 5.
Initially, we focused our attention on identifying the E2F species that localized to the
nucleus and therefore likely participate in the transcriptional regulation of E2F-responsive genes.
In G1 cells most, if not all, of the nuclear activity arose from a single complex, Complex B (Figure
4b and 5). The supershift experiments revealed that this band comprised a mixture of E2F
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species, of which E2F-4 was the most prevalent (Figure 5, nuclear G1 phase). These nuclear, G 1
complexes also contained an associated regulatory protein. Although p107 accounted for a small
subset of these nuclear E2F species, the vast majority (>90%) contained the retinoblastoma
protein. As described above, the level of nuclear E2F DNA binding activity dropped dramatically
as cells entered S-phase. Even though present at low level, it was important that we identify these
nuclear species. To achieve this goal, we used five fold higher levels of the S-phase, nuclear
extract in the gel retardation assays (Figure 5, nuclear S-phase). Under these conditions, we were
able to demonstrate that the constituent E2F activity was generated by three distinct E2F
complexes. First, these S-phase cells contained a low level of the pRB*E2F complex (complex
B). The reduction in the level of this species (relative to G1 cells) is entirely consistent with the
known dissociation of the pRB*E2F complex at the G1/S transition (reviewed in Beijersbergen and
Bernards, 1996). Whether the remaining pRB*E2F complexes are a true component of S-phase
cells or whether they are derived from the low level of contaminating GI cells is unclear. The
other two species, labeled A and C, were both identified as E2F-4 complexes. This is consistent
with our previous finding that the nucleus contains low levels of E2F-4 protein at this stage of the
cell cycle (Figure 4a). Further analysis identified these species as free E2F-4 (complex A) and
pl07*cyclin A*E2F-4 (complex C; Figure 5).
Having characterized the nuclear E2F activity, we turned our attention to the cytoplasmic
complexes. Regardless of the cell cycle stage, we found that E2F-4 accounted for all of the
cytoplasmic activity (Figure 5). The G1 cells contained high levels of three different E2F-4
complexes, A, C and C'. Consistent with our analysis of the nuclear E2F activity, the A and C
species were identified as free E2F-4 and p1079E2F-4 respectively (Figure 5, cytoplasmic G1
phase). The remaining complex, complex C', was specifically recognized by antibodies against
p130. Although pRB*E2F was present at high levels in the nucleus of G 1 cells, this complex was
absent from the cytoplasmic fraction. Upon S-phase entry, we detected changes in the cytoplasmic
complexes that were consistent with the known cell cycle regulation of p130*E2F and pl07*E2F.
Specifically, p130*E2F-4 disappeared while the level of p107*E2F-4 increased steadily. Notably,
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this p107 complex was enriched in cytoplasmic fractions and now included the S-phase kinase,
cyclin A*cdk2, whose subcellular localization has been shown to be cell cycle-regulated (Pines and
Hunter, 1991). Finally, the level of cytoplasmic, free E2F-4 also increased considerably in cells
that had entered S-phase.
In summary, our analysis of the cell cycle fractions confirms that the endogenous E2F
complexes are regulated at the level of subcellular localization. Most importantly, the individual
E2F species were found to be preferentially located in either the cytoplasm or the nucleus. The
vast majority of the nuclear E2F activity is generated by a single species, the pRB.E2F complex,
that is present at high levels in the G 1 population In contrast, the vast majority of the remaining
E2F complexes, p130.E2F, pl07*E2F and free E2F are predominantly located in the cytoplasm.
Consistent with previous studies, the p130oE2F complex is only detected during the early stage of
the cell cycle. In contrast, the level of both the p107*E2F and free E2F species increases as cells
progress through the cell cycle and this results in a steady increase in the level of cytoplasmic E2F
activity. In each case, the cytoplasmic localization of these three E2F species correlates with the
presence of E2F-4 within the complex. This directly supports our conclusion that cytoplasmic
localization is a particular property of E2F-4 and not E2F- 1, -2 or -3. However, our data also
indicate that E2F-4 is not sufficient to ensure cytoplasmic localization, since this E2F family
member is also the major E2F component of the nuclear, pRB*E2F complex.
C6. E2F-1, -2 and -3 contain a nuclear localization signal that is absent in E2F-4.
Our data indicate that a significant proportion of the endogenous E2F species are localized
in the cytoplasm and not the nucleus. This observation suggested that subcellular localization
could have a profound influence upon the biological properties of the individual E2F complexes.
To address this issue, we need to identify the molecular mechanism(s) that control this process.
Our previous experiments suggest that this may be determined by two distinct factors. First,
localization of the E2F complexes appears to be partially dependent upon the localization properties
of the constituent E2F proteins. Complexes containing E2F-1, -2 or -3 are exclusively nuclear,
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while the cytoplasmic localization of the endogenous E2F complexes seems to be dependent upon
the presence of E2F-4. Second, although monomeric E2F-4 is predominantly cytoplasmic, this
E2F family member participates in both cytoplasmic and nuclear E2F complexes in vivo. This
suggests that the localization of the E2F-4 may be altered by the presence of one or more of its
associated proteins.
Our first goal was to identify the signal(s) that establish the localization of the monomeric
(i.e. non-DP associated) E2F proteins. To address this issue, we generated a series of chimeras in
which one or more domains (the N-terminal, DNA binding, dimerization/transactivation or
pRB/p 107/p130-binding) were exchanged between these proteins (see Figure 6). The resultant
mutants were named to indicate the origin of each domain; for example, 2224 contains the N-
terminal, DNA binding and dimerization/transactivation domains of E2F-2 and the
pRB/p107/p 130-binding domain of E2F-4. The localization properties of each chimera was
determined by indirect immunofluorescence after transient transfection into U20S cells (Figure 6).
Consistent with our micro-injection studies, the transiently transfected E2F-2 was predominantly
nuclear while the exogenous expressed E2F-4 preferentially localized to the cytoplasm. We next
examined the localization of mutants in which various functional domains of E2F-2 had been
replaced with the corresponding region of E2F-4 (2224, 2242, 2244 and 2444). In each case,
these mutants localized to the nucleus with similar or greater efficiency than the parental E2F-2
protein (Figure 6). In fact, it was possible to exchange all of the E2F-2 sequences from the start of
the DNA binding domain to the end of the protein (amino acids 118 - 437) with the corresponding
region of E2F-4 (amino acids 2 - 416) without impairing nuclear import. We therefore conclude
that E2F-2 contains a nuclear localization signal (NLS) within its N-terminal domain that, when
fused to E2F-4, can induce this normally cytoplasmic protein to enter the nucleus.
To precisely map the E2F-2 nuclear localization signal, we examined the localization
properties of N-terminal deletion mutants (Figure 6). Deletion of the first 83 amino acids of E2F-
2 did not affect its nuclear localization. However, deletion of an additional 5 amino acids (to
generate F2A88) caused the protein to shift from being predominantly nuclear (75% of cells) to
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being predominantly cytoplasmic (69% of cells) in a similar manner to E2F-4. Deletion of
additional N-terminal sequences (F2A117) did not further increase cytoplasmic localization. We
therefore concluded that E2F-2 contains a single NLS that encompasses residues 83 and 88. This
region encompasses a short motif, PAKRKLDL (residues 84-91), that is closely related to the
nuclear localization signal of the c-myc protein (Dang et al., 1988). Moreover, this sequence is
highly conserved in the other nuclear E2F proteins, E2F-1 (PVKRRLDL) and E2F-3
(PAKRRLEL), and represents the only region of homology in the N-terminal domain of these
three E2F family members. To directly demonstrate the importance of this domain, we used site
directed mutagenesis to alter the basic residues within this motif. When tested in the transient
transfection assay, the resulting mutant (named F2ANLS) localized to the cytoplasm in a similar
manner to either F2A88 or E2F-4 (Figure 6). We therefore conclude that the nuclear localization
of E2F-1, E2F-2 and E2F-3 is mediated by the P(A/V)KR(K/R)L(D/E)L motif.
In addition to the mutants shown in Figure 6, we have tested the localization properties of
several other chimeric and deletion mutants (data not shown). The localization properties of these
mutants did not yield any evidence for the existence of a nuclear export signal (NES) within E2F-
4. Although we cannot rule out the possibility that E2F-4 contains a weak NES, our data argues
that the predominant cytoplasmic localization of this protein results from the lack of a nuclear
localization signal. This conclusion is supported by the finding that E2F-2 mutants that lack the
NLS (F2A88, F2A117, F2ANLS) localize to the cytoplasm with a similar efficiency to E2F-4.
C7. Associated proteins can mediate the nuclear localization of E2F-4.
Our data suggest that monomeric E2F-4 is unable to enter the nucleus because it lacks a
nuclear localization signal. However, our analysis of the cellular E2F complexes indicates that
E2F-4 participates in both cytoplasmic and nuclear E2F complexes in vivo (Figure 5). What
mediates the localization of these nuclear E2F-4 complexes? One likely possibility is associated
proteins. Indeed, our analysis of the endogenous E2F complexes revealed a clear difference in the
localization of the E2F-4 complexes that were associated with p107 or p130 (predominantly
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cytoplasmic) rather than pRB (exclusively nuclear; Figure 5). To determine whether any of the
known associated proteins could influence E2F-4 localization, we used micro-injection assays to
compare the localization of E2F-4 that had been expressed in either the absence or presence of
these proteins (Figure 7). Since functional E2F activity requires the formation of an E2FoDP
heterodimer, we initiated this study by examining the effect of the known E2F heterodimeric
partners, DP-1 and DP-2. The monomeric DP-1 protein was found to be predominantly
cytoplasmic and this protein caused little or no change in the nuclear uptake of the co-expressed
E2F-4 protein. In contrast, E2F-4 became almost exclusively nuclear when co-expressed with
DP-2 and this localization clearly reflects the nuclear localization properties of the monomeric DP-
2 protein. We therefore conclude that the association of DP-2, but not DP-1, is sufficient to trigger
the nuclear localization of E2F-4.
Since our in vivo studies indicate that the association of pRB, but not p107 or p1 30, also
correlates with the nuclear localization of E2F-4, we also investigated whether the retinoblastoma
protein was able to induce nuclear uptake of the cytoplasmic E2F-4DP- I1 complex (Figure 7).
When co-expressed in the micro-injection assays, the retinoblastoma protein had no effect upon
the localization of either the E2F-4*DP- 1 (predominantly cytoplasmic) or the E2F-4*DP-2
(nuclear) species. Although we cannot rule out the possibility that the retinoblastoma protein will
play some role in determining the localization of E2F-4 in vivo, these experiments indicate that it is
not sufficient to induce the nuclear uptake of this E2F family member. In contrast, our data
suggest that the differential localization properties of the two DP proteins could provide the
underlying basis for the differential localization of the individual E2F-4 complexes.
C8. Nuclear localization of the individual E2F proteins correlates with their ability to
activate transcription.
The transcriptional role of the individual E2F species has been the focus of extensive study.
Over-expression experiments suggest that the free E2F*DP complexes each induce the activation
of E2F-responsive genes while complexes containing either pRB, p107 or p130 repress their
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transcription. In this study, we have shown that a significant proportion of these complexes are
localized in the cytoplasm and not the nucleus in vivo. This observation raised clear questions
about how these species' subcellular localization effects their ability to regulate transcription. To
directly address this issue, we have examined the functional properties of various nuclear or
cytoplasmic versions of the E2F-2 and E2F-4 proteins. Initially, we wanted to verify that the
construction of these mutants did not disrupt their ability to dimerize with DP and/or bind to DNA.
To this end, the relevant chimeric and deletion mutants were transiently transfected into C-33A
cells, along with CMV-DP , and whole cell extracts were then screened in gel retardation assays
(Figure 8a). In each case, we recovered a significant proportion of E2F DNA binding activity
confirming the structural integrity of these proteins. We then examined the transcriptional activity
of these mutants by transiently transfecting their eukaryotic expression vectors into C-33A cells
along with the E2F reporter plasmid, E2F4-CAT, and an internal control for transfection
efficiency, pRSV-LUC (Figure 8b). That each of these proteins were expressed at similar levels
was confirmed by western blotting (data not shown). Consistent with our analysis of the E2F-
inducible cell lines (Figure 1), E2F-2 activated the transcription of the reporter with a much greater
efficiency than E2F-4. However, the deletion or mutation of the E2F-2 nuclear localization signal
(mutants F2A88 and F2ANLS) significantly reduced its transcriptional activity. In contrast, the
transcriptional activity of E2F-4 was significantly increased when this protein was fused in frame
to either the N-terminal domain of E2F-2 (mutant 2444) or the nuclear localization signal of the
SV40 large T antigen (mutant F4+NLS). In fact, the transcriptional activity of the latter mutant
significantly exceeded that of the wild-type E2F-2 protein.
In every case, the transcriptional activity of the deletion and chimeric proteins correlated
with their localization properties rather than the origin (either E2F-2 or E2F-4) of their
transactivation domain. This suggests that the mutants each have a similar capacity to activate
transcription but this is restricted by their ability to localize to the nucleus. If this hypothesis is
true, we would predict that the association of DP-2, which was sufficient to induce the nuclear
uptake of E2F-4 (Figure 7), should active the transcriptional potential of the cytoplasmic mutants.
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To test this idea, we compared the transcriptional activity of each mutant after co-transfection with
DP-2. The presence of DP-2 was sufficient to mediate the nuclear localization of all of the mutants
(data not shown). Under these conditions, the chimeric and deletion mutants activated
transcription with similar efficiency (Figure 8b). We therefore conclude that E2F-2 and E2F-4
have a similar potential to activate transcription but these activities are dependent upon their
subcellular localization.
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D. Discussion
The cellular transcription factor E2F plays a critical role in directing the cell cycle dependent
transcription of the genes that control cellular proliferation. It is well established that E2F activity
arises from the combined properties of multiple E2F*DP heterodimers. However, despite
extensive study, the precise role of the individual E2F*DP species is not well understood. We
have focused our attention on one member of the E2F family, E2F-4, for the following reasons.
First, this E2F protein accounts for the vast majority of the endogenous E2F complexes, including
most of pRB-, p107- or pl30-associated E2F activity (Ikeda et al., 1996; Moberg et al., 1996).
This observation suggests that E2F-4 plays a pivotal role in establishing the properties of the
endogenous E2F activity. Second, free E2F-4*DP complexes accumulate early in the cell cycle
but they are unable to induce the transcription of known E2F responsive genes (Moberg et al.,
1996). This finding led us to propose two possible, although not mutually exclusive, models of
E2F-4 action; either the transcriptional activity of E2F-4 is directed at an unknown set of target
genes or it is regulated by a previously unknown mechanism.
To distinguish between these two models, we generated a stable cell line that showed
inducible E2F-4 DNA binding activity but, surprisingly, did not show inducible E2F
transcriptional activity. Although this prevented us from addressing whether or not E2F-4
activates a novel set of target genes in vivo, this observation led us to the finding that monomeric
E2F-4 is sequestered in the cytoplasm. The transcriptional activity of this protein was rescued by
the induction of its nuclear uptake. Moreover, under these conditions E2F-4 can activate
transcription with similar efficiency to the other E2F family members. Taken together, these data
lead us to conclude that E2F-4 may activate transcription in vivo but, in contrast to E2F-1, -2 and
-3, this is dependent upon an additional step that mediates the nuclear localization of this protein.
These findings suggest the need to re-evaluate previous studies concerning the biological
properties of the individual E2F proteins. Over-expression studies have revealed several
differences in both the transcriptional and cell cycle effects of E2F-4 versus those of E2F- 1, -2 and
-3 (Dimri et al., 1996; Hofmann et al., 1996; Lukas et al., 1996). For example, Lukas et al. (1996)
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have shown that micro-injection of either E2F- 1, -2 or -3 is sufficient to induce quiescent cells to
initiate DNA synthesis whereas E2F-4 is unable to trigger these events. That study and another
(Dimri et al., 1996) further showed that over-expression of E2F-1 but not E2F-4 can override the
G1-arrest induced by either p16 or p21. Our data suggest that these biological differences arise as
a direct consequence of the differential localization properties of these over-expressed proteins. In
addition, our data also affect the interpretation of E2F- I1 mutants. Previous studies have identified
a short motif within the N-terminus of E2F- 1, -2 and -3 that mediates their cyclin A*cdk2 binding
properties (Adams et al., 1996; Krek et al., 1994). This kinase is thought to ensure the S-phase
specific inactivation of the E2F-1 *DP, E2F-2*DP and E2F-3*DP species through its interaction
with the E2F subunit and phosphorylation of the associated DP protein (Dynlacht et al., 1994;
Dynlacht et al., 1997; Krek et al., 1995; Xu et al., 1994). Interestingly, our mapping studies
indicate that this domain is also responsible for mediating the nuclear localization of these three
E2Fs. At this point, the biological consequences of the co-localization of the cyclin A binding and
nuclear localization functions are unclear. However, it will be important to re-evaluate studies that
have used deletion mutagenesis to assess the role of cyclin A binding in E2F regulation (for
example see Krek et al., 1995), given our finding that these mutations also disrupt the nuclear
localization of the E2F proteins.
D1. Cell cycle regulation of the endogenous E2F-4 localization.
The localization properties of E2F-4 are only relevant if they extend to the endogenous
protein. Both subcellular fractionation and immunofluorescence confirmed that a significant
proportion of the endogenous E2F-4 protein is localized in the cytoplasm. Moreover, the relative
levels of nuclear to cytoplasmic E2F-4 protein alter dramatically as cells progress through the cell
cycle. While cytoplasmic E2F-4 exists throughout the cell cycle, nuclear E2F-4 protein is
primarily detected during Go and G1. These observations strongly suggest that the regulation of
E2F-4 subcellular localization plays a critical role in controlling the activity of the endogenous
E2F-4 complexes.
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Our previous studies have shown that E2F-4 accounts for a large proportion of the
endogenous E2F complexes, including the majority of pRB-, p107- or p130-associated E2F
activity (Moberg et al., 1996). This result raised the possibility that a significant proportion of
these complexes might localize to the cytoplasm at one or more stages of the cell cycle. We
addressed this issue by examining the localization of the individual E2F complexes in actively
dividing cells (Figure 9). As predicted by our overexpression experiments, the endogenous free
E2F-4 complexes were found to be predominantly cytoplasmic. Surprisingly, we did not detect
any obvious redistribution of free E2F-4 from the cytoplasm to the nucleus in any of the cell cycle
fractions. This observation suggests that we can rule out a model in which the activation of E2F-
responsive genes is triggered by the wholesale nuclear import of free E2F-4.
The pl07*E2F and p130*E2F complexes, which consist primarily of E2F-4 are also
predominantly cytoplasmic in actively dividing cells. As with free E2F-4, we did not detect any
obvious change in the ratio of nuclear to cytoplasmic forms of these species at any particular stage
of the cell cycle. This finding seems at odds with the recent report that coexpression with p107 or
p130 can increase the nuclear uptake of E2F-4 in transient transfection assays (Lindeman et al.,
1997). We have conducted similar experiments and, under these overexpression conditions, have
also found that p107 and p130 can trigger the nuclear localization of coexpressed E2F-4
(unpublished data). Given the difference between transient transfection and in vivo assays, we
assume that the overexpression of these proteins must somehow perturb the mechanism(s) that
establishes their subcellular localization. The analysis of this difference may provide the key to
understanding how the localization of endogenous E2F complexes is regulated. As with the E2F
proteins, these observations suggest that we need to be cautious in interpreting the results of
experiments performed with overexpressed p107 or p130 protein.
Consistent with the role of E2F as a cellular transcription factor, some of the endogenous
E2F complexes were detected in the nucleus. However, supershift experiments indicated most of
the nuclear E2F activity was generated by a single E2F species, the pRB*E2F complex. In
contrast to the other E2F complexes, pRB*E2F was found to be exclusively nuclear despite the
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fact that E2F-4 was its major component. The nuclear pRB*E2F complex was present at high
levels during G1 but not in S-phase cells. The disappearance of this species correlates closely with
the known timing of phosphorylation of pRB and is sufficient to account for the reduction in
nuclear E2F-4 protein at later stages of the cell cycle.
Our finding that the transcriptional potential of a given E2F complex is dependent upon its
nuclear localization strongly suggests that the endogenous E2F-responsive genes are regulated by
the subset of E2F species that can localize to the nucleus. We therefore conclude that the
transcriptional regulation of E2F-responsive genes in actively dividing cells is largely dependent
upon the properties of the pRB*E2F complex. Overexpression studies indicate that the pRB*E2F
complex mediates the basal repression of E2F responsive genes through sequestration of other
transcription factors that are bound at the promoter (Adnane et al., 1995; Bremner et al., 1995;
Sellers et al., 1995; Starostik et al., 1996; Weintraub et al., 1992; Weintraub et al., 1995).
Therefore, the current model of E2F action suggests that dissociation of the pRB*E2F complex
leads to the induction of target genes by both relieving basal repression and releasing free,
transcriptionally active E2F. Our observation that the pRB*E2F complex is present in the nucleus
at high levels during G1 strongly supports the notion that the dissociation of the pRB*E2F
complex contributes to the induction of E2F-responsive genes by relieving their repression.
However, although we did detect low levels of free E2F activity in the nuclei of S-phase cells, the
dissociation of the pRB*E2F complex did not lead to a commensurate increase in the levels of free,
nuclear E2F activity. Moreover, supershift experiments indicate that free E2F-4 is selectively lost
from the nuclear compartment after release from pRB. It is unclear whether the this free E2F-4 is
translocated to the cytoplasm or is subject to ubiquitin-mediated proteolysis (Hofmann et al., 1996;
Hateboer et al., 1996). Whatever the mechanism, dissociation of the high levels of nuclear
pRB*E2F complex results in surprisingly little nuclear free E2F activity. The reduction in the level
of nuclear E2F activity is consistent with in vivo footprinting studies which demonstrate that the
E2F-responsive elements of known target genes are only occupied during Go/G1 (Zwicker et al.,
1996). We assume that the low levels of nuclear, free E2F species contribute to the activation of
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E2F responsive genes. However, our data suggest that we need to reconsider the relative
contributions that pRB*E2F repression and free E2F activation make to the transcriptional
regulation of E2F-responsive genes.
D2. The pRBoE2F, p107*E2F and p130*E2F complexes are preferentially sequestered in
different subcellular compartments.
Analysis of both human tumors and mutant mouse strains suggests that pRB plays a
critical role in the regulation of cellular proliferation that cannot be fulfilled by either p107 and/or
p130. Our investigation of the endogenous E2F activity has led to the unexpected finding that the
p 107E2F and p130*E2F species are preferentially localized in a different subcellular compartment
from the pRB*E2F complex. As discussed above, the nuclear localization of the pRB*E2F
complex suggests that it will play a major role in repressing the transcription of E2F responsive
genes prior to the G1/S transition. In contrast, it seems likely that the cytoplasmic retention of the
p1 30*E2F and pl07*E2F species significantly reduces the ability of these complexes to repress
transcription. These data raise the possibility that the different localization properties of these
species contribute to the distinct biological consequences of pRB, p107 and p130 action.
At this point, we have restricted our analysis of E2F complexes to actively dividing cells.
The resultant findings raise questions about the role of E2F in quiescent cells. It has been shown
that p 130*E2F is the sole E2F species in Go cells, and it was therefore assumed that this complex
would mediate the repression of E2F-responsive genes in this setting (Chittenden et al., 1993;
Moberg et al., 1996; Smith et al., 1996). Given the findings of this study, it will be important to
determine the localization of p 130*E2F in quiescent cells. Similarly, when these cells are
stimulated to reenter the cell cycle, the pRB*E2F complex accumulates at high levels during S, G2,
and M (Moberg et al., 1996; Smith et al., 1996). If nuclear, this complex may contribute to the
down-regulation of E2F-responsive genes after the G1-S transition. Alternatively, it is possible
that localization is regulated by cell cycle staging rather than being an intrinsic property of the
individual E2F complexes and that the pRB*E2F complex will be found to be cytoplasmic when
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cells reenter the cell cycle from Go. Further analysis of quiescent cells should lead to a better
understanding of both the mechanism and biological consequences of the subcellular localization
of the individual E2F complexes.
In addition to E2F, pRB, p107 and p130 have been reported to regulate many other
transcription factors (reviewed in Beijersbergen and Bernards, 1996). Clearly our data only
address the localization of the pRB*E2F, pl07*E2F, and p130*E2F species. Consistent with our
findings, immunofluorescence studies have confirmed that the endogenous pRB protein localizes
to the nucleus (Mittnacht et al., 1994). In contrast, we are unaware of any analysis of the
localization of the endogenous p107 and p130 proteins. It is therefore unclear whether significant
proportions of these proteins are localized in the cytoplasm in vivo or whether this property is
specific to the pool of p107 and p130 that is bound to E2F. A comparison of the relative levels
and localization of E2F-associated versus total p107 and p130 proteins may provide critical
information about the relative importance of E2F in either p107 or p130 function.
D3. Potential mechanisms of E2F-4 localization.
There are two mechanisms that could account for the cytoplasmic localization of the E2F-4
protein, the lack of a nuclear localization signal (NLS) or the presence of a nuclear export signal
(NES). Although we cannot rule out the possibility that E2F-4 contains a weak NES, our analysis
of both E2F-4 deletion mutants and chimeric proteins suggest that the predominant cytoplasmic
localization of this protein results from its lack of an NLS. In contrast, this deletion strategy
identified a short motif, P(A/V)KR(K/R)L(D/E)L(D/E), that is both necessary and sufficient to
mediate the nuclear localization of E2F-1, -2 and -3. The presence or absence of these motifs
explains the localization properties of the monomeric E2F proteins. However, in some situations,
most noticeably when pRB is associated with the complex, E2F-4 complexes are able to enter the
nucleus. How this occurs is unclear, but associated proteins almost certainly play a role in this
process. Our preliminary studies suggest that the association of the retinoblastoma protein is
unable to induce the nuclear uptake of E2F-4. Instead, our experiments implicate the DP proteins
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in the control of E2F-4 localization. While interaction with DP- 1 does not significantly alter the
localization of E2F-4, DP-2 binding is sufficient to drive E2F-4 into the nucleus. The monomeric
DP proteins also localize to different compartments of the cell and this correlates with the presence
of a stretch of basic residues within DP-2 that is absent in DP- 1. These observations suggest that
the DP proteins will act to establish the localization of the associated E2F-4 complex. Future
experiments will focus on comparing the DP components of the nuclear and cytoplasmic E2F-4
complexes.
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E. Figure Legends
Figure 1. The transcriptional activity of E2F-4 is impaired by its in vivo expression. Parental
U2tTA10, U2F2 or U2F4 cell lines were cultured in either the presence (uninduced) or absence
(induced) of tetracycline for 36 hours and cell extracts were generated as previously described
(Moberg et al, 1996). The levels of E2F-2 or E2F-4 protein and DNA binding activity were then
analyzed in either western blots (A) or gel retardation assays (B) using monoclonal antibodies
against either E2F-2 (LLF2-1) or E2F-4 (LLF4-1) as indicated. (C) The parental U2tTA10, U2F2
or U2F4 cell lines were transiently transfected with 5 gg of the E2F-responsive reporter, E2F4-
CAT, and 2 gg of pRSV-Luciferase, as an internal control of transfection efficiency. The cells
were then cultured in duplicate in either the presence (uninduced) or absence (induced) of
tetracycline and the levels of CAT and luciferase activity were measured after 24 hours. The fold
induction represents the average of three transfections.
Figure 2. Exogenously expressed E2F-4 localizes to the cytoplasm. (A) R12 cells were micro-
injected with CMV expression constructs, encoding the indicated E2Fs, along with CMV-P-
galactosidase, to mark injected cells (data not shown). Immunofluorescence was carried out using
either control (data not shown), anti-E2F-1 (KH20), anti-E2F-2 (LLF2-1), anti-E2F-3 (LLF3-1)
or anti-E2F-4 (LLF4-1) antibodies along with DAPI as indicated. (B) The U2F2 or U2F4 cell
lines were plated on coverslips and then cultured in the absence (induced) of tetracycline for 36
hours. Immunofluorescence was carried out using control (data not shown), anti-E2F-2 (LLF2-1)
or anti-E2F-4 (LLF2-1) antibodies along with DAPI as indicated.
Figure 3. Localization of the endogenous E2F-4 protein is regulated in a cell cycle dependent
manner. (A) Asynchronous WI-38, U20S, T98G, ML-1, C33-A, SAOS-2 and 293 cells were
fractionated using standard methods. Equivalent volumes of cytoplasmic or nuclear extracts were
resolved by 10% SDS-PAGE and transferred to nitrocellulose. These blots were probed as
indicated with antibodies that specifically recognize either E2F-1(KH20) or E2F-4 (LLF4-1). (B)
U20S cells were cultured in the presence of thymidine (for 12 hours) and then nocodazole (for 24
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hours) to generate a synchronized cell population. These were plated on coverslips and cultured in
normal media. Fractions were removed every 6 hours and the cell cycle staging was assessed by
FACS analysis. Immunofluorescence was carried out on asynchronous, peak G 1 or S-phase
populations using either control (data not shown), or anti-E2F-4 (LLF4-1) antibodies along with
DAPI as indicated. (C) WI38 cells synchronized in Go/GI by starvation or released in to S-phase
by readdition of serum were subject to indirect immunofluorescence localization of E2F-4 protein
as described above.
Figure 4. Localization of the endogenous E2F-4 complexes is regulated in a cell cycle dependent
manner. Human HL60 cells were separated by centrifugal elutriation and the cell-cycle distribution
was determined by FACS analysis of a proportion of the resultant populations (as indicated). The
remainder of the cells were then fractionated to yield nuclear and cytoplasmic extracts. (A)
Equivalent volumes of cytoplasmic and nuclear extracts were subject to Western blot analysis of
E2F-1 (KH20 monoclonal) and E2F-4 (LLF4-1 monoclonal). (B) Cytoplasmic and nuclear
extracts from the elutriated fractions were screened for the presence of E2F DNA binding activity
in gel retardation assays.
Figure 5. The pRB*E2F, p107*E2F and p130*E2F complexes preferentially localize to either the
cytoplasm or the nucleus in actively dividing cells. To identify the constituent components, the
cytoplasmic and nuclear fractions of the peak G 1 (93% GI, 5% S and 2% G2/M) and S-phase
(14% G 1, 78% S and 8% G2/M) populations were analyzed in the gel retardation assays in the
absence or presence of monoclonal antibodies specific for the individual E2F or regulatory
proteins as indicated. The anti-E2F antibodies all supershift pocket protein-containing E2F
complexes as efficiently as their free E2F*DP counterparts (Moberg et al. 1996). Similar results
were obtained with multiple other anti-E2F-1, -2 -3 or -4 monoclonal or polyclonal antisera.
Figure 6. Localization properties of chimeric E2F proteins. U20S cells were transiently
transfected as described previously with 1 pg of the indicated CMV-E2F constructs along with
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CMV- -galactosidase to mark transfected cells. Immunofluorescence was performed as
described (Materials and Methods) using anti-E2F-2, anti-E2F-4, and anti-f-gal antibodies (data
not shown). Two hundred -galactosidase positive cells were scored for E2F protein localization
and the percent of cells displaying exclusively nuclear, exclusively cytoplasmic or both nuclear and
cytoplasmic staining was determined.
Figure 7. Associated proteins modulate the localization of E2F-4. Murine 3T3 fibroblasts were
microinjected with CMV expression constructs encoding HA-tagged human DP-1 or DP-2 either
alone or in combination with the indicated plasmids. CMV-f-galactosidase was included to mark
injected cells. Immunofluorescence was performed as described (Materials and Methods) using
anti-E2F-4, anti-HA and anti-P3-galactosidase antibodies.
Figure 8. Localization of E2F proteins determines their ability to activate transcription in vivo.
The properties of the chimeric E2F molecules were assayed by transfection into human C33-A
cells. (A) DNA binding activity was determined by transfection of 10 gg of the relevant CMV-
E2F expression constructs together with 10 gg CMV-HA-DP-1 as indicated. Whole cell extracts
were generated as described (Moberg et al. 1996) and assayed for E2F DNA binding activity in
gel shift assays (Materials and Methods). (B) The transcriptional activity of these chimeric E2F
molecules in vivo was tested by cotransfection of 200ng of the relevant CMV-E2F, 4gg of E2F 4-
CAT, 2gg RSV-Luciferase in the presence or absence of jg CMV-HA-DP-2. Normalized CAT
values were used as a measure of transcriptional induction.
Figure 9. Summary of the nuclear and cytoplasmic E2F complexes through the cell cycle.
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F. Materials and Methods
Cell Culture.
Human cell lines ML-1 (premyeloid leukemia), C33-A (cervical carcinoma), WI-38 (normal
diploid lung fibroblast), 293 (renal adenocarcinoma), T98G (glioblastoma), R12 cells (RatlA
derivative cell line), U20S and SAOS-2 (osteosarcomas) were grown under standard conditions
of 5% CO 2 in DMEM supplemented with 10% heat-inactivated fetal bovine serum. Murine 3T3
fibroblasts were grown in DMEM supplemented with 10% calf serum. The HL60 (human
lymphoma) cell line was cultured in RPMI medium supplemented with 20% fetal bovine serum.
Transient transfections were carried out exactly as described previously (Moberg et al., 1996).
Cell Synchronization.
U20S cells were arrested at metaphase by culturing sequentially in media containing 2mM
thymidine (12 hours) and then 1.7 tM nocodazole (24 hours), washed several times and re-plated
in fresh media on coverslips. Cells were collected every 6 hours and processed for either
immunofluorescence or FACS analysis. HL60 were separated by centrifugal elutriation using
standard procedures and a small proportion of each fraction was subjected to FACS analysis to
determine cell cycle staging. Synchronized Go/G 1 WI38 human diploid fibroblasts were obtained
by starvation of early passage cells in 0.1% serum for 48hrs; enriched S-phase populations were
generated by replating arrested cells in 20% fetal bovine serum for 14hrs (Mittnacht et al., 1994).
Plasmids.
The following plasmids have been described previously: pCMV-E2F-1, -2, -3, and -4 (Moberg et
al., 1996); pCMV-DP-1, -2 and pCMV-pRB (Wu et al., 1995). The E2F-responsive reporter
E2F4-CAT have pRSV-Luciferase have been described in Helin et al. (1993). Chimeric E2F
cDNAs were constructed in a derivative of the pBKSII+ vector (Strategene) in which the XbaI site
had been deleted. Briefly, domains of either E2F-2 or E2F-4 were amplified by PCR using
primers containing silent restriction sites which did not alter codon usage within the relevant ORF.
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Hybrid cDNAs were created by the ligation of these individual domains together in the
pBKSII+AXba vector using the engineered restriction sites. Full-length chimeric cDNAs were
then subcloned as BamHI fragments into the BamHI site of the pCMV-Neo-Bam vector (Baker et
al., 1990). The E2F-2 and E2F-4 specific primer pairs are as follows.
(i) E2F-2: 10.18: 5'-GGATCCATGCTGCAAGGGCCCCGGGCCTTG-3' and 10.24Xba: 5'-
CCT-AAGCTTCTAGAACGTTGGTGATGTCATAG-3'; 10.23Xba: 5'-
CGTTCTAGAAGGCACT-CAGCTCATC-3' and 10.22HIII: 5'-
GAGAAGCTTATCAGAGGGGAG-3'; 10.21HIII: 5'-GATAAGCTTCTCCCCATCCTTG-3'
and 10.20: 5'-GGTGGTACCGGATCCTCAATTAATC-AACAGGTCC-3'.
(ii) E2F-4. 4.13 :5'-GGATCCATGGCGGAGGCCGGGCCACAG-3' and 4.19Xba: 5'-
CCTAAG-CTTCTAGAACATTGGTAATGTCGTA-3'; 4.18Xba: 5'-
TGTTCTAGAAGGTATC-GGGCTAATC-3' and 4.17HIII: 5'-
GAAAAGCTTAGCAGAGGGGCAAACACT-3'; 4.16HIII: 5'-
GCTAAGCTTATCTCCACCCCCGGGAGAC-3' and 4.15: 5'-GGTGGTACCGGATCC-
TCAGAGGTTGAGAACAGG-3'
For pCMV-2444, the N-terminus of E2F-2 was amplified by PCR using the primers 10.18
(above) and 10.2N: 5'-GATGGATCCGAGGCCATCCACTCTGAT-3'. The N-terminal
deletions of E2F-2, A83, A88, and Al 17 were constructed by PCR amplification of wildtype E2F-
2 cDNA template using the following primers together with primer 10.20 (above): 10.83: 5'-
GGTGGATCCAT-GGCCAAAAGGAAGCTGG-3', 10.88: 5'-GGTGGATCCATGCTG-
GATCTGGAGGG-GATTG-3' and 10.117: 5'-GGTGGATCCATGGGCCCCAA-
AACCCCCAAATC-3'. The F2ANLS construct was generated by PCR amplification of E2F-2
cDNA using the primer pairs 10.18 (above) & 10.ANLS2: 5'- CTTCAAGCTTCTACAGGC-
ACTCAGCCGTCCTG-CCGGCAG-3' and 10.20 (above) & 10ANLS1: 5'-GTTGAAGCTTG-
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TTTGTGGCGGGGATTGGGAGGCC-3'. The two fragments were then ligated together to yield
an E2F-2 cDNA containing a novel HindIII site within the altered NLS sequences.
E2F Transactivation Assays.
CAT and luciferase assays were performed as described in Helin et al. (1993). Briefly, cells were
harvested 36h post-transfection and lysed in 0.025M Tris-HCl (pH 8.0) by three rapid freeze-thaw
cycles. Extracts were clarified by a 15,000g spin for 10 min and the supernatants were assayed for
CAT and luciferase activities.
E2F Inducible Cell Lines.
E2F-2 or E2F-4 inducible cell lines were generated using the technique of Gossen and Bujard
(1992). U20S cells were cotransfected with pUHD15-1 and pCMVneo by the calcium phosphate
method. After selection in G418 (250gg/ml), stable cell lines were assayed by transient
transfection for tetracycline regulated activity of a luciferase reporter (pUHC13-3). One line,
U2tTA10, which showed a 2x103 increase in luciferase activity upon tetracycline withdrawal, was
transfected with pTK-HYG and the pUHD10-3 expression vector containing either the E2F-2 or
E2F-4 cDNA. After selection in the presence of hygromycin (100Rg/ml) and tetracycline
(0. l1 g/ml), extracts from stable cell lines were screened by western blotting for the induction of
the relevant E2F.
Microinjection and Immunofluorescence.
3T3 and R12 cells were plated on glass coverslips and grown to 70% confluency. E2F expression
plasmids (25 ptg/ml) were coinjected with a plasmid encoding B-galactosidase (5 [tg/ml) to mark
injected cells. After injection, the cells were grown in DME-HEPES supplemented with 10%
serum for 3-4 hours. Following fixation and permeabilization, cells were incubated for 30 min
with rabbit anti-f-galactosidase antibodies (1:50 dil.; 5 Prime-3 Prime, Inc.) and a cocktail of
mouse anti-E2F monoclonals (1:25 dil). E2F antibodies used were KH20 (anti E2F-1), LLF2-1
(anti E2F-2), LLF3-1 (anti E2F-3), and LLF4-1 (anti E2F-4). KH20, LLF2-1 and LLF3-1 have
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been described previously. The LLF4-1 monoclonal hybridoma cell line was isolated from
BALB/c mice immunized with 6X His-tagged E2F-4 (amino acids 147-413) exactly as described
by Moberg et. al. (1996). Following incubation in primary antibody, cells were washed with PBS
and then incubated for 30 min in secondary antibody (FITC-conjugated goat anti-mouse at a
1:1000 dil, Cappel) and rhodamine-conjugated goat anti-rabbit at a 1:1000 dil, Cappel). The cells
were then washed four times with PBS, incubated with DAPI (0.1 mg/ml) for 5 min, washed
again and mounted on glass slides with Mowiol.
For detection of transfected proteins, 50% confluent U20S cells, plated on coverslips 48h
prior, were transfected with the indicated expression constructs together with CMV-P-
galactosidase to mark transfected cells and processed 24h later for immunofluorescence exactly as
described above. The murine anti-influenza hemagglutinin antibody 12CA5 was used to detect
HA-tagged proteins.
For detection of endogenous E2F-4, synchronous or asynchronous U20S cells or WI38
cells were plated on glass coverslips and immunofluorescence was performed as described above
with the following modifications. After fixing and permeabilizing, block solution (5% goat serum,
0.2 % fish skin gelatin (Sigma), and 0.2% Tween-20) was added for 60 min. Cells were then
incubated with mouse anti-E2F-4 monoclonals (dil 1:25 in blocking solution) for 60 min, washed
twice with PBS+0.2% Tween-20, and incubated with FITC-conjugated goat anti-mouse for 30
min. After several washes with PBS+Tween-20 and DAPI staining for 5 min, the cells were
mounted on glass slides with VectaShield (Vector).
Subcellular Fractionation, Western Blots and Gel Shift Assays.
Fractionation of cultured cells was performed as follows. Cell pellets were resuspended in two
packed-cell volumes (PCV) of hypotonic buffer ( 10 mM HEPES, pH 7.5, 10 mM KC1, 3 mM
MgC12, 0.05% Nonidet P-40, I mM EDTA, pH 8.0, 10mM NaF, 0.1 mM Na3VO4, 1 mM
PMSF, 1 mM DTT, Img/ml aprotinin, Img/ml leupeptin) and incubated 5 min on ice. Nuclei
were separated by a 500g spin for 5 min and washed twice more in hypotonic buffer. Nuclei were
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then lysed in 3 PCV of Lysis Buffer and clarified by a 45 min spin at 100,000 g as described
previously (Moberg et al., 1996). The cytoplasmic supernatant of the original 500g spin was
supplemented with glycerol to 35% (3 PCV final volume) and clarified by a 20,000g spin for 10
min. Protein concentrations were determined with Protein Dye Reagent (BioRad). As the final
volumes of cytoplasmic and nuclear extract from a given cell population were equivalent, the ratio
of protein concentrations was taken as a measure of the per-cell ratio of cytoplasmic and nuclear
proteins.
Western blots and gel shift assays were performed exactly as described previously
(Moberg et al., 1996). Briefly, equal volumes of cytoplasmic and nuclear extract were assayed for
E2F protein (western blotting) or E2F DNA binding activity (gel shift) in the presence of the
indicated antibodies. E2F-4 was detected in both assays with the LLF4-1 monoclonal supernatant
described above. Additional antibodies used were KH20 (anti-E2F-1), XZ55 (anti-pRB), SD15
(anti-p107), and sc-317X (anti-pl30; Santa Cruz).
159
G. Acknowledgments
We thank Laura Attardi and Barbara Panning for technical assistance with the microinjection and
immunofluorescence assays and E. Nunnerley for her contribution to the preparation of the
figures. We are also grateful to members of the Lees laboratory for helpful discussion and to
Steve Bell, Nicholas Dyson and David Housman for critical reading of the manuscript. S.E. was
supported by an Anna Fuller fellowship. This work was supported by the Harcourt General
Charitable Foundation.
160
References
Adams, P.D., W.R. Sellers, S.K. Sharma, A.D. Wu, C.M. Nalin, and W.G. Kaelin Jr.. 1996. Identification of a
cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell
Biol. 16, 6623-6633.
Adnane, J., Z. Shao, and P.D. Robbins. 1995. The retinoblastoma susceptibility gene product represses
transcription when bound directly to the promoter. J. Biol.Chem. 270, 8837-8843.
Bagchi, S., R. Weinmann, and P. Raychaudhuri. 1991. The Retinoblastoma Protein Copurifies with E2F-I, an
E1A-Regulated Inhibitor of the Transcription Factor E2F. Cell 65, 1063-1072.
Baker, S.J., S. Markowitz, E.R. Fearon, J.K.V. Willson, and B. Vogelstein. 1990. Suppression of human
colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915.
Bandara, L.R. and N.B. La Thangue. 1991. Adenovirus E1A prevents the retinoblastoma gene product from
complexing with a cellular transcription factor. Nature 351, 494-497.
Bandara, L.R., V.M. Buck, M. Zamanian, L.H. Johnston, and N.B. La Thangue. 1993. Functional synergy
between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. EMBO J. 12, 4317-4324.
Bartek, J., J. Bartkova and J. Lukas. 1996. The retinoblastoma protein pathway and the restriction point.
Current Opin. in Cell Biol. 8, 805-814.
Beijersbergen, R.L., and R. Bernards. 1996. Cell cycle regulation by the retinoblastoma family of growth
inhibitory proteins. Biochem. Biophys. Acta. 1287, 103-120
Beijersbergen, R.L., R.M. Kerkhoven, L. Zhu, L. Carlee, P.M. Voorhoeve, and R. Bernards. 1994. E2F-4, a
new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes & Dev.
8, 2680-2690.
Bremner, R., B.L. Cohen, M. Sopta, P.A. Hamel, C.J. Ingles, B.L. Gallie, and R.A. Phillips. 1995. Direct
Transcriptional Repression by pRB and Its Reversal by Specific Cyclins. Mol. Cell Biol. 15, 3256-65.
Cao, L., B. Faha, M. Dembski, L. Tsai, E. Harlow, and N. Dyson. 1992. Independent binding of the
retinoblastoma protein and p107 to the transcription factor E2F. Nature 355, 176-179.
Chellappan, S.P., S. Hiebert, M. Mudryj, J.M. Horowitz, and J.R. Nevins. 1991. The E2F Transcription Factor
Is a Cellular Target for the RB Protein. Cell 65, 1053-1061.
Chittenden, T., D.M. Livingston, and J.A. DeCaprio. 1993. Cell Cycle Analysis of E2F in Primary Human T
Cells Reveals Novel E2F Complexes and Biochemically Distinct Forms of Free E2F. Mol. and Cell Biol. 13,
3975-3983.
Clarke, A.R., E.R. Maandag, M. van Roon,N.M.T. van der Lugt, M. van der Valk, M.L. Hooper, A. Berns, and
H. te Riele. 1992. Requirement for a functional Rb-1 gene in murine development. Nature 359, 328-330.
Cobrinik, D., M.-H. Lee, G. Hannon, G. Mulligan, R.T. Bronson, N. Dyson, E. Harlow, R.A. Weinberg and T.
Jacks. 1996. Shared role of the pRB-related p130 and p107 proteins in limb development. Genes and Dev. 10,
1633-1644.
Cobrinik, D., P. Whyte, D.S. Peeper, T. Jacks, and R.A. Weinberg. 1993. Cell cycle-specific association of
E2F with the p130 E1A-binding protein. Genes and Dev. 7, 2392-2404.
Dang, C.V., and W.M.F. Lee. 1988. Identification of the human c-myc protein nuclear translocation signal.
Mol. and Cell. Biol. 8, 4048-4054.
161
DeGregori, J., T. Kowalik, and J.R. Nevins. 1995. Cellular targets for activation by the E2F-1 transcription
factor include DNA-synthesis and G1/S-regulatory genes. Mol. Cell Biol. 15, 4215-4224.
Devoto, S.H., M. Mudryj, J. Pines, T. Hunter, and J.R. Nevins. 1992. A Cyclin A-Protein Kinase Complex
Possesses Sequence-Specific DNA Binding Activity: p 3 3 cdk2 Is a Component of the E2F-Cyclin A Complex.
Cell 68, 167-176.
Dimri, G.P., M. Nakanishi, P-.Y. Desprez, J.R. Smith, and J. Campisi. 1996. Inhibition of E2F activity by the
cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein.
Mol. Cell Biol. 16, 2987-2997.
Dynlacht, B.D., O. Flores, J.A. Lees, and E. Harlow. 1994. Differential regulation of E2F trans-activation by
cyclin/cdk2 complexes. Genes and Dev. 8, 1772-1786.
Dynlacht, B.D., K. Moberg, J.A. Lees, E. Harlow and L. Zhu. 1997. Specific regulation of E2F Family
members by cyclin-dependent kinases. Mol. Cell Biol. 17, 3867-75.
Dyson, N., M. Dembski, A. Fattaey, C. Ngwu, M. Ewen, and K. Helin. 1993. Analysis of p107- Associated
Proteins: p107 Associates with a Form of E2F That Differs from pRB-Associated E2F-1. Journal of Virology
67, 7641-7647.
Ewen, M.E., H.K. Sluss, C.J. Sherr, H. Matsushime, J.Y. Kato, and D.M. Livingston. 1993. Functional
Interactions of the Retinoblastoma Protein with Mammalian D-type Cyclins. Cell 73, 487-497.
Ewen, M.E., Y. Xing, J.B. Lawrence, and D.M. Livingston. 1991. Molecular Cloning, Chromosomal Mapping,
and Expression of the cDNA for p107, a Retinoblastoma Gene-Product-Related Protein. Cell 66, 1155-1164
Field, S.J., F-.Y. Tsai, F. Kuo, A.M. Zubiaga, W.G. Kaelin, Jr., D.M. Livingston, S.H. Orkin, and M.E.
Greenberg 1996. E2F-1 Functions in Mice to Promote Apoptosis and Surpress Proliferation. Cell 85, 537-548.
Ginsberg, D., G. Vairo, T. Chittenden, Z.X. Xiao, G. Xu, K.L. Wydner, J.A. DeCaprio, J.B. Lawrence, and D.M.
Livingston. 1994. E2F-4, a new member of the E2F trancription factor family, interacts with p107. Genes &
Dev. 8, 2665-2679.
Gossen, M. and H. Bujard. 1992. Tight control of gene expression in mammalian cells by tetracycline-
responsive promoters. Proc. Natl. Acad. Sci. USA 89, 5547-5551.
Hannon, G., D. Demetrick, and D. Beach. 1993. Isolation of the Rb-related p130 through its interaction with
CDK2 and cyclins. Genes & Dev. 7, 2378-2391.
Hateboer, G. R.M. Kerkhoven, A. Shvarts, R. Bernards and R.L. Beijersbergen. 1996. Degradation of E2F by the
ubiquitin-proteasome pathway: regulation by the retinoblastoma family proteins and adenovirus transforming
proteins. Genes & Dev. 10, 2960-2970.
Helin, K., C. Wu, A.R. Fattaey, J.A. Lees, B.D. Dynlacht, C. Ngwu, and E. Harlow. 1993a. Heterodimerization
of the transcription factors E2F-1 and DP-1 leads to cooperative trans- activation. Genes & Dev. 7, 1850-1861.
Helin, K., E. Harlow, and A. Fattaey. 1993b. Inhibition of E2F-1 Transactivation by Direct Binding of the
Retinoblastoma Protein. Mol. and Cell. Biol. 13, 6501-6508.
Hiebert, S.W., S.P. Chellappan, J.M. Horowitz, and J.R. Nevins. 1992. The interaction of RB with E2F
coincides with an inhibition of the transcriptional activity of E2F. Genes & Dev. 6, 177-185.
Hijmans, E.M., P.J. Voorhoeve, R.L. Beijersbergen, L.J. van't Veer, and R. Bernards. 1995. E2F-5, a New E2F
Family Member that interacts with p130 In Vivo. Mol. and Cell. Biol. 15, 3082-3089.
162
Hinds, P.W., S. Mittnacht, V. Dulic, A. Arnold, S.I. Reed, and R.A. Weinberg. 1992. Regulation of
Retinoblastoma Protein Functions by Ectopic Expression of Human Cyclins. Cell 70, 993-1006.
Hofmann, F. and D. Livingston. 1996. Differential effects of cdk2 and cdk3 on the control of pRB and E2F
function during GI exit. Genes & Dev. 10, 851-861.
Hofmann, F., F. Martelli, D. Livingston and Z. Wang. 1996. The retinoblastoma protein product protects E2F-1
from degradation by the ubiquitin-proteosome pathway. Genes & Dev. 10, 2949-59.
Hsiao, K.M., S.L. McMahon, and P. Farnham. 1994. Multiple DNA elements are required for the growth
regulation of the mouse E2F1 promoter. Genes & Dev. 8, 1526-1537.
Hu, Q., J.A. Lees, K.J. Buchkovich, and E. Harlow. 1992. The retinoblastoma protein physically associates
with the human cdc2 kinase. Mol. and Cell. Biol. 12, 971-980.
Ikeda M., L. Jakoi, and J.R. Nevins. 1996. A unique role for the Rb protein in controlling E2F accumulation
during cell growth and differentiation. Proc. Natl. Acad. Sci. USA 93, 3215-3220.
Jacks, T., A. Fazeli, E.M. Schmitt, R.T. Bronson, M.A. Goodell, and R.A. Weinberg. 1992. Effects of an Rb
mutation in the mouse. Nature 359, 295-300.
Krek, W., D.M. Livingston, S. Shirodkar. 1993. Binding to DNA and the retinoblastoma gene product
promoted by complex formation of different E2F family members. Science 262, 1557-1560.
Krek, W., M.E. Ewen, S. Shirodkar, Z. Arany, W.G. Kaelin Jr., and D.M. Livingston. 1994. Negative regulation
of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell
78, 161-172..
Krek, W., G. Xu, and D.M. Livingston. 1995. Cyclin A-Kinase Regulation of E2F-1 DNA Binding Function
Underlies Suppression of an S Phase Checkpoint. Cell 83, 1149-1158.
Lee, E.Y., C.Y. Chang, N. Hu, Y.C. Wang, C.C. Lai, K. Horrup, W.H. Lee, and A. Bradley. 1992. Mice
deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359, 288-294.
Lee, M.-H., B. Williams, G. Mulligan, S. Mukai, R.T. Bronson, N. Dyson, E. Harlow, and T. Jacks. 1996.
Targeted disruption of p107: functional overlap between p107 and pRb. Genes and Dev. 10, 1621-1632.
Lees, E., B. Faha, V. Dulic, S.I. Reed, and E. Harlow. 1992. Cyclin E / cdk2 and cyclin A / cdk2 kinases
associate with p107 and E2F in a temporally distinct manner. Genes and Dev. 6, 1874-1885.
Lees, J.A., K.J. Buchkovich, D.R. Marshak, C.W. Anderson, and E. Harlow. 1991. The retinoblastoma protein
is phosphorylated on multiple sites by human cdc2. EMBO J. 10, 4279-4290.
Lees, J.A., M. Saito, M. Vidal, M. Valentine, T. Look, E. Harlow, N. Dyson, and K. Helin. 1993. The
Retinoblastoma Protein Binds to a Family of E2F Transcription Factors. Mol. Cell Bio. 13, 7813-7825.
Li, Y., C. Graham, S. Lacy, A.M.V. Duncan, and P. Whyte. 1993. The adenovirus E1A-associated 130-kD
protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and
E. Genes & Dev. 7, 2366-2377.
Lindeman, G.J., S. Gaubatz, D.M. Livingston, and D. Ginsberg. 1997. The subcellular localization of E2F-4 is
cell-cycle dependent. Proc. Natl. Acad. Sci. USA 94, 5095-5100.
Lukas, J., B. O. Peterson, K. Holm, J. Bartek, and K. Helin. 1996. Deregulated expression of E2F family
members induces S-phase entry and overcomes pl6INK4A-mediated growth suppression. Mol. Cell Biol. 16,
1047-1057.
163
Matsushime, H., D.E. Quelle, S.A. Shurtleff, M. Shibuya, C.J. Sherr, and J.Y. Kato. 1994. D-Type Cyclin-
Dependent Kinase Activity in Mammalian Cells. Mol. and Cell. Biol. 14, 2066-2076.
Mayol, X., X. Grana, A. Baldi, N. Sang, Q. Hu, and A. Giordano. 1993. Cloning a new member of the
retinoblastoma gene family (pRb2) which binds to the ElA transforming domain. Oncogene 8, 2561-2566.
Meyerson, M., and E. Harlow. 1994. Identification of G1 Kinase Activity for cdk6, a Novel Cyclin D Partner.
Mol. and Cell. Biol. 14, 2077-2086.
Mittnacht, S., J.A. Lees, D. Desai, E. Harlow, D.O. Morgan, and R.A. Weinberg. 1994. Distinct sub-
populations of the retinoblastoma protein show a distinct pattern of phosphorylation. EMBO J. 13, 118-127.
Moberg, K., Starz, M.A., and J. A. Lees. 1996. E2F-4 switches from p130 to p107 and pRB in response to cell
cycle re-entry. Mol. and Cell. Biol. 16; 1436-1449.
Mudryj, M., S.H. Devoto, S.W. Hiebert, T. Hunter, J. Pines, and J.R. Nevins. 1991. Cell Cycle Regulation of
the E2F Transcription Factor Involves an Interaction with Cyclin A. Cell 65, 1243-1253.
Nevins, J.R. 1992. A closer look at E2F. Nature 358, 375-376.
Pines, J., and T. Hunter. 1991. Human cyclins A and BI are differentially located in the cell and undergo cell
cycle-dependent nuclear transport. J. Cell Biol. 115, 1-17.
Sardet, C., M. Vidal, D. Cobrinik, Y. Geng, C. Onufryk, A. Chen, and R.A. Weinberg. 1995. E2F-4 and E2F-5,
two members of the E2F family , are expressed in early phases of the cell cycle. Proc. Natl. Acad. Sci. USA
92, 2403-2407.
Sellers, W.R., J.W. Rodgers, and W.G. Kaelin, Jr. 1995. A potent transrepression domain in the retinoblastoma
protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA 92, 11544-11548.
Shirodkar, S., M. Ewen, J.A. DeCaprio, J. Morgan, D.M. Livingston, and T. Chittenden. 1992. The
Transcription Factor E2F Interacts with the Retinoblastoma Product and a pl07-Cyclin A Complex in a Cell
Cycle-Regulated Manner. Cell 68, 157-166.
Smith, E.J., G. Leone, J. Degregori, L. Jakoi and J.R. Nevins. 1996. The accumulation of an E2F-pl30
transcription repressor distinguishes a Go cell state from a GI cell state. Mol. and Cell. Biol. 16, 6965-6976.
Starostik, P., K.N.B. Chow and D.C. Dean. 1996. Transcriptional repression and growth suppression by the p107
pocket protein. Mol. Cell Biol. 16, 3606-3614.
Vairo, G., D.M. Livingston , and D. Ginsberg. 1995. Functional interaction between E2F-4 and p130: evidence
for distinct mechanisms underlying growth suppression by different retinoblastoma family members. Genes &
Dev. 9, 869-881.
Weinberg, R.A. 1992. Tumor Suppressor Genes. Science 254, 1138-1146.
Weinberg, RA. 1995. The Retinoblastoma Protein and Cell Cycle Control. Cell 81, 323-330.
Weintraub, S.J., C.A. Prater, and D.C. Dean. 1992. Retinoblastoma protein switches the E2F site from positive
to negative element. Nature 358, 259-261.
Weintraub, S.J., K.N.B. Chow, R.X. Luo, S.H. Zhang, S. He, and D.C. Dean. 1995. Mechanism of active
transcriptional repression by the retinoblastoma protein. Nature 375, 812-815.
Wu, C.L., L.R. Zukerberg, C. Ngwu, E. Harlow, and J.A. Lees. 1995. In Vivo Association of E2F and DP
Family Proteins. Mol. and Cell. Biol. 15, 2536-2546.
164
Xu, M., K.-A. Sheppard, C.-Y. Peng, A.S. Yee, and H. Piwnica-Worms. 1994. Cyclin A/CDK2 binds directly to
E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. and Cell. Biol. 14, 8420-
8431.
Yamasaki, L., Jacks, T, Bronson, R., Goillot, E., Harlow, E., and N.J. Dyson. 1996. Tumor Induction and
Tissue Atrophy in Mice Lacking E2F-1. Cell 85, 549-560.
Zhu, L., S. van der Heuvel, K. Helin, A. Fattaey, M. Ewen, D.M. Livingston, N. Dyson, and E. Harlow. 1993.
Inhibition of cell proliferation by p107, a relative of the retinoblastoma protein. Genes & Dev. 7, 1111-1125.
Zwicker, J., N. Liu, K. Engeland, F.C. Lucibello, and R. Miller. 1996. Cell cycle regulation of E2F site
occupancy in vivo. Science 271, 1595-1597.
165
CHAPTER 4
"Specific Regulation of E2F family members
by cyclin-dependent kinases"
Brian D. Dynlacht, Ken Moberg, J.A. Lees, E. Harlow, and L. Zhu
Molecular and Cellular Biology, July 1997, Vol.17, No.7, p.3 8 6 7 -3 8 7 5
(Author's contribution: Figure 4, and additional data in Figure 2, Appendix)
A. Abstract
The transcription factor E2F-1 interacts stably with cyclin A via a small domian near its
amino terminus and is negatively regulated by the cyclin A-depnedent kinases. Thus, the activities
of E2F, a family of transcription factors involved cell proliferation, are regulated by at least two
types of cell growth regulators: the retinoblastoma protein family and the cyclin-dependent kinase
family. To investigate further the regulation of E2F by cyclin-dependent kinases, we have
extended our studies to include additional cyclins and E2F family members. Using purified
components in an in vitro system, we show that the E2F-1 *DP-1 heterodimer, the functionally
active form of the E2F activity, is not a substrate for the active cyclin D-dependent kinases but is
efficiently phosphorylated by the cyclin B-dependent kinases, which do not form stable complexes
with the E2F- 1 *DP- 1 heterodimer. Phosphorylation of the E2F- 1 *DP- 1 heterodimer by cyclin B-
dependent kinases, however, did not result in down-regulation of its DNA-binding activity, as is
readily seen after phosphorylation by cyclin A-dependent kinases, suggesting that phosphorylation
per se is not sufficient to regulate E2F DNA-binding activity. Furthermore, heterodimers
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containing E2F-4, a member of the family lacking the cyclin A-binding domain found in E2F-1,
are not efficiently phosphorylated or functionally down-regulated by cyclin A-dependent kinases.
However, addition of the E2F-1 cyclin A binding-domain to E2F-4 conferred cyclin A-dependent
kinase-mediated down-regulation of the E2F-4*DP-1 heterodimer. Thus, both enzymatic
phosphorylation and stably physical interaction are necessary for the specific regualtion of E2F
family members by cyclin-dependent kinases.
167
B. Introduction
Regulation of the mammalian cell cycle involves the concerted interplay of both positive
and negative regulators. Often , the central targets of these regulators are transcription factors.
One such example is the transcription factor E2F, which is believed to play an important role in the
controlled expression of genes that are essential for the G1/S phase transition and DNA replication.
The E2F family encompasses two distantly related subfamilies, E2F and DP. One subunit
of E2F and one subunit of DP combine to form the heterodimers that are the active E2F activities
in the cell. The E2F family thus far includes six E2F members and two DP members. For clarity
in this report, we will refer to a particular E2F member using a numerical designation, and we will
use the term E2F for the active E2F*DP heterodimer. Evidence for an important role for E2F in
cell cycle progression stems from several findings. First, the promoters of a number of genes
whose products are required for cell proliferation contain E2F sites (including the genes encoding
B-myb, DNA polymerase a, dihydrofolate reductase, thymidine kinase, and E2F-1). Secondly,
E2F can act as a potent growth-promoting factor. Overexpression of E2F- 1 prevents cell cycle
arrest of fibroblasts following serum withdrawl and stimulates quiescent cells to enter S phase
(Johnson et al., 1993). Under other cirumstances, overexpression of E2F promotes cellular
transformation (Bieijersbergen et al., 1994; Ginsberg et al., 1994; Singh et al., 1994; Xu et al.,
1995). In still other cases, E2F drives cells into S phase, then induces apoptosis (Kowalik et al.,
1995; Qin et al., 1994; Shan and Lee, 1994; Wu et al., 1994). Third, the importance of E2F in cell
growth regulation is strongly implicated by its regulators. The retinoblastoma protein, pRB,
inhibits the activity of E2F, and mutations in pRBthat render the protein incapable of inhibiting
E2F are frequently found in human tumors. Surprisingly, a growth-suppressive role for E2F was
uncovered by loss of E2F-1 function in mice, which results in proliferative defects and tumor
formation (Field et al., 1996; Yamasaki et al., 1996)
The best-studied upstream regulators of E2F are the retinoblastoma protein family of
proteins, including pRB, p107, and p130. The first E2F, E2F-1, was cloned based on its
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interaction with pRB (Helin et al., 1992; Kaelin et al., 1992; Shan et al., 1992). Members of the
pRB family of proteins stably associate with E2F and repress its trans activation activity, as
determined by transient transfection of E2F binding site-containing promoter constructs into cells
and by in vitro transcription assays (Dynlacht et al., 1994; Helin et al., 1993; Hiebert et al., 1992;
Weintraub et al., 1992; reviewed in Dyson, 1994). The ability of pRB and related proteins to
repress E2F activity correlates with their growth suppression function, suggesting that E2F
repression may be an essential component of pRB-mediated growth suppression (reviewed in
Helin and Harlow, 1993; and in Nevins, 1992). Different members of the pRB family apparently
regulate specific E2F family members as pRB primarily binds to E2F-1, E2F-2, and E2F-3, and
E2F-4 (Ikeda et al., 1996; Moberg etal., 1996). In contrast, p107 and p130 interact specifically
with E2F-4 and E2F-5 (Beijersbergen et al., 1994; Ginsberg et al., 1994; Vairo et al., 1995).
Based on these findings it has been suggested that different E2F members, together with their
primary pRB protein regulators, control different sets of genes at different stages of the cell cycle.
A second regulatory mechanism for E2F connects E2F directly with the cell cycle
machinery. E2F-1 stably interacts with cyclin A*cdk2 via a small domain near the amino terminus
of the transcription factor, and one consequence of this interaction is the inhibition of E2F
transcription factor activity by the cyclin A-dependent kinases (Dynlacht et al., 1994; Krek et al.,
1994; Xu et al., 1994). The cyclin A binding domain of E2F-1 is conserved in E2F-2 and E2F-3
but not in E2F-4 or E2F-5. E2F-4 and E2F-5 can, however, interact with cyclins through p107 or
p130, and possible regulation of E2F-4 by cyclin A*cdk2 in the cyclin A*cdk2pl07oE2F-4
complex has been demonstrated in vitro (Zhu et al., 1995). This level of E2F regulation has the
great potential of revealing important, and remarkably direct, actions of the basic cell cycle
machinery on the celluar transcription apparatus and may provide exciting targets for therapeutic
intervention. At this stage, however, our understanding of this important level of regulation is
limited. Most notably, the specificities of different cyclins towards different E2F members and the
molecular mechanisms for this cyclin-dependent kinase-mediated regulation have not been
systematically examined.
169
To address these issues, we have tested substrate phophorylation and functional regulation
of additional E2F and cyclinokinase pairs. Based on the functional relationships between different
E2F members and different cyclins, we then performed domain fusion experiments to
demonstrate that both enzymatic phosphorylation and stable physical interaction are the necessary,
and sufficient, underlying mechanisms for this cyclin-E2F regulatory relationship.
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C. Results
C1. Phosphorylation of E2F-1*DP-1 by specific cyclinekinases
Using the in vitro system we have developed (Dynlacht et al., 1994), we first extended our
studies on E2F-1 regulation by cyclin*kinases. Previously, we tested cyclin E*cdk2 and cyclin
A*cdk2 complexes, kinases that are active primarily during late G 1 and S phases. Here, we
continued our studies to include the cyclin*kinases that functioned in other stages of the cell cycle.
Cyclin D*cdk4 is an important player in early Gi while cyclin B*cdc2 is activated during the G2/M
phase transition (reviewed in Hunter and Pines, 1994). The kinetics of cell cycle-dependent
activation of these kinases is therefore considerably different from that of cyclin E- and cyclin A-
dependent kinases.
Each of the kinases was produced by co-infection of insect cells with recombinant
baculoviruses and purified by affinity chromatography (data not shown). In this manner, we
produced both cdk2 and cdc2 complexes with cyclins A and B, as well as cdk4 complexes with
cyclin D1. In addition, cyclin D1 complexes containing cdk2 or cdk6 and cyclin D2 complexes
with cdk6 were also purified using immunoaffinity methods (data not shown).
Unlike most cyclinecdks, cyclin Docdk4 and cyclin D*cdk6 phosphorylate pRB
preferentially to histone H1 (Matsushime et al., 1992; Matsushime et al., 1994; Meyerson and
Harlow, 1994). Therefore we tested these cyclin D*cdk complexes in parallel kinase reactions
containing either pRB or E2F. In each case, reactions were normalized so that similar levels of
pRB or histone H1 kinase units (compared to cyclin Aecdk2) were used. In Figure 1A, the cyclin
D complexes were purified by immunoprecipitation and kinase assays were performed using a
GST fusion protein containing a carboxy-terminal fragment of pRB or the E2F- 1 *DP- 1
heterodimer as substrates. Although the cyclin D2*cdk6 and cyclin D1 cdk4 complexes were
potent pRB kinases, neither of these complexes was able to phosphorylate the E2F-1 *DP-1
heterodimer. In addition, we used a purified, soluble form of cyclin D1*cdk4 complex to avoid
possible problems with immunopurified, solid-phase complexes (Figure 1B). Again, the results
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show that cyclin D1* cdk4 complexes were not able to phosphorylate the E2F-1 heterodimer. In
each of these experiments, an amount of cyclin A*cdk2 that gives rise to similar levels of pRB
phosphorylation relative to purified cyclin D kinases efficiently phosphorylated the E2F-1
heterodimer, and a mixing experiment ruled out the presence of inhibitors in the E2F- I1
preparations (Figure 1B lane 13). We conclude that the E2F-1 heterodimer is not a substrate for
the cyclin D kinases.
In experiments shown in Figure 2, we tested the cyclin B-dependent kinases in a similar
manner as described above. Interestingly, cyclin B*cdc2 and cyclin B*cdk2 behaved almostly
identically with cyclin A*cdk2 in their ability to phosphorylate E2F-1 heterodimers. Further,
cyclin A*cdc2 phosphorylated the heterodimer with a specific activity indistinguishable from that
of cyclin A*cdk2.
From this series of experiments, we have learned that (1): E2F-1 is phosphorylated by
specific cyclin dependent kinases, since cyclin D-associated kinases are clearly unable to use E2F-
1 as substrates; and (2): phosphorylation of E2F-1 apparently does not require stable protein-
protein interaction, since cyclin B-dependent kinases efficiently phosphorylated E2F-1 without
stably binding to it (see Figure 5 below).
C2. Functional regulation of E2F-1oDP-1 by specific cyclin *kinases
The next important question was to determine the effects of each of these cyclin kinases on
the DNA-binding activity of the E2F-1 heterodimer. To do so, each of the purified kinases was
tested in gel mobility shift assays containing purified E2F-1 and DP-1 (Figure 3). To avoid the
possibility that the differences in the extent of phosphorylation of the E2F- 1 heterodimer may be
the cause of different effects, the amounts of cyclin A- and cyclin B-dependent kinases in the E2F
gel shift reactions were equalized based on their kinase activities toward the E2F-1 dimer.
Although cyclin D1 ocdk4 did not phosphorylate this substrate, we still used an equivalent amount
of pRB kinase units relative to cyclin Aocdk2.
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As expected, cyclin Aocdk2, as well as cyclin A*cdc2, effectively abolished E2F DNA-
binding activity in this assay (Figure 3, lanes 3 and 7). Cyclin D1 cdk4, which did not
phosphorylate E2F, had no effect on its DNA-binding activity (lane 12). Notably, however, cyclin
B*cdc2 and cyclin B*cdk2 failed to down-regulate the DNA-binding activity of E2F-1, despite the
fact that the cyclin B-associated kinases could efficiently phosphorylate the heterodimer.
To understand the reason for the different effects of the cyclin A- and cyclin B-associated
kinases on E2F-1 DP- 1 dimer, we first sought to determine whether these two kinases
phophorylated the same sites on E2F-1 and DP-1. We performed tryptic 2-dimensional gel
electrophoresis on E2F-1 and DP-1, which were phosphorylated by either cyclin A*cdk2 or cyclin
B*cdk2. As shown in Figure 4, the phosphotryptic patterns of E2F-1 and DP-1 phosphorylated
by cyclin A*cdk2 are the same as those phosphorylated by cyclin B*cdk2.
We next compared the abilities cyclin Aocdk2 and cyclin B'cdk2 to stably associate with
E2F-1. We immunoprecipitated either cyclin B*cdk2 or cyclin Aocdk2 complexes from reactions
containing E2F- 1 DP-1 and probed the resulting immunoblots with antibodies against E2F-1 and
DP-1. Clearly, while cyclin A*cdk2 formed stable complexes with E2F- 1 DP-1, no significant
interaction between cyclin B*cdk2 and E2F-1*DP-1 was detected (Figure 5A, compare lanes 5 and
7). Furthermore, interactions between the cyclin A-associated kinases and the E2F-1*DP-1
heterodimer were productive, as demonstrated by kinase assays performed after
immunoprecipitation of these kinases (Figure 5B). In this assay, which is considerably more
sensitive than the immunoblotting experiment shown in Figure 5A, interactions between either
cyclin A*cdk2 or cyclin Aocdc2 and E2F-1 *DP-1 resulted in the phosphorylation of this
heterodimer, while the cyclin Bocdk2 complex was without effect, since it did not stably interact
with the heterodimer (Figure 5B, compare lanes 2, 4, and 5).
We went further to ask whether the stable association between cyclin A and E2F-1 was
sufficient for down-regulation of E2F-1. A complex containing cyclin A and a catalytically
inactive, dominant-negative version of cdk2 (cdk2-DN; van den Heuvel and Harlow, 1993) was
purified and tested in an assay similar to the one described in Figure 3. Purified cyclin Aocdk2-
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DN formed a stable association with E2F-1, resulting in a slower mobility complex (Figure 6,
compare lanes 1 and 2). However, the DNA binding activity of this complex was not affected by
the inactive cyclin A*cdk2-DN complex, as it was with the corresponding wild-type kinase
(compare lanes 2 and 7). Furthermore, we wanted to learn whether down-regulation of E2F-1
could be achieved by providing the enzymatic phosphorylation through cyclin B*cdk2 and the
stable physical interaction through cyclin Aocdk2-DN in trans. As shown in Figure 6 lanes 4 and
5, the DNA-binding activity of E2F-1 was not affected in this way, either when these two kinase
complexes were added together or when cyclin B cdk2 was used to phosphorylate E2F-1 first and
cyclin Aocdk2-DN was added subsequently. When the E2F heterodimer was first treated with
cyclin A*cdk2 and then subsequently incubated with cyclin A*cdk2-DN, the DNA binding activity
of E2F-1 was abolished, as expected. We conclude that the function of E2F-1 is specifically
regulated by cyclin A-associated kinases in a manner dependent upon coupled phosphorylation and
stable interaction.
C3. Regulation of specific E2F members by cyclin A kinases
In the next series of experiments we investigated the regulation of different members of the
E2F family by cyclin-dependent kinases. Each of the E2F polypeptides was produced in bacteria
and purified extensively via a carboxy-terminal tubulin tag (Figure 1 and data not shown)
(Dynlacht et al., 1994; Huber et al., 1993; Ivey-Hoyle et al., 1993). Because of difficulties related
to expression of E2F-2 in bacteria (B.D.D. and J.L., unpublished data), we did not include E2F-2
in this study. Each of these purified proteins was shown to bind E2F site-containing
oligonucleotides in a DP-1-dependent manner (Figure 7A and data not shown). For E2F-4, we
further demonstrated its ability to form a higher order complex with p107 and cyclin A*cdk2
(Figure 7A, and 53), and to stimulate transcription, in a DP-1-dependent manner, from a template
containing four E2F-binding sites using a reconstituted transcription assay (Figure 7B, compare
lanes 2-4 with 5-7). Thus, these recombinant proteins are fully functional.
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We tested the effects of cyclin A*cdk2 on the DNA-binding activities of various E2F
proteins (Figure 7C). Treatment with cyclin A*cdk2 promoted the loss of DNA-binding by E2F-
3*DP-1, as well as E2F-1 oDP-1, but not E2F-4*DP-1 or E2F-5*DP-1. In fact, the DNA-binding
activity of E2F-5 even increased slightly upon treatment with cyclin A*cdk2, although the
significance of this finding, if any, remains to be clarified. The non-specific DNA-binding
proteins present in reactions containing E2F-3 and E2F-5 served as good internal controls since
their activities were not affected (lanes 4-6 and 10-12). In other experiments, E2F-3, but not E2F-
4 or E2F-5 (Figure 8B below and data not shown), served as a good substrate for phosphorylation
by cyclin Aocdk2, further suggesting a link between phosphorylation and regulation of DNA-
binding.
Protein sequence analysis of the five E2F members has revealed extensive homology
among them, but this homology does not extend to amino-terminal sequences. E2F-1, E2F-2,
and E2F-3 share a short sequence near their amino-termini that was previously shown to be the
cyclin A-binding domain of E2F-1 (Krek et al., 1994). This sequence is conspicuously absent
from E2F-4 and E2F-5 (Ginsberg et al., 1994; Hijmans et al., 1995; Sardet et al., 1995). We
therefore compared the ability of E2F-4 to bind cyclin Aocdk2 with that of E2F-1. As shown in
Figure 5A, E2F-4*DP-1 was not co-immunoprecipitated with cyclin A*cdk2, while in parallel
reactions, a large fraction of E2F-1 *DP-1 was co-immunoprecipitated with this kinase (compare
lanes 1 and 5 with 2 and 6). These results were corroborated by subsequent incubation of identical
immunoprecipitates under kinase assay conditions (Figure 5B). Under these conditions, E2F-
4*DP-1 complexes are not co-immunoprecipitated with cyclin A*cdk2, unlike the corresponding
E2F-1-containing complexes (compare lanes 2 and 3). These experiments and the DNA-binding
experiments shown in Figure 4 suggest that cyclin A*cdk2 specifically regulates only those
members of the E2F family that can stably associate with it.
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C4. The cyclin A binding domain of E2F-1 as both a necessary and sufficent mechanism of
regulation
The studies described above point to cyclin A-binding as an important determinant in the
specific regulation of E2F by cyclin A-dependent kinases. We next asked whether cyclin A
binding was sufficient for E2F regulation. We addressed this question by fusing the previously
defined cyclin A binding domain of E2F-1 (residues 67-108; Krek et al., 1994) to the amino
terminus of E2F-4 and testing the regulation of this fusion protein, called E2F-4(+A), by cyclin
A*cdk2. A mutant form of E2F-1 (termed E2F-1 (DA)), in which the cyclin A binding domain
was deleted, was also constructed to further demonstrate the role of this domain in E2F-1
regulation by cyclin A*cdk2.
We over-produced and purified these two recombinant E2F proteins with carboxy-terminal
tubulin tags as before (Figure 8A). In kinase assays shown in Figure 8B, the E2F-1*DP-1
heterodimer was potently phosphorylated by cyclin A*cdk2, while the E2F-4*DP-1 complex was
not. Strikingly, however, when the cyclin A binding domain was deleted from E2F-1 (E2F-
1(DA)) and added to E2F-4 (E2F-4(+A)), the substrate specificity was switched.
Phosphorylation of the E2F-4(+A)*DP- 1 heterodimer by cyclin A*cdk2 was comparable to that of
E2F-1 *DP-1. In parallel experiments, regulation of the DNA-binding activities of these proteins
was also tested (Figure 8C). Both the E2F-4(+A) and E2F-1 (DA) proteins heterodimerized with
DP- 1 and bound DNA in the absence of added kinase with a specific activity similar to the parental
proteins (Figure 8B). In the presence of increasing amounts of cyclin A*cdk2, the activity of full-
length E2F-1, but not E2F-4, was inhibited (lanes 1-4 and 9-12). In contrast, the E2F-1 mutant,
E2F- 1 (DA), was not affected by the kinase (lanes 5-8). Conversely, addition of the cyclin A-
binding domain to E2F-4 (to produce E2F-4(+A)), generated a protein that was down-regulated
by kinase treatment (lanes 13-16) in a manner similar to E2F-1. Therefore, we conclude that the
cyclin A binding domain of E2F- I1 is not only necessary but also sufficient in determining the
specific regulation by cyclin A-dependent kinases.
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D. Discussion
In this report, we have investigated the regulation of E2F family members by various
cyclin-dependent kinases. We demonstrate that this regulation specifically pertains to certain E2F
family members and particular cyclin-dependent kinases and that the underlying mechanism for
this specificity involves both physical association and enzymatic phosphorylation. These findings
have significant implications for a number of important issues.
D1. Substrate specificity of cyclinokinases determined by a novel enzyme-substrate
relationship
When the E2F-1 *DP-1 heterodimer was tested for regulation by various cyclinekinases,
three distinct outcomes were obtained: no phosphorylation and no functional regulation by cyclin
D-dependent kinases, phosphorylation and functional down-regulation by cyclin A-dependent
kinases, and phosphorylation but no functional regulation by cyclin B-dependent kinases. While
this set of results convincingly indicates that the cyclin D-dependent kinases do not recognize E2F-
1 *DP-1 as substrates, the difference between the effects by cyclin A-dependent kinases and cyclin
B dependent kinases was unexpected. Cyclin B-associated kinases phosphorylated E2F-1*DP-1 to
the same extent as cyclin A-dependent kinases and on similar phosphorylation sites as determined
by phosphotryptic mapping, yet they were without effect on the DNA-binding activity of the
heterodimer.
Clearly, the inability of cyclin B-associated kinases to affect the DNA-binding activity of
E2F- 1 DP-1 could be attributed to its lack of stable association with E2F-1. This lack of stable
interaction could not be corrected in trans by treatment with cyclin Aocdk2-DN, which binds to
E2F-1 but cannot phosphorylate it (Figure 6). In this respect, it is interesting to note that the E2F-
1-A mutant was not phosphorylated efficiently by the cyclin A*cdk2 kinase (Figure 8). This
would sugget that cyclin A*cdk2 needs to stably interact with E2F-1 in order to phosphorylate it
efficiently, while cylcin B*cdk2 can efficiently phosphorylate E2F-1 without stably bound to it.
Furthermore, when the cyclin A-binding domain of E2F-1 was fused to the amino-terminus of
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E2F-4, a protein that does not contain this domain and is not phosphorylated or functionally
regulated by cyclin Aocdk2, both phosphorylation and down-regulation were transferred from
E2F-1 to E2F-4 (Figure 8).
The mechanisms underlying this requirement of stable interaction between cyclin A*cdk2
and E2F-1 for efficient phosphorylation and functional regulation, as opposed to the classic
enzyme-substrate relationship between cyclin B*cdk2 and E2F-1, needs to be further investigated.
Stuctural features of cyclin A and cylcin B that contribute to these different relationships with E2F-
1 are currently being determined.
In general, our currently study suggest that certain targets may require two events in order
to be functionally regulated by cyclin-dependent kinases. In addition to phosphorylation, stable
interaction between a cyclin*cdk complex and its target is also required for a particular functional
regulation. This additional level of complexity could confer a second layer of specificity. We
suggest that this previously unrecognized mechanism may be involved in other enzyme-substrate
relationships as well. Indeed, a related situation may exist for cyclin D*cdk4 and pRB, since pRB
interacts with cyclin Docdk4 and is thought to be the principal substrate for cyclin D*cdk4 (Dowdy
et al., 1993; Ewen et al., 1993; Kato et al., 1993).
D2. Cyclin A-dependent kinases directly regulate only a subset of E2F members
By systematically examining the members of the E2F family we demonstrate a remarkable
distinction in their regulation by cyclin Aokinases. E2F-1 and E2F-3 (E2F-2 was not tested
because of difficulties in expression but most likely would share similarities with E2F-1 and E2F-
3 due to the presence of the cyclin A-binding domain) are regulated by cyclin A-dependent
kinases, while E2F-4 and E2F-5 are not. As discussed above, this specificity is achieved through
a novel mechanism involving a domain of E2F-l and E2F-3 that is absent in E2F-4 and E2F-5.
Thus, different E2F family members have evolved to use a separate domain to ensure the
specificity of regulation of cyclin A-dependent kinases.
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The direct regulation of E2F-1, E2F-2 and E2F-3, but not E2F-4 and E2F-5, by cyclin A-
associated kinases strongly suggests that these two groups of E2Fs have distinct functional
properties. The group represented by E2F-1 probably has certain functions that must be down-
regulated efficiently by cyclin A-dependent kinases during S phase. It was recently reported that
when an E2F-1 mutant that could not bind cyclin A was ectopically expressed in fibroblasts, S
phase progression was blocked (Krek et al., 1995). It will be of interest to compare the effects of
overexpression of other members of the E2F family. In order to understand the mechanisms of
E2F function, it is essential to elucidate the functional differences among the different E2Fs.
Investigation of their regulation by cyclin A*kinases may provide an entry to this difficult, and until
now unyielding, question.
Although E2F-4 and E2F-5 do not directly interact with cyclin A-dependent kinases, they
are nevertherless indirectly connnected to cyclins through the p107 and p130 proteins (Cao et al.,
1992; Devoto et al., 1992; Faha et al., 1992; Lees et al., 1992; Shirodkar et al., 1992; Zhu et al.,
1995). Thus, these pRB-related proteins are found in complexes containing E2F-4*DP-1 and
cyclin A*cdk2 or cyclin Eocdk2, although the functional consequences of this association have yet
to be fully determined.
D3. The cyclin A binding domain of E2F-1 is conserved in other cyclin binding proteins
Finally, it is important to point out that the cyclin A binding domain of E2F- 1 is related to
a number of other cyclin binding domains identified in p21, p27 and p107, and it is an essential
component for cyclin binding to these proteins (Chen et al., 1996a; Chen et al., 1996b; Lin et al.,
1996; Luo et al., 1995; Zhu et al., 1995). Moreover, the crystal structure of a p27*cyclin A*cdk2
ternary complex has recently been solved, and this conserved domain forms the p27-cyclin A
binding interface (Russo et al., 1996). While the interaction between p21 or p27 with cyclin-
dependent kinases confers negative regulation upon the kinase, an interaction between cyclin A-
dependent kinases and E2F-1 serves to negatively regulate E2F-1 activity. It appears, therefore,
that stable physical interaction is an important mechanism for regulation both of, and by, the
179
cyclin-dependent kinases. We anticipate that our current study will lead to the discovery of other
examples of regulation whereby cyclin-binding domains may be used to stably recruit substrates
for phosphorylation.
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E. Figure legends
Figure 1: Cyclin D kinases do not phosphorylate E2F-1*DP-1 heterodimers.
Various recombinant cyclin D*cdk complexes were purified from over-expressing insect cells
either in the form of immune complexes (A) or soluble protein (B) and tested in parallel kinase
reactions containing either E2F-1 *DP-1, pRB, or histone H1 as indicated above each panel. (A)
Immuno-purified cyclin D complexes were prepared by purification on protein A sepharose beads
containing affinity-purified antibodies against either cyclin Dl (lanes 3-6 and 13-17) or cdk6 (lanes
1-2). The purity of each cyclin D immune complex was assessed by Coomassie-staining SDS-
PAGE gels; in each case, complexes were greater than 90% pure (data not shown). The mobility
of phosphorylated E2F-1, DP-1, pRB, and histone H1 are indicated to the left or right of each
panel. As a positive control, parallel reactions were performed with 0.1 (lanes 9 and 11) or 0.25
ng of cyclin A*cdk2 (lanes 10 and 12). In addition, purified cyclin Dl (approximately 50 ng, lanes
5-6, and 17) alone failed to phosphorylate either substrate. (B) Phosphorylation assays with
kinases purified by an alternate method. The gel in this panel was over-exposed to show the
inability of purified cyclin D1*cdk4 (1, 3, and 10 ng, lanes 10-11 and 13, in that order) to
phosphorylate E2F, although it is a potent pRB kinase (same amounts, lanes 3, 4, and 13). Nor
does purified cdk4 (15 and 60 ng, lanes 6-7, respectively) have pRB or E2F (60 ng cdk4, lane 12)
kinase activity. In contrast, 0.5 ng (lanes land 8) or 2.5 ng (lanes 2 and 9) of cyclin A*cdk2
potently phosphorylates both E2F-1 DP-1 (lanes 8-9) and pRB (lanes 1-2). A shorter exposure
indicates that similar amounts of cyclin A*cdk2 (lanes 1-2) and cyclin D1*cdk4 (lanes 3-5) RB
kinase units were added to reactions containing E2F-1 DP-1 (lanes 8-11).
Figure 2: E2F is a substrate for cyclin A- and cyclin B-type kinases.
Kinase reactions were reconstituted as described in Figure 2 using purified cyclin A and cyclin B
kinases. Reactions contained the kinases and substrates indicated above each panel: 0.5 (lanes 1
and 3), 1 (lane 4), 2.5 (lanes 2 and 5), or 10 ng (lane 6) of cyclin Bqcdk2; 1 (lanes 7 and 10), 5
(lanes 8 and 11), or 15 ng (lanes 9 and 12) of cyclin B*cdc2; 1 (lanes 13 and 16), 2.5 (lanes 14 and
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17), or 10 ng (lanes 15 and 18) of cyclin A*cdk2; and 1, 5, or 10 ng of cyclin Aecdc2 (lanes 19-21
and 22-24, in that order) were used in each reaction. As indicated on the right-hand side of the
figure, cyclin A becomes phosphorylated in these kinase reactions, which accounts for the
phosphorylated protein migrating between DP-1 and E2F-1 (lanes 13-18).
Figure 3: E2F-1*DP-1 heterodimers are down-regulated solely by the cyclin A kinases.
(A) Gel mobility shift assays were performed using 5-10 ng of E2F-1 DP-1 and each of the
cyclin*kinases shown at the top of the figure. Reactions contained either no added kinase (lanes 1
and 13), 2.5 or 10 ng of cyclin A*cdk2 (lanes 2 and 3, respectively), 2.5 or 10 ng of cyclin B*cdk2
(lanes 4 and 5 respectively), or 1 or 10 ng of cyclin A*cdc2 (lanes 6 and 7, respectively), 1 or 10
ng of cyclin B*cdc2 (lanes 8 and 9, respectively), 12 or 60 ng of cyclin D1*cdk4 (lanes 10 and 11,
respectively), or 300 ng of cdk4 alone (lane 12). Inhibition of DNA-binding activity by cyclin
A*cdc2 is linear with respect to amount of kinase added (data not shown) and is not due to a
threshold effect as suggested here (lanes 6 and 7).
Figure 4: Two-dimensional phosphopeptide mapping of E2F-1 and DP-1 phosphorylated in vitro
by cyclin A*cdk2 and cyclin B*cdk2.
DP-1 (A) and E2F-1 (B) phosphorylated by the indicated kinases were isolated and trypsinized,
and the resulting peptides were separated by two-dimansional electrophoresis. Maps were also
obtained from a mixture (Mix) of these phosphopeptides. The origin (0) and direction of both
electrophoresis (horizontal arrow) and chromatography (vertical arrow) are indicated.
Figure 5: Interaction between E2F-1 or E2F-4 and cyclin-dependent kinases.
(A) Purified cyclin A*cdk2 or cyclin B*cdk2 was incubated with either purified E2F-loDP-1 or
purified E2F-4*DP-1. In the two panels on the left, the input E2F and DP proteins (indicated at
the top of each panel) were checked by western blot analysis with, sequentially, anti-DP- 1, anti-
E2F-1 and anti-E2F-4 antibodies (lanes 1, 2, 3, and 4). On the right, after incubation of the cyclin
A or cyclin B kinases with E2F heterodimers, complexes were immunoprecipitated with anti-
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hemagglutinin (HA) antibodies that recognize the HA-tagged cdk2 protein, and Western blots of
the resulting immunoprecipitates were probed sequentially with antibodies against E2F-1, E2F-4,
and DP-1 (lanes 5, 6, 7, and 8). (B) Each of the immunoprecipitates obtained in (A) was
incubated in kinase assays. The labeled band in lane 3 is cyclin A, which is potently
phosphorylated (see also Figure 3); the faint band in lane 4 is most likely cyclin B since it
becomes phosphorylated during kinase reactions, and its mobility is indistinguishable from that of
recombinant GST-DP-1.
Figure 6: Inhibition of E2F activity by cyclin A kinases requires both binding and
phosphorylation.
Down-regulation of E2F-1 *DP-1 DNA-binding activity requires a cyclin A-binding and active
kinase domain in cis. Reactions were carried out with E2F-1 *DP-1 heterodimers as described in
Figure 4 and contained either no additional protein (lane 1), cyclin Aecdk2-DN (lane 2), cyclin
B*cdk2 (lane 3), a mixture of each of cyclin A*cdk2-DN and cyclin B*cdk2 (lane 4), or cyclin
A'cdk2 alone (lane 7). Order-of-addition reactions (order is indicated by an arrow; lanes 5 and 6)
were carried out as follows. E2F complexes were first incubated with cyclin B*cdk2 (lane 5) or
cyclin A*cdk2 (lane 6) and subsequently treated with cyclin A*cdk2-DN.
Figure 7: Cyclin A*cdk2 selectively inhibits the DNA-binding activity of certain E2F family
members.
(A and B) E2F-4*DP-1 is a fully functional transcription factor. (A) Gel shift reactions were
reconstituted with 5 ng of E2F-4 alone (lane 1), 5 ng each of E2F-4 and DP-1 (lane 2), or the
E2F-4*DP-1 heterodimer with approximately 100 ng of recombinant p 107 (lane 3) or p107*cyclin
A*cdk2 complex (lane 4) purified from over-expressing insect cells. Addition of these proteins
generates "supershifted" p107-E2F and p107*cyclin A*cdk2oE2F complexes. (B) In vitro
transcription reactions were reconstituted either without added E2F-4*DP-1 (lane 1), with 8, 25,
and 50 ng of E2F-4 alone (lanes 2-4, respectively) or 8, 25, and 50 ng each of E2F-4 and DP- 1
(lanes 5-7, respectively). (C) Gel shift reactions were reconstituted with 10 ng of E2F-1*DP-1, 10
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ng E2F-3*DP-1, 3 ng of E2F-4*DP-1, or 10 to 20 ng of E2F-5*DP-1 containing either no added
kinase (lanes 1, 4, 7 and 10) or 2 (lanes 2, 5, 8, and 11) or 15 (lanes 3, 6, 9, and 12) ng of cyclin
A*cdk2. A nonspecific DNA-binding activity apparent in some reactions (indicated at left; see also
Fig. 8) serves as a good internal control, since it was unaffected by any treatment (lanes 4 through
6, and 10 through 12).
Figure 8: The cyclin A binding domain confers the ability of cyclin A*cdk2 to phosphorylate and
negatively regulate E2F heterodimers.
(A) A tubulin-tagged version of E2F-4 with an amino-terminal fusion containing the minimal
cyclin A binding domain of E2F-1 [residues 67 to 108; termed E2F-4(+A)] (lane 1) and a deletion
mutant of E2F-1 lacking this domain [in which residues 79 to 103 were removed; termed E2F-
1 (DA)] (lane 2) were expressed in E. coli and purified by using affinity chromatography as
described for E2F-1, -3, -4 and -5 in Materials and Methods. An arrowhead indicates the position
of each recombinant protein. (B) Kinase reaction mixtures containing purified recombinant
proteins were reconstituted as in the experiment shown in Fig. 2. Increasing amounts of cyclin A
(CycA)*cdk2 were titrated into the reaction mixtures. For each heterodimer tested, 5 (lanes 2, 4, 6,
8, and 10) or 25 (lanes 1, 3, 5, 7, and 9) ng of purified kinase was used. Reaction mixtures also
included50ng of each E2F and DP- 1 protein indicated at the top of the panel. We confirmed by
immunoblotting that equal amounts of each E2F heterodimer were added to the reaction mixtures
(data not shown). Histone H1 (1 gg) was also added to parallel reaction mixtures as a control for
kinase activity. The mobility of each phosphoryklqted protein is indicated. Reaction products
were seperated on SDS-10%PAGE gels and autoradiographed. (C) Each of these recombinant
E2F proteins [2 ng of E2F-1(DA) in lanes 5 through 8, or 25 ng of E2F-4(+A) in lanes 13
through 16] was tested in gel mobility shift assays in the presence of increasing amounts of cyclin
A*cdk2 in parallel with intact E2F-1 (lanes 1 through 4) and E2F-4 (lanes 9 through 12).
Recombinant proteins were tested in the absence (lanes 1, 5, 9, and 13) or presence of 3 ng (lanes
2, 6, 10, 14), 10 ng (lanes 3, 7, 11, and 15), or 20 ng (lanes 4, 8, 12, and 16) of purified cyclin
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A*cdk2. A non-specific DNA-binding protein present in preparations of E2F- 1 (DA) shifts the
mobility of the labeled probe, as indicated on the left, in a manner independent of DP-1 addition
(data not shown).
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F. Materials and Methods
Plasmid construction
Bacterial expression plasmids encoding full length E2F-3, E2F-4, and E2F-5 with a three amino
acid carboxy-terminal tubulin epitope were generated essentially as described (Ivey-Hoyle et al.,
1993). For E2F-3, PCR reactions included the oligos (5') CCAGAG GATCCA TTGGAG
GATGAT TAAATG AGAAAG GGAATC CAGCCC and (3') GAGAGC AAGCTT AGAACT
CCTCAC TACACA TGAAGT CTTCCA CCAG; for E2F-4, (5') CCAGAG GATCCA
TTGGAG GATGAT TAAATG GCGGAG GCCGGG CCACA and (3') GAGAGC AAGCTT
AGAACT CCTCGA GGTTGA GAACAG GCACAT CAAA; for E2F-5, (5') CCAGAG
GATCCA TTGGAG GATGAT TAAATG GCGGCG GCAGAG CCCGC and (3') GAGAGC
AAGCTT AGAACT CCTCAT AATTTA GTATCT GGACAT CAAACA G. cDNAs of E2F-4
and E2F-5 in pBluescript were kind gifts of R. Beijersbergen and R. Bernards (E2F-4) and C.
Sardet and R. Weinberg (E2F-5).
pT5T-E2F-1(DA) was constructed by replacing the BssHII-SmaI fragment (spanning
E2F-1 amino acids 23 to 122) of pT5T-E2F-1 (Dynlacht et al., 1994; Huber et al., 1993) with the
corresponding fragment from pRcCMV-HA-E2F-1(D24) (Krek et al., 1994) that contains a
deletion in the cyclin A binding domain of E2F- 1. pT5T-E2F-4(+A) was constructed in several
steps as follows. Amino acid sequences in E2F-1 necessary for cyclin A binding (residues 67 to
108; Krek et al., 1994) were amplified by PCR using the following primers: 5' primer (L43) 5'
CCG GGA TCC ATT GGA GGA TGA TTA ACC ATG GCC ACA CCG CAG GCG CCC 3'
and 3' primer (L42) 5' GA AGA TCT AGC TGG CCC ACT GCT CTC 3'. The PCR product
was digested with BamHI and BglII and inserted into the BamHI site of pCMV-E2F-4 (Ginsberg
et al., 1994) so that the cyclin A binding domain of E2F-1 was fused in-frame with full-length
E2F-4. This fusion product was then amplified with 5' primer (L44) 5' CCG GGA TCC ATT
GGA GGA TGA T 3' and 3' primer (E2F-4-2) 5' GAG AGC AAG CTT AGA ACT CCT CGA
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GGT TGA GAA CAG GCA CAT CAA A 3', cut with BamHI and HindIII and inserted into
BamHI/HindIII digested pT5T vector.
Expression and purification of recombinant proteins
Insect cells (High Five; Invitrogen) were infected with recombinant baculoviruses, harvested 40-48
hours post infection, lysed in NP-40 buffer, and proteins were purified as described (Dynlacht et
al., 1994), except for the cyclin D*cdk4 complexes. GST-cyclin A, GST-cyclin B, cdk6, cyclin D1
and D2, cdk2-HA, cdc2-HA, and cdk2-dn-HA viruses have been described (Desai et al., 1992;
Dynlacht et al., 1994; Meyerson et al., 1994; Peeper et al., 1993). GST-cdk4 virus was a kind gift
of W. Harper. Cyclin D 1 GST-cdk4 complexes were isolated after disruption of infected cells by
sonication in D buffer (50 mM Hepes, pH 7.6, 150 mM NaCl, 1mM EDTA, 2.5 mM EGTA,
0.1% Tween-20, 10% glycerol, 1 mM DTT, 0.2 mM AEBSF, 5 mg/ml leupeptin, 5 mg/ml
aprotinin, 10 mM NaF, and 50 mM sodium f-glycerophosphate; Matsushime et al., 1994) instead
of NP-40-containing lysis buffer. Eluates from glutathione-agarose beads were then dialyzed
against D buffer. Immuno-affinity purification of cyclin D1 and cdk6 complexes was carried out
as follows. Cell lysates in D buffer were incubated with affinity-purified polyclonal antibodies
against cyclin D1 or cdk6 pre-bound to protein A for 1 hour and washed with D buffer. The
purity of these complexes was assessed by Coomassie and silver staining electrophoresed
proteins. A recombinant p107 baculovirus that expresses a p107 fragment has been described
(Zhu et al., 1995). p107 protein was purified in a single step by affinity chromatography on
columns bearing an HPV E7 peptide exactly as described for the purification of recombinant pRB
(Dynlacht et al., 1994). Recombinant p107*cyclin A*cdk2 complexes were generated by triply
infecting insect cells with each of these viruses and purification on glutathione-agarose beads using
methods for other GST proteins listed above. Recombinant E2F-1, E2F-3, E2F-4, and E2F-5
were produced and purified by anti-tubulin antibody affinity chromatography followed by heparin
sepharose chromatography as previously described, as was GST-tagged DP-1 (Dynlacht et al.,
1994). In order to obtain active E2F-4 and the E2F-4(+A) derivative, the purified protein was
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solubilized at room temperature in 4.5 M guanidine-HCI (Gd-HC1) in the presence or absence of
purified GST-DP-1. The proteins were renatured either by dialysis against 0.1 HEMG (0.1 M
KC1, 25 mM Hepes, pH 7.6, 0.1 mM EDTA, 10 mM MgC12, 10% glycerol, and 1 mM DTT)
containing 0.01% NP-40 or by dilution into 0.1 HEMG buffer with 0.1% NP-40. Purification of a
bacterially produced, GST-tagged, carboxy-terminal fragment of RB (Meyerson et al., 1994) was
achieved as for all other GST-tagged proteins except that D Buffer was used in place of 0.1
HEMGN lysis buffer. Protein eluted from the glutathione-agarose beads was subsequently
dialyzed against D buffer and concentrations determined by staining with Coomassie (GST-RB) or
silver (all other proteins).
In vitro binding, immunoprecipitations, western blotting, and kinase reactions
Protein association and coupled association/kinase reactions were performed by incubating 10 to
20 ng of various cyclinekinase complexes with E2F and DP-1 proteins in 0.1 HEMGN containing
0.1% NP-40 for 20 minutes at room temperature and then immunoprecipitating complexes with
12CA5-protein A beads. Immune complexes were washed three times with 0.1 HEMGN. To
perform kinase reaction, the immunoprecipitates were washed once more with kinase buffer.
Kinase reactions with [y-32P] ATP were carried out as described below.
Kinase assays
Kinase assays were performed in buffer containing 50 mM Hepes, pH 7.0, 5 mM MnC12, 10 mM
MgC12, 0.2 mg/ml BSA, ImM DTT, 1 gM ATP, 2.5 gCi of [y-32P]ATP (3000 Ci/mmole), and
either 100 ng of E2F-1*DP-1, 2.5 gg of histone H1, or 1-2 jLg of GST-pRB substrate by
incubation at 370 C for 30 minutes, unless otherwise noted.
Gel mobility shift assays
Gel mobility shift assays with recombinant E2F were carried out essentially as described
(Dynlacht et al., 1994). Reactions contained approximately 5-10 ng of DP-1 and 5-10 ng E2F-1,
E2F-3, E2F-5, E2F-1(DA), E2F-4(+A), or 5 ng of E2F-4*DP-1, as indicated.
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In vitro transcription assays
In vitro transcription reactions were reconstituted and performed using recombinant TFIIB and
TFIIE as well as partially purified HeLa cell TFIIA, TFIID, TFIIF/H, and RNA polymerase II
fractions exactly as described (Dynlacht et al., 1994). Reactions contained recombinant E2F-4 or
E2F-4*DP-1 as indicated.
Two dimensional tryptic phosphopeptide mapping
For phosphopeptide mapping experiments, approximately 5 ng of either purified, recombinant
cyclin A*cdk2 or cyclin B*cdk2 (the amounts of each enzyme were normalized using histone H1
as a substrate; data not shown) was incubated with 100 ng of the E2F-1 DP-1 heterodimer using
kinase assay conditions described above. Phosphorylated substrates were resolved on a 10%
SDS-PAGE gel, transferred to Immobilon, and visualized by autoradiography. The relevant
bands were excised, and two dimensional tryptic phosphopeptide mapping was performed
essentially as described (Dynlacht et al, 1994).
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CHAPTER 5
"Inhibition of CDK2 by p21 is necessary for pRB-mediated
G1 Arrest following y-Irradiation"
James Brugarolas, Ken Moberg, Scott D. Boyd, Yoichi Taya, Tyler Jacks
and Jacqueline A. Lees
Genes and Development, in press
(Author's contribution: Figure 3)
A. Abstract
In mammalian cells, DNA damaging agents result in a G1 arrest that is dependent upon the
tumor suppressor p53 and its transcriptional target p21. Using primary cell lines lacking specific
cell cycle regulators, we demonstrate that this pathway functions through the growth suppressive
properties of the pRB tumor suppressor. Specifically, y-irradiation inhibits the phosphorylation of
pRB at cdk2- but not cdk4-specific sites in a p21-dependent manner. Most importantly, we show
that pRB is a critical component of this DNA damage checkpoint. These data indicate that the p53
=> p21 checkpoint pathway uses the normal cell cycle regulatory machinery to induce the
accumulation of the growth suppressive form of pRB.
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B. Introduction
The retinoblastoma gene (Rb) was originally cloned by virtue of its absence in
retinoblastomas (for review, see Weinberg 1992). Subsequent studies showed that Rb gene
mutations exist in approximately one third of all human tumors (for review, see Weinberg 1992).
These mutations result in either complete loss or functional inactivation of the retinoblastoma
protein and reintroduction of the wild-type gene is sufficient to reverse the tumorigenicity of
several Rb negative cell lines.
The growth suppressive properties of the retinoblastoma protein (pRB) are thought to be
dependent upon its ability to regulate the cellular transcription factor E2F (for review, see Nevins
1997). pRB binds to E2F in vivo and this association is sufficient to inhibit its transcriptional
activity. Moreover, the resulting pRB*E2F complex is capable of mediating the transcriptional
repression of E2F-responsive genes (Weintraub et al. 1992; Bremner et al. 1995; Weintraub et al.
1995). Many E2F-responsive genes have been identified and they each play a critical role in the
control of cellular proliferation (for review, see Nevins et al. 1997). In addition, E2F binding maps
to the "growth suppression" domain of pRB and mutant, tumor derived-forms of the
retinoblastoma protein all lack the ability to bind to E2F (for review, see Nevins et al. 1997).
The retinoblastoma protein is phosphorylated in a cell cycle dependent manner and these
modifications are sufficient to inactivate its ability to bind to E2F and to block cell division (for
review, see Dyson and Harlow 1992). Several pRB phosphorylation sites have been identified and
they each match the consensus recognition sequence of the cyclin-dependent kinases (cdks; Lees et
al. 1991). The GI cdks, cyclin D*cdk4/6 and cyclin E*cdk2, can both phosphorylate pRB in vitro
(Hinds et al. 1992; Ewen et al. 1993; Matsushime et al. 1994; Meyerson and Harlow 1994). In
these in vitro assays, cyclin D*cdk4 and cyclin E*cdk2 preferentially phosphorylate distinct but
overlapping pRB sites (Connell-Crowley et al. 1997; Zarkowska and Mittnacht 1997). Cyclin
D*cdk4 is the first cdk to be activated in response to growth factors (Matsushime et al. 1994) and
in vivo studies confirm that it is essential for pRB inactivation (Lukas et al. 1995a; Lukas et al.
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1995b). Indeed, pRB appears to be the only essential target of this kinase (Lukas et al. 1995a;
Lukas et al. 1995b). Studies addressing the role of cyclinE*cdk2 in pRB regulation have yielded
conflicting conclusions (Connell-Crowley et al. 1997; Ezhevsky et al. 1997; Lundberg and
Weinberg 1998). One study showed that cyclin D1/cdk4 was sufficient to inactivate both the E2F
binding and growth suppressive properties of pRB (Connell-Crowley et al. 1997). However, two
other labs have reported that inhibition of cdk2 (by either treatment with TGFi or over-expression
of dominant negative cdk2) resulted in the accumulation of an under-phosphorylated form of pRB
that can still bind to E2F (Ezhevsky et al. 1997; Lundberg and Weinberg 1998). These latter
studies suggest that cyclinE*cdk2 contributes to inactivation of the growth suppressive properties
of pRB. In contrast to the D-type kinases, cyclinE-cdk2 is known to have at least one other
substrate whose phosphorylation is essential for S-phase entry (Ohtsubo et al. 1995).
Superimposed on the normal cell cycle regulation are a number of checkpoint mechanisms.
These are not required for normal cell cycle progression but are critical for the cellular response to
stress (for review, see Paulovich et al. 1997). One of the best characterized of the mammalian
checkpoint pathways is the DNA damage-induced G1 arrest. This checkpoint is dependent upon
the tumor suppressor p53 (Kastan et al. 1992). The loss of p53 abrogates the DNA damage
response and this is thought to contribute to tumorigenesis by permitting the propagation of
mutations (for review, see Lane 1992). The mechanism by which p53 imposes the DNA-damage
induced G1 arrest has been partially elucidated. In response to irradiation, p53 induces the
transcription of the p21 gene (El-Deiry et al. 1993), which encodes an inhibitor of cyclin-
dependent kinases (Gu et al. 1993; Harper et al. 1993; Xiong et al. 1993). Analysis of p21-
deficient cells confirms that the p21 protein is essential for the integrity of the DNA damage-
induced G1 arrest (Brugarolas et al. 1995; Deng et al. 1995; Waldman et al. 1995). In normal
cells, this p21-dependent arrest correlates with the accumulation of hypo-phosphorylated pRB
(Dulic et al. 1994; Slebos et al. 1994). Although this change in pRB phosphorylation could arise
as an indirect consequence of the GI arrest, the presence of the pRB-binding, papilloma virus E7
protein has been shown to abrogate the DNA damage checkpoint (Slebos et al. 1994). These data
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suggest that pRB is involved in the DNA damage response, however, the multifunctional nature of
E7 makes it difficult to eliminate other possible mechanisms (Funk et al. 1997; Jones et al. 1997).
In this study, we investigate how the p53 = p21 DNA damage checkpoint pathway
interfaces with the normal cell cycle machinery. Using cell lines derived from mutant mouse
strains, we demonstrate that the p21-mediated arrest is dependent upon the presence of active,
growth suppressive pRB. Induction of the checkpoint by low doses of y-irradiation, results in the
downregulation of cdk2, but not cdk4, kinase activity and the accumulation of partially
phosphorylated pRB. Phosphopeptide specific antibodies confirm that this form of pRB has been
phosphorylated on cdk4- but not cdk2-specific sites. Thus, p21 arrests cells by blocking the
inactivation of pRB that normally occurs as cells progress through the GI phase of the cell cycle.
Our data supports a model whereby this checkpoint blocks cell cycle progression by co-opting
normal cell cycle regulatory mechanisms.
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C. Results
y-irradiation of fibroblasts results in the activation of the DNA damage checkpoint
pathway and thereby induces cell cycle arrest (Kastan et al. 1991). It is well documented that p21
acts as an important downstream target of this p53-dependent radiation response but the
mechanism of p21 action is unknown (Dulic et al. 1994; Brugarolas et al. 1995; Deng et al. 1995;
Waldman et al. 1995). Because the pRB-binding, papilloma virus E7 protein is sufficient to
override the DNA damage checkpoint (Slebos et al. 1994), we tested if pRB is required for the p53
> p21-mediated arrest. To address this question, we generated primary mouse embryo
fibroblasts (MEFs) from wild-type, p53-/-, p21-/- and Rb-/- mouse strains and tested their
response to DNA damage. Wild-type and mutant cells were exposed to y-irradiation and the
degree of GI arrest was assessed by comparing the proportion of S-phase cells in irradiated versus
unirradiated populations (Fig. 1). Consistent with previous studies, loss of p53 dramatically
impairs the G1 cell cycle block. In contrast, loss of p21 significantly reduced, but did not abolish,
this y-irradiation induced arrest. This supports previous conclusions that p21 is a critical
downstream target of p53 but it is not the only mechanism by which p53 can mediate the DNA
damage-induced GI arrest (Brugarolas et al. 1995; Deng et al. 1995).
When tested in this assay, Rb-deficient fibroblasts were also impaired in their ability to
arrest in G 1 in response to DNA damage. Significantly, the magnitude of this defect was similar
to that observed in the p21-/- cells, suggesting that p21 and pRB act in the same DNA damage
response pathway. To test this hypothesis, we generated mouse embryos that were deficient for
both p21 and Rb and then compared the irradiation response of single and double mutant MEFs
derived from littermate embryos (Fig. 1). The G1 arrest response of the p21-/-;Rb-/- cells was
indistinguishable from that of either of the single mutant MEFs. We therefore conclude that p21
and pRB likely act in the same p53-dependent checkpoint pathway.
To investigate the mechanism by which p21 and pRB participate in the p53-dependent GI
arrest, we first tested whether the absence of these proteins affects the regulation of the cell cycle
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dependent kinases that control the G1/S-transition. p21 is known to inhibit the activity of both
cyclin D*cdk4 and cyclin E*cdk2 (Gu et al. 1993; Harper et al. 1993; Xiong et al. 1993) and these
G1 kinases are downregulated in response to a variety of DNA damaging agents (Terada et al.
1995; Poon et al. 1996). We therefore compared the level of cdk4 and cdk2 kinase activity in
wild-type and p21-deficient cells either with or without y-irradiation treatment (Fig. 2A). We did
not detect any effect of y-irradiation on the level of cdk4 kinase activity in either cell type. In
contrast, y-irradiation significantly reduced the level of cdk2 kinase activity in wild-type but not
p21-/- cells. These data suggest that the observed p21-dependent, radiation induced GI arrest is
mediated through the specific inhibition of cdk2 but not cdk4 kinase activity.
As pRB is known to control the expression of the cdk2 regulatory subunit, cyclin E, it
seemed possible that the loss of pRB could impair the DNA damage response by altering the
regulation of cdk2 kinase activity. To address this possibility, we directly compared the level of
cdk2 kinase activity in wild-type and pRB-/- cells both before and after y-irradiation (Fig. 2A).
Although the radiation response was significantly impaired in the Rb-/- fibroblasts (Fig. 1), both
the basal level of cdk2 kinase activity and the degree of its downregulation in response to y-
irradiation were similar to those observed in the wild-type cells (Fig. 2A). Moreover, the radiation
induced inhibition of cdk2 kinase activity was completely abolished in the p21-/-;Rb-/- MEFs
confirming that downregulation of this kinase in the absence of pRB is still dependent upon p21
(Fig. 2A). We therefore conclude that loss of pRB does not interfere with either the induction of
p21 or the specific inhibition of the cdk2 kinase activity in response to y-irradiation. These
observations strongly suggest that pRB acts downstream of p21 in the p53-dependent checkpoint
pathway.
There is good evidence to suggest that the cdk2 kinase contributes to the phosphorylation
of the retinoblastoma protein and that this is required to inactive its growth suppressive properties
(Ezhevsky et al. 1997; Lundberg and Weinberg 1998). To test the role of pRB phosphorylation in
the DNA damage response, we immunoprecipitated pRB from wild-type (downregulated cdk2
kinase) and p21-/- (normal cdk2 kinase) irradiated cells that had been metabolically labeled with
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32pi (Fig. 2B). Consistent with the continued presence of cdk4 kinase activity (see Fig. 2A), we
detected phosphorylated pRB in extracts of wild-type irradiated cells (Fig. 2B). This
phosphorylated pRB was present in two distinct forms, a slower migrating species (labeled band
A) and a faster migrating species (labeled band B), that were detected at roughly equal levels. Both
of these pRB species were also present in the irradiated p21-deficient cells. In these cells,
however, the slower migrating form of pRB (band A) was present at much higher levels than the
faster migrating form (band B). This suggested that y-irradiation results in a change in the degree
of pRB phosphorylation in a p21-dependent manner.
To assess the relative levels of each pRB species (instead of the degree of 32p
incorporation), we also performed immunoprecipitation followed by immuno-blotting of whole
cell extracts of wild-type and p21-/- irradiated cells (Fig. 2C). In this assay, we were able to detect
three distinct pRB species. The fastest migrating form (band C) was not detected by 32P labeling,
indicating that it represents unphosphorylated pRB. This was present at a similar low level in both
the wild-type and p21 -/- irradiated cells. The remaining bands co-migrated with the 32p-labeled
band A and band B. Comparison of the 32P and immunoblotting signals for bands A and B
suggested that band A corresponds to the hyperphosphorylated form of pRB whereas band B
results from the partial phosphorylation of the pRB protein. Significantly, whereas the protein
levels of partially phosphorylated pRB (band B) were similar in the wild-type and mutant
irradiated cells, the fully phosphorylated form of pRB was significantly reduced in wild-type cells.
We therefore conclude that y-irradiation blocks the conversion of partially- to hyper-
phosphorylated pRB in a p21-dependent manner.
The difference between the partially- and hyper-phosphorylated forms of pRB could be due
to differences in either the specific sites of phosphorylation or the extent to which pRB is
phosphorylated. To distinguish between these two possibilities, we compared the two dimensional
tryptic phosphopeptide maps of pRB species isolated from either wild-type (predominantly band
B) or p21-/- (band A and B) irradiated cells. In wild-type irradiated cells, we detected six
prominent pRB tryptic phosphopeptides (1-6; Fig. 3). Thus, pRB is phosphorylated at multiple
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sites in wild-type cells after y-irradiation. The two-dimensional phosphopeptide map of pRB from
p21-/- cells was considerably more complex, containing more than 15 major phosphopeptides (1-
15; Fig. 3). Six of these phosphopeptides (1-6) were identical to those detected in the map of pRB
from wild-type cells. The remainder (phosphopeptides 7-15) were either greatly under-represented
or completely absent from the two dimensional map of pRB derived from wild-type cells (Fig. 3).
The simplest interpretation of these data is that the novel phosphopeptides are derived from the
p21-/- specific species of pRB, band A, and that transition from partially- to hyper-phosphorylated
pRB must therefore involve the phosphorylation of a novel set of sites. By extension of this logic,
we conclude that the p21-/- cells must contain at least two pRB-kinases with different site
specificities; one that is similarly active in wild-type and p21-/- irradiated cells and results in
phosphorylation of a subset of pRB sites (phosphopeptides 1-6) and one that is exclusively active
in p21-/- irradiated cells and results in the hyper-phosphorylation of pRB through the specific
modification of a distinct set of sites (phosphopeptides 7-15).
Our kinase assays (Fig. 2A) showed that cdk4 kinase activity was present at similar levels
in both wild-type and p21-/- irradiated cells but cdk2 activity was only present in p21-/- irradiated
cells. This suggested that cdk4 accounts for the partial phosphorylation of pRB (phosphopeptides
1-6), whereas cdk2 is responsible for phosphorylating the second set of sites that switch pRB from
the partially- to the hyper-phosphorylated form (phosphopeptides 7-15). To test this hypothesis,
we employed a panel of antibodies that specifically recognize individual pRB-phosphopeptides that
are preferentially phosphorylated by either cyclinD*cdk4 or cyclinE*cdk2 in vitro (Kitagawa et al.
1996). These antibodies were used to screen immunoblots of pRB-immunoprecipitates from
either wild-type or p21-/- irradiated cells (Figure 4). CyclinD*cdk4 is known to specifically
phosphorylate Ser780 of human pRB with a 20-60 fold higher efficiency than either Cyclin
E*cdk2 or Cyclin A*cdk2 (Kitagawa et al. 1996). Antibodies specific for phospho-Ser780,
recognized both the partially and the hyper-phosphorylated form of pRB indicating that the cdk4
kinase contributes to the phosphorylation of both of these species (Fig. 4). In contrast, an antibody
directed against a cdk2-specific pRB site, a-phospho-Ser811 of human pRB (Connell-Crowley et
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al. 1997; Y. Taya, unpublished data), recognized the hyper-phosphorylated form of pRB in p21-/-
irradiated cells but failed to detect the partially phosphorylated pRB species in either wild-type or
p21-/- irradiated cells (Fig. 4). Similar results were obtained with a second cdk2-specific
phosphorylation site antibody, a-phospho-Thr350 (Fig 4). Taken together, these data indicate that
the cdk4 kinase is responsible for the partial phosphorylation of pRB in vivo, but active cdk2
kinase is required to phosphorylate the additional sites specifically modified in hyper-
phosphorylated pRB. Most importantly, our data suggest that the p53 => p21 pathway arrests cells
in response to low doses of y-irradiation by specifically inhibiting the cdk2 kinase and thereby
preventing the transition of pRB from the partially phosphorylated to the hyper-phosphorylated
form. Given the requirement of pRB for the integrity of the G1 arrest, we conclude that partially
phosphorylated pRB is essential for this growth arrest.
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D. Discussion
The ability of cells to arrest in G 1 in response to DNA damage is dependent upon the
accumulation of the tumor suppressor, p53 (Kastan et al. 1992). This p53-dependent G 1 arrest is
largely mediated through the induction of the cdk inhibitor p21 (Brugarolas et al. 1995; Deng et al.
1995). By analyzing primary cell lines lacking specific cell cycle regulators, we have investigated
the mechanism by which p21 brings about a G1 arrest following treatment with low dose 7-
irradiation. Our data indicate that the induction of p21 results in the specific inhibition of cdk2 but
not cdk4 kinase activity. Moreover, the consequent G 1 arrest is dependent upon the presence of
functional retinoblastoma protein. Absence of pRB does not significantly alter either the basal
level of cdk2 kinase activity or the ability of p21 to downregulate it in response to y-irradiation.
Instead, in wild-type cells y-irradiation results in a p21-dependent alteration in the phosphorylation
status of pRB. This arises from the loss of phosphorylation at cdk2- but not cdk4-specific sites.
Although we cannot rule out the possibility that pRB participates in the p53-dependent checkpoint
pathway in an indirect manner, these observations strongly suggest that pRB acts as a downstream
target of p21. We therefore favor a model in which p21 acts to impose the G 1 arrest by
specifically inhibiting the cdk2 kinase and thereby preventing inactivation of the growth
suppressive properties of the pRB tumor suppressor (Fig. 5). In this manner, pRB plays a critical
role in determining whether or not a cell will initiate DNA replication in the presence of DNA
damage.
Our observations also provide considerable insight into the role of pRB in normal cell cycle
control (see Figure 5). Recent studies suggest that pRB is phosphorylated in a two step process
during the normal cell cycle (Kitagawa et al. 1996; Ezhevsky et al. 1997; Lundberg and Weinberg
1998). CyclinD*cdk4/6 specifically phosphorylates pRB at a subset of its phosphorylation sites.
However, complete phosphorylation of pRB requires cyclinE*cdk2 to specifically target the
remaining phosphorylation sites. In each case, inhibition of cdk2 resulted in a G 1 block that
correlates with inhibition of the second step of pRB phosphorylation (Ezhevsky et al. 1997;
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Lundberg and Weinberg 1998). Our current data are entirely consistent with the notion that
cyclinD*cdk4/6 and cyclinE*cdk2 mediate the sequential phosphorylation of pRB through the
phosphorylation of distinct subsets of sites within this protein. These findings further indicate that
the p53 =- p21 checkpoint pathway is able to impose a G 1 block by specifically inhibiting cdk2
kinase activity and thereby only the second step of pRB phosphorylation. These findings do not
rule out the possibility that there are other cdk2 substrates whose phosphorylation is critical for S-
phase entry. Indeed, Serrano et al. (1995) have shown that over-expression of p21 can inhibit cell
cycle entry in an pRB-negative tumor cell line. However, our data strongly suggest that partially
phosphorylated pRB retains the ability to prevent cell cycle progression. By extension of this
logic, cyclinD*cdk4-dependent phosphorylation is insufficient to inactivate the growth suppressive
properties of pRB. Although these conclusions were derived from the analysis of the DNA
damage response, it seems highly likely that the same mechanisms will control the timing of S-
phase entry in the normal cell cycle.
This model raises clear questions about the role of cyclinD*cdk4 in the regulation of pRB.
It is possible that this kinase affects a pRB function that is unrelated to the control of cell cycle
entry. However, there is extensive data to suggest that cyclinD*cdk4 plays a critical role in
overriding the growth suppressive properties of pRB (Hinds et al. 1992; Matsushime et al. 1994;
Lukas et al. 1995a; Lukas et al. 1995b). Alternatively, the inactivation of pRB by cyclinE*cdk2
may be entirely dependent upon the prior phosphorylation of pRB by cyclinD*cdk4. This
mechanism would provide two distinct points at which extracellular signals and/or checkpoint
pathways could influence the state of pRB phosphorylation and therefore the cell division process.
Significantly, very high doses of y-irradiation can result in the inhibition of both cdk2 and cdk4
kinase activity (Terada et al. 1995). Together with our data, this observation suggests that the
DNA damage checkpoint can block pRB phosphorylation by specifically inhibiting either one
(cyclinE*cdk2) or both (cyclinD*cdk4 and cyclinE*cdk2) of the pRB kinases depending on the
severity of the DNA damage. The mechanism of inactivation of cyclinD*cdk4 in this response has
yet to be established. However, it is now clear that the modulation of the site-specific
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phosphorylation state of pRB is a critical control point in both normal cell cycle regulation and the
DNA damage checkpoint.
Our observation that pRB is a key component of the p53-dependent G1 arrest may also
help to explain how chemotherapeutic agents target tumor versus normal cells. Many anti-
neoplastic treatments cause DNA damage that results in the activation of p53. Significantly, these
events have a differential effect on normal and tumor cells; the tumor cells are more likely to
undergo p53-dependent apoptosis whereas their normal cellular counterparts preferentially activate
the p53-dependent G arrest pathway (Lowe et al. 1993). Given the high frequency of pRB
inactivation in human tumors (for review, see Weinberg 1992), our data suggest that the
propensity of tumor cells to undergo p53-dependent apoptosis could arise from their inability to
enforce a pRB-dependent cell cycle arrest. This hypothesis is directly supported by the observation
that certain antineoplastic drugs cause Rb+/+ and Rb+/- fibroblasts to arrest but induce Rb-/-
fibroblasts to apoptose (Almasan et al. 1995). Taken together, these findings suggest that the
clinical efficacy of chemotherapeutic agents will be influenced by both the p53 and pRB status of
the target tumor.
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Figure 1. Analysis of the genetic requirements of the DNA damage-induced GI arrest response.
Asynchronous cultures of wild-type, p53-/- , p21-/-, Rb-/- and p21-/-;Rb-/- fibroblasts were
irradiated with a dose of 5.5 Gy and labeled with BrdU for 4 hours beginning 14 hours after
irradiation. Histogram shows the S-phase fraction of irradiated versus untreated samples with the
mean and standard deviations (error bars) from four independent experiments.
Figure 2. Effect of y-irradiation upon G 1 cdk kinase activity and pRB phosphorylation. (A)
Normalized protein extracts from untreated or y-irradiated (18 hours) cells were precleared with
protein A beads, immunoprecipitated with the indicated antibodies and then assayed for kinase
activity by incubation with an excess of [y-32P]ATP and substrate (histone H1 or a C-terminal
fragment of pRB). (B) SDS-PAGE analysis of [32 P]pRB from wild-type and p21-/- cells 18
hours after irradiation. (C) Western blot analysis of [32 P]pRB with an a-pRB monoclonal
antibody.
Figure 3. Two-dimensional phospho-tryptic mapping of pRB derived from wild-type or p21-/-
irradiated cells. pRB was immunoprecipitated from either wild-type or p21-/- irradiated cells and
subjected to trypsin digestion. The resulting phosphopeptides were resolved by electrophoresis
and ascending chromatography and visualized by autoradiography. (The asterisk denotes
phosphopeptides that were present in maps from Rb-/- cells and are therefore not derived from
pRB.)
Figure 4. Phosphorylation status of cdk2- and cdk4-specific pRB phosphorylation sites.
Immunoblot analysis of immunporecipitated pRB with a-P-S780 (cdk4 site), (-P-S811 (cdk2
site) and a-P-T350 (cdk2 site).
Figure 5. Model of DNA damage induced GI-arrest.
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F. Materials and Methods
Irradiation and cell cycle analysis
Sparse cultures of MEFs were irradiated with 5.5 Gy using a y-cell irradiator with a Cs source.
Untreated and irradiated cultures were harvested for cell cycle analysis 18 hours after y-irradiation.
Cell cycle analysis were performed as described (Brugarolas et al. 1995).
In vitro kinase assays
Cdk2 and cdk4 in vitro kinase assays were performed as described (Brugarolas et al. 1998).
Briefly, cell lysates were precleared with equilibrated protein A beads (Pierce) and incubated with
anti-cdk4 (Santa Cruz, C-22) or anti-cdk2 antibody (kindly provided by G. J. Hannon, CSH, NY)
for 4 hours. Immune complexes were precipitated with protein A beads (Pierce) and incubated in
the kinase buffer containing 4 mM ATP, 20 gCi [y-32P] ATP (NEN-DuPont) and 6 gg of GST-
RB (GST fusion with amino acids 792-928 from the C-terminus of pRB) or 2 ptg of histone Hi
(Sigma), for 30-60 minutes at 300 C. Quantitation was performed by phosphorimager analysis.
3 2 P-labeling and pRB immunoprecipitation
Subconfluent MEFs cultures were labeled with 5 mCi per ml HCl free 32 P-orthophosphate (NEN-
DuPont) in DME supplemented with 5% dialyzed fetal bovine serum. Labeling proceeded for 4
hours starting 14 hours after y-irradiation. Protein extracts were prepared as described
(Brugarolas et al. 1998), normalized for 32P incorporation and used for pRB immunoprecipitation
using monoclonal antibodies XZ104, XZ133 and 21C9 (kindly provided by E. Harlow). pRB was
then resolved in a 6% polyacrylamide SDS gel, blotted onto Immobilon-P (Millipore) and
visualized by autoradiography.
Anti-phospho pRB antibodies.
a-phospho-Ser870 and a-phospho-Ser811 have been previously described (Kitagawa et al.,
1996). These antisera were raised against phospho-peptides derived from human pRB that are
absolutely conserved in the mouse protein (Ser 773 and Ser 804 respectively). a-phospho-Thr350
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was raised against the murine pRB sequence. The phosphopeptide, SFETERT(P0 3)PRKNNPC,
was chemically synthesized, conjugated with KLH and then injected into rabbits as previously
described (Kitagawa et al., 1996). The resulting polyclonal antibodies were purified by column
chromatography with the same phosphopeptide linked to Sepharose CL-4B followed by a column
of Sepharose CL-4B coupled to the corresponding unphosphorylated peptide,
SFETERTPRKNNP. Purified antibodies specifically recognized the phosphopeptide in ELISA
assays (data not shown).
Immunoblotting
Membranes were blocked in TBS-T (10 mM Tris (pH 7.5), 150 mM NaCl, 0.03% Tween-20)
containing 5% non-fat dry milk. pRB was detected using mouse monoclonal G3-245
(Pharmingen) at a dilution 1:175 and a three step protocol using a rabbit anti-mouse secondary
antibody and an anti-rabbit tertiary antibody conjugated to HRP. Phosphoserine 780,
phosphoserine 811 and phosphothreonine 350 (Kitagawa et al. 1996) were detected using rabbit
polyclonal antibodies at 1:300 and 1:100 dilution respectively and a secondary anti-rabbit antibody
conjugated to HRP. Detection was performed by enhanced chemiluminescence.
Two-dimensional phosphopeptide mapping
[32P]pRB was immunoprecipitated, blotted and visualized as described above. Both band A and
band B were excised and subjected to two dimensional tryptic phospho-peptide mapping as
described (Lees et al. 1991).
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CHAPTER 6
SUMMARY COMMENTS
We have focused our efforts on analysis of the cell cycle-dependent properties of
endogenous E2F proteins. Our work reveals novel modes of E2F regulation that operate at
multiple levels to restrict E2F-dependent transcription to specific cell cycle stages, and has
expanded our understanding of the role of E2F activity downstream of pRB. Most significantly,
the data presented here clarify models of the transcriptional roles of individual E2F proteins, and
provide a molecular understanding on which to base genetic analysis of the role of E2F in pocket
protein-dependent pathways of growth control and tumor suppression.
A. Previous model of E2F function
Prior to these experiments, the prevailing model of the unique biological properties of pRB
versus p107/p130 was based upon the observation that pRB interacts with a subset of E2Fs
distinct from those regulated by p107/p130. Both in vivo and in vitro, the E2F-1, -2 and -3
proteins physically interact with pRB, and not p107/p130 (Dyson et al., 1993; Lees et al., 1993).
This specificity is a property of endogenous, and to some extent overexpressed, E2FopRB
complexes, and is apparent in both DNA-dependent and -independent assays. Conversely,
overexpressed E2F-4 and -5 have been observed to interact specifically with p107/p 130, and not
pRB (Beijersbergen et al., 1994; Ginsberg et al., 1994; Hijmans et al., 1995; Sardet et al., 1995;
Vairo et al., 1995). These findings lead to a molecular model of E2F function in which E2F-1, -2
and -3 function downstream of pRB, and E2F-4 and -5 function downstream of p107/p 130. The
unique tumor suppressive property of pRB might then actually be a reflection of a transcriptional
role(s) specific to E2F-1, -2 and -3. This specificity could possibly arise at the level of distinct
target gene(s), or in the timing of the regulation of shared target promoters. In any case, this
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model predicted that deregulation of E2F-1, -2 and -3-specific transcriptional events promotes
tumorigenesis, whereas deregulation of E2F-4 and -5, -dependent transcription does not.
This model places E2F-1, -2 and -3 at the bottom of the pl 6*cyclin DepRB pathway, and
makes specific predictions regarding the ability of these E2Fs to drive cell cycle transitions. A
number of published studies support a specific role for E2F-1, -2 and -3 in driving G 1/S, which
are not shared by E2F-4 or E2F-5 (reviewed in Bernards, 1997) . These data suggest, consistent
with known physical interactions, that E2F-1, -2 and -3 are functionally downstream of pRB and
that each of these transcription factors is equally capable of inducing the transcription of genes
sufficient to drive entry into S-phase. By extension, it is inferred from these data that the
transcriptional activity of overexpressed E2F-4 is insufficient to drive G1/S progression.
Together, these observations tend to support the contention that accumulation of active, "free"
E2F-4 or -5 activity is insufficient to bypass the molecular mechanisms underlying critical G1
regulatory pathways.
B. Implications for the model: Inactivity of E2F-4
Prior to a discussion of the implications of this work and the prospects for further research,
it is necessary to examine the effect of our findings on the model of E2F function outlined above.
The demonstration that endogenous, free E2F-4*DP complexes localize predominantly to the
cytoplasm strongly suggests that these complexes do not participate directly in transcriptional
regulation. This does not mean that these heterodimers are intrinsically incapable of driving
transcription, but that this activity may be preempted by their cytoplasmic location. In this regard,
the observation that overexpressed E2F-4 protein localizes to the cytoplasm in all cell types tested
to date has an immediate impact upon the interpretation of previous studies of the transcriptional
properties of E2F-4. It is now apparent that the failure of E2F-4 to drive Gl progression in
transfection assays does not represent a measure of the ability of E2F-4 to drive the transcription
of genes required for Gl/S, but rather is direct consequence of its failure to localize to the nucleus.
In fact, when E2F-4 is directed to the nucleus by addition of the SV40 Tag NLS, or by fusion with
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the NLS-containing N-terminal domain of either E2F-1 or E2F-2, this transcription factor is now
able to overcome both p16-mediated G arrest, and cell cycle withdrawal induced by serum
starvation (Muller et al., 1997; S. Estes, unpub.). These data tend to undermine the contention that,
because the pRB-specific E2Fs drive G1/S and E2F-4 does not, the different E2F classes are
predicted to regulate a different subset of genes, and that the failure of overexpressed E2F-4 to
drive G1/S is a direct reflection of E2F functional differences which underlie the tumor
suppressive function of pRB. Clearly, E2F-4 is capable of driving entry into S-phase when it is
overexpressed in a nuclear form. This observation does not by any means prove that the
endogenous population of E2Fs will all regulate the same responsive gene-promoters in vivo,
although it suggests that the transcriptional properties of overexpressed, nuclear E2Fs are
sufficiently similar as to promote similar biological outcomes.
C. Molecular evidence of function
C1. E2F-dependent repression and activation
In spite of the extent to which our findings have provided valuable insight into the
biological effects of overexpression, the more significant ramifications of our findings are the
extent to which they strongly suggest functional roles of endogenous mammalian E2F species.
The potential for non-equivalence between E2F proteins is first suggested by our analysis of the
cell cycle-dependent regulation, abundance, and pocket-protein binding properties of individual
E2Fs (summarized in Fig. 1). One of the most salient features of this data is the extent to which
E2F-4 accounts for the majority of cellular E2F activity. The abundance of E2F-4, and its in vivo
interactions with all three members of the retinoblastoma family, suggest that E2F-4 will play an
important role in E2F/pocket protein-regulated proliferation control pathways. Specifically, our
demonstration of a direct and significant interaction between E2F-4 and pRB in vivo suggests that
E2F-4 functions in pRB-mediated growth suppression pathways. The timing and subcellular
compartmentalization of this interaction in cycling cells supports a model in which E2F-4 is the
DNA-binding component of an abundant, G transcriptional repressor complex. Thus, E2F-4,
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Figure 1. Summary of the cell cycle-dependent regulation of E2Fs
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together with E2F-1, -2 and -3, functions in a pRB-dependent pathway of growth control. The
role of each of these E2Fs in this pathway is linked to their ability to act as sequence-specific,
DNA binding proteins. However, the different localization properties of E2F-1, -2 and -3 versus
E2F-4 are predicted to directly influence the precise transcriptional role each of these proteins plays
in pRB-dependent mechanisms of G1/S control (see Fig. 2). The cell cycle-dependent nuclear
localization of E2F-4 suggests this protein is necessary for full repression of responsive gene
transcription during G1, but that it plays a minimal role in the induction of these promoters during
S-phase. In contrast, the localization and relative abundance of E2F-1, -2 and -3 suggests that
these E2Fs also act as limiting activators of transcription during S-phase. The unique role of pRB
in controlling the activity of both of these classes of E2Fs suggests that loss of pRB results in
simultaneous derepression, and inappropriate activation, of E2F-responsive genes in a manner
which does not occur following inactivation of p107 or p130. Thus, the specificity of the
"activatory" E2Fs for pRB provides one explanation for the non-tumorigenic consequences
associated with p107/p130 inactivation, as loss of p107/p130 may only lead to derepression of
transcription and not inappropriate activation. This concept in and of itself is not necessarily novel.
What is novel is our contention that these transcriptional effects of pRB-loss are a consequence of
deregulation of groups of functionally distinct E2F species, and that both elements may be
required for tumorigenicity. According to this model, each of these effects is primarily mediated
by distinct E2F species. If this proves to be the case, genetic analysis of E2F function in the pRB
pathway will allow us to separate these two processes, and to assess the extent to which each
contributes to tumorigenesis.
A requirement for "compound" deregulation of the E2F pathway in tumorigenesis could
have a number of potential explanations. First and foremost, it is possible that distinct classes of
E2F-responsive genes are differentially susceptible to deregulation by the two different
mechanisms; increased expression of either "set" alone is required, but not sufficient, to promote
tumorigenicity. At the other extreme, it may be that all E2F responsive genes are equally
susceptible to deregulation by both mechanisms, but that only by the combined effect of both are
228
the levels of responsive-gene transcription sufficiently elevated as to constitutively promote G1
progression and S-phase entry. Clearly, both of these models assume that transformation
processes downstream of E2F require the transcriptional deregulation of multiple cellular gene
products. It is highly likely that all E2F target genes are not equal in their transforming potential,
and that only a few particular promoters (eg. cyclin E) represent the crucial oncogenic targets of the
pRB*E2F tumor suppression pathway. In this case, it will be necessary to determine which of the
above models more accurately describes the E2F-dependent transcriptional regulation of these
specific promoters. Resolution of these issues will likely have to await improved biochemical
analysis of the promoter specificity of endogenous E2Fs, and ultimately will have to be confirmed
by genetic dissection of the role of E2F and its targets in the pRB pathway of growth control.
C2. E2F-1, -2 and -3
Analysis of the endogenous populations of E2F has also revealed potentially significant
differences among the pRB-specific E2Fs. These differences are predicted to have a significant
impact upon the functional consequences of E2F activity. First, it is now apparent that E2F-2 is an
extremely rare protein in vivo. The protein is undetectable by immunoblotting, and E2F-2 DNA
binding activity is only barely detectable by EMSA. The timing of its appearance in primary
human T cells reentering the cell cycle mirrors that of the considerably more abundant E2F-1 and
-3, suggesting that these E2Fs are all active during the same cell cycle interval. Unless E2F-2 has
a function which is non-overlapping with the other E2Fs, these data suggest that this protein plays
little role in the cell cycle-dependent expression of responsive genes.
The differences we have observed between the E2F-1 and E2F-3 proteins are likely to have
significant impact upon the transcriptional roles of these proteins. In the post-G1/S samples from
the human T cell system, E2F-1 is detected primarily in the free form, while E2F-3 is primarily
complexed with pRB (Fig. 2). This molecular observation immediately suggests that these
proteins do not fulfill the same transcriptional function during this stage of the cell cycle, and that
they are differentially targeted for inhibition by pRB. The presence of E2F-1 in the free form
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suggests that this E2F is primarily an activator of responsive gene transcription during cell cycle
reentry in human T cells. Significantly, it has recently been reported that E2F-1-/- MEFs take
longer to reach S-phase following GO-exit than do wildtype cells (Yamasaki et al., 1998). While
this deficiency has not been demonstrated to correlate with the altered expression of E2F-
responsive genes, it is highly likely that this prolonged G 1-transit reflects a requirement for E2F-1
in the timely expression of target genes at G1/S. Thus, data from both human T cells and murine
fibroblasts support a role for E2F- 1 as an activator of transcription during cell cycle reentry. In
contrast, the appearance of E2F-3 in complexes with pRB at G1/S suggests that this E2F functions
as the DNA binding-component of a transcriptional repressor complex during S-phase. Given the
G1/S induction of most known E2F responsive genes, it is likely that the targets of this repressive
complex are as yet unidentified. In this regard, it is possible that E2F-3*pRB functions to repress
certain E2F-responsive promoters required for G1 transit in human T cells, but which must be
down-regulated upon S-phase entry.
The different pRB binding properties of E2F-1 and E2F-3 in human T cells contrasts
sharply with numerous reports that document approximately equivalent binding of E2F-1 and -3
to pRB. This result therefore implies that the pRB-binding capacity of E2Fs can be modulated at
the post-translational level. Two published reports suggest that cdk-mediated phosphorylation of
E2F-1 can alter its pRB-binding properties (Fagan et al., 1994; Peeper et al., 1995). If such a
mechanism were to selectively target different E2Fs, it would have a significant impact upon the
relative roles of individual E2Fs in vivo. E2Fs rendered refractory to the inhibitory effects of pRB
would be predicted to contribute exclusively to the activation of target genes, whereas those
competent to bind pRB would be predicted to participate in transcriptional repression and, upon
cyclin*cdk mediated inactivation of pRB, activation. Determination of the exact nature of such
modification may therefore enable one to predict the extent to which a given E2F functions to
promote proliferation, or functions in collaboration with pRB to inhibit cell cycle progression.
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C3. Differences between the pocket proteins
Our cellular fractionation data in the human HL-60 cell line suggests that the
retinoblastoma family members p107 and p130 localize primarily to the cytoplasm in cycling cells.
This finding is indirectly supported by immunofluorescence analysis of the localization of E2F-4
protein during S-phase in both U20S and Wi38 human cells. It is well established that p107
interacts in vivo specifically with E2F-4, and that the E2F-4*p107 complex is most abundant
during S-phase (Schwarz et al., 1993; Shirodkar et al., 1992). Strong aE2F-4 cytoplasmic
staining, and the relative lack of nuclear signal in S-phase cells, implies this E2F-4-containing
complex is also cytoplasmic. If true, this might help explain the long standing paradox between
high levels of E2F-responsive gene transcription during S-phase correlating temporally with high
levels of an apparent transcriptional repressor complex E2F-4p 107.
If p107 and p130 are indeed primarily cytoplasmic proteins in these cells, it is logical to
suggest that these proteins are not direct transcriptional regulators, and that only pRB plays a
significant role in regulation of E2F-dependent transcription. However, our immunofluorescence
data also reveal that E2F-4 protein is localized to the nuclei of GO cells. In fact, the staining pattern
in these experiments shows that the majority of E2F-4 is nuclear during GO in the human Wi38
cell line. It is well established, by our work and others', that the most abundant GO complex in a
wide variety of both human and murine cell types is E2F-4*p 130, and that little if any free E2F
exists in quiescent cells(Chittenden et al., 1993; Cobrinik et al., 1993; Vairo et al., 1995). As in
cycling cells, this places E2F-4 in the nucleus at a time when E2F-responsive genes are
transcriptionally inactive, and implies a role for E2F-4 in this process in cooperation with pocket
protein(s). As loss of p130 (or p107) derepresses a subset of E2F-responsive genes in MEFs
reentering the cell cycle from GO (Hurford et al., 1997), E2F-4 and p130 appear to form a DNA-
binding repressor complex which is localized to the nucleus of quiescent cells.
This apparent inconsistency between the cytoplasmic localization of p 107/p130 in HL-60
cells, and the inferred nuclear localization of p130 in quiescent Wi38s and MEFs, may actually
represent an important difference between cycling and non-cycling cells. It is well established that
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the patterns of E2F complexes in cycling cells and in those stimulated to reenter the cell cycle from
GO are quite different (Chellappan et al., 1991; Chittenden et al., 1993; Schwarz et al., 1993).
Despite this, many E2F-responsive genes are induced at G1/S in both systems. It is therefore
possible the molecular mechanisms underlying the E2F-dependent aspects of G1/S induction of
responsive genes may actually be different in these two systems, and that p107/p130 make a more
significant contribution to the regulation of E2F activity in non-cycling, quiescent cells due to an
increased affinity for the nuclear compartment. Regardless of the validity of this somewhat
speculative model, the original observation of p107 and p130 in the cytoplasm has yet to be
confirmed or refuted by immunofluorescent localization studies of these proteins. Such
experiments will clearly represent an important test of this model of the unique biological
properties of the different members of the pRB family of proteins.
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D. Future directions
D1. E2F-4 mislocalization
An improved molecular understanding of the transcriptional roles of individual E2Fs has
led to a number of significant predictions regarding the manner in which each E2F contributes to
the G1/S regulatory properties of pRB. The extent to which these transcriptional properties are
predicted to depend upon subcellular localization suggests that disruption of the normal localization
properties of individual E2Fs may affect the rate of G1/S progression. In particular, loss of E2F-4
from the nuclei of G 1 cells may sufficiently relieve pRB-mediated repression so as to accelerate
G 1 exit and S-phase entry. A test of this prediction in cell culture clearly depends upon
understanding the cellular pathways which normally act to enforce the cell cycle dependent
localization of E2F-4. Such data would inform attempts to develop reagents which cause the
mislocalization of endogenous E2F-4 protein complexes. A considerable amount of effort was
directed towards determining the pathway(s) responsible for the Gl/S-regulated nuclear exit of
E2F-4 (see Appendix, Section D). This work was did not uncover such a mechanism, and to date
we have been unable to test our predictions of E2F-4 function by gene transfection into cultured
cells. A recent report demonstrates that the HPV type 16 E7 oncoprotein is able to cause the
accumulation of free, nuclear E2F-4*DP-1 complexes, and that this accumulation correlates with
the anchorage-independent induction of the cyclin A gene (Schulze et al., 1998). This observation
suggests that cellular pathways that regulate the cell cycle-dependent localization of E2F-4*DP-1
are disrupted by E7 expression, and raises the possibility that E7-driven mislocalization of free
E2F-4 represents an important cell cycle deregulatory event during the course of HPV-mediated
transformation. In order to address these questions, it will first be necessary to define the regions
of E7 required for nuclear accumulation of free E2F-4. Given the well documented functional
properties of the E7 protein, this data may provide important clues as to the mechanisms which
normally regulate E2F-4*DP-1 localization in non-HPV infected cells. Genetic disruption of this
region(s) may also permit an assessment of the extent to which E2F-4 mislocalization is required
for E7-induced phenotypes (eg. apoptosis and transformation) in cultured cells.
233
D2. Genetic analysis of E2F function in mice
Our predictions regarding the manner in which each E2F contributes to the growth and
tumor suppressive properties of pRB are clearly best addressed within the context of preexisting
genetic models of murine pocket protein-mediated growth suppression. As a step towards this,
the field has now begun to develop genetic models of E2F function in an effort to understand the
role these proteins play in proliferation control in murine development and tumorigenesis.
D2.1 E2F-1
The E2F-1 gene has already been inactivated by targeted deletion in the mouse (Field et al.,
1996; Yamasaki et al., 1996). This has allowed an direct assessment of the role of this member of
the E2F family in developmental control of cell proliferation, and in oncogenic processes
promoted by loss of pRB. Interestingly, E2F-1 seems to be largely dispensable during murine
development: homozygous null mice are viable and fertile. This suggests that the activity of the
E2F-1 protein is not necessary during the many highly regulated cell divisions between early
embryogenesis and adulthood. This phenotype, however, is not altogether unexpected. It is in
some ways reminiscent of phenotypes associated with dE2F null mutations in the fly (Royzman
et al., 1997). Flies deficient for dE2F survive well into late larval stages, and S-phase occurs,
however slowly, in all tissues examined. As was discussed previously, this may occur due to
partial compensation by an additional dE2F activity (present in Drosophila EST database; B.
Fairchild, pers. comm.), or by derepression of transcription by loss of a DNA-bound dE2F*RBF
complex on relevant promoters. Either mechanism may also apply to the E2F-1-/- animals.
However, the smaller fraction of total E2F activity which E2F-1 represents in the mouse suggests
that the potential for compensation by other E2F activities is even greater than in the fly; this raises
the possibility that the variable effect of E2F- 1 deficiency on different murine tissues reflects to
some degree the extent of functional overlap between E2F family members. Clearly, such
compensation would only be revealed by compound deficiency for additional E2F family
members. Given the current model of pRB-specific E2F function as a necessary element of a
234
G1/S transcriptional program which is intrinsic to almost all types of cell cycles, it is unlikely that
the pRB-specific E2Fs are collectively dispensable for proper development. However, the
intercrossing necessary to test this hypothesis will have to await the generation of these strains.
The adult growth phenotypes associated with a null E2F-1 mutation can be interpreted to
support the proposed molecular role of this protein in both transcriptional activation and repression
of genes required for S-phase entry. Adult E2F-1 null mice display atrophy in some tissues and
infrequently, tumors in others. These findings demonstrate that E2F-1 can not only act as a
promoter of cell proliferation, but that E2F- 1 also inhibits proliferation to the extent that it fulfills a
tumor suppressor function during adulthood. That E2F-1 heterozygous mice are as susceptible to
these lesions as are their homozygous litter mates strongly suggests that loss of the remaining
wildtype E2F-1 allele is not rate limiting for this process, but that following the accumulation of
additional genetic alterations, E2F-1 deficiency accelerates oncogenesis. Whereas the role of E2F-
1 in promoting cell proliferation is likely a direct result of its ability to transactivate genes necessary
for S-phase entry, there are two quite different mechanistic explanations for the tumor suppressive
properties of E2F- 1. Firstly, it may reflect the fact that E2F- 1 can participate in a growth
inhibitory complex with pRB, and that loss of this E2F- 1pRB complex represents a growth
deregulatory event which is not compensated for, or redundant with, other E2Fs. If this is the
case, then one might expect some overlap between the tissues which develop tumors in E2F-1-/-
animals and those which are tumor prone in pRB heterozygotes. While there is no such overlap, it
is possible that late-onset tumors, of the sort seen in E2F-1 null condition, would eventually also
occur in pRB+/- mice if they were able to survive to that age. Alternatively, the tumor suppressor
function of E2F-1 may be attributable to an apoptosis promoting function specific to E2F-1 (Hsieh
et al., 1997; Phillips et al., 1997). In this case, it is of note that E2F-1-/- animals show an
increased incidence of lymphoma (Field et al., 1996). Lymphomas are common in mice deficient
for the p53 gene (Jacks et al., 1994), whose tumor suppressor function has been directly linked to
its ability to promote apoptotic cell death in response to specific signaling pathways (reviewed in
Levine, 1997). The finding that certain apoptotic pathways seem to be partially compromised in
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E2F-1 null lymphoid cells, suggests that loss of E2F-1 compromises an apoptotic program whose
normal function is to inhibit cellular transformation in vivo (Field et al., 1996).
The ability of pRB to inhibit E2F-1, and the demonstration of the constitutively nuclear
localization of this protein, implies that in the absence of pRB, E2F- 1 may be a potent oncogene.
The oncogenicity of E2F-1 is confirmed by genetic analysis of the requirement of E2F-1 in the
pRB tumorigenesis pathway. Generation of compound pRB+/-;E2F-1-/- mice completely rescues
the thyroid tumors, and partially rescues the pituitary tumors which normally occur in pRB+/-
mice (Yamasaki et al., 1998). Thus, genetic analysis of E2F-1 function demonstrates a
requirement for E2F- 1-driven activation of target genes during tumorigenesis. The extent to which
specific deregulation of E2F-1 is sufficient to promote tumorigenesis has been assessed rather
crudely by tissue-specific transgenic mouse models (Pierce et al., 1998). In these systems, ectopic
E2F-1 expression can induce hyperplasia and is capable of cooperating with other activated
oncogenes to produce tumors. A more relevant method to assess the tumorigenic potential of
endogenous E2F- 1 would be to create, by targeted mutation of the E2F-1 genomic locus, a strain
of mice carrying a version of E2F- 1 that is refractory to inhibition by pRB. Such an experiment is
currently ongoing, and promises to reveal the set of pRB-loss developmental and tumor
phenotypes specifically due to deregulation of E2F- 1.
Interestingly, the pRB-- x E2F-1-/- cross also rescues some forms of the developmental
apoptosis observed in pRB nullizygous mice. This provides direct evidence that apoptosis is a
physiologically relevant consequence of deregulated E2F- 1 activity and raises the possibility that
the widespread developmental apoptosis seen in pRB-null embryos is a product of elevated E2F
activity. In this regard, it is significant that pRB--;E2F-1-- animals display an extended survival
time compared to pRB-- alone (d13.5 p.c. to d15.5 p.c.). Whereas the developmental process(es)
rescued by this cross remains unclear, this finding clearly suggests that one function of pRB
during development is to inhibit E2F-1, and that ectopic E2F-1 activity perturbs a growth
regulatory pathway(s) necessary for proper development.
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The requirement for E2F- 1 in full-penetrance of the developmental and tumorigenic
phenotypes in pRB-deficient mice is in direct contrast to its dispensability during murine
development. It demonstrates that E2F-1 plays a non-redundant function during tumorigenesis,
but that a developmental role, if it has one, overlaps with that of other E2Fs whose activity suffices
during development. This differential requirement for E2F- 1 in these two types of proliferative
processes may simply reflect the difference between overlapping and non-overlapping expression
patterns. However, it is clear that E2F-3, for example, is expressed at levels comparable to E2F-1
in pRB-/- tumor cell lines (K. Moberg, unpub.). Alternatively, this differential requirement may
also arise if E2F-1 performs distinct transcriptional roles during development and tumorigenesis.
This may occur due to differences in the extent to which E2F-1 contributes to repression and
activation during the two processes; or it may reflect the ability of pRB to alter/modulate the
spectrum of target genes regulated by E2F- 1. With regards to the former possibility, it is clear that
E2F- 1 is very likely to fulfill a required role as an activator of transcription in pRB-/- tumors. The
partial rescue of pRB-/- developmental lethality by homozygous inactivation of E2F-1 suggests
that these two proteins do cooperate in a developmentally regulated repressor complex; the lack of
developmental phenotype in E2F-1-/- mice suggests that loss of this E2F- I1 repressive function is
either redundant with, or compensated by, other E2Fs. According to this model, E2F- 1-driven
transactivation in pRB null cells is required to deregulate GI/S progression and its loss is not
rescued by the activity of other E2Fs, while loss of E2F- 1 pRB repressive complexes from those
same promoters is either insufficient to deregulate Gl/S, or is compensated by other E2Fopocket
protein complexes. Such a model makes many predictions which are testable by both molecular
and genetic means. It also emphasizes the fact that establishing the biological properties of a single
E2F is dependent upon the development of molecular and genetic models of the role of other E2Fs
in the pRB pathway.
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D2.2 E2F-3
The failure of the E2F- 1 deficiency to completely rescue the developmental and tumor
phenotypes of pRB+/- mice suggests that the deregulated activity of other proteins is partially
responsible for these effects. Due to the very low abundance of E2F-2, it is likely that one source
of this activity is E2F-3. Obviously, the proper test of this hypothesis would be to cross the
pRB+/- genotype into an E2F-3 deficient background. As E2F-3-/- mice are viable and fertile (P.
Humbert, pers. comm.), this cross is underway. There are a number of possible phenotypic
consequences of combining these genotypes, each of which would be quite informative regarding
the roles of E2F- 1 and -3 in tumorigenesis.
(1): E2F-3 deficiency rescues the same pRB-loss phenotypes as does loss of E2F-1. This
would suggest that E2F-1 and E2F-3 activity cooperate to produce this subset of phenotypes, and
that the deregulated activity of each is necessary, but not sufficient, for these effects. This result
implies that these E2Fs function in the same tissues to promote proliferation in the absence of
pRB. Such cooperativity would be evident if E2F-1 and E2F-3 function in distinct proliferative
pathways within these tissues, but would also be evident if E2F-1 and E2F-3 collaborate in a
shared pathway. This outcome would therefore immediately raise the question of whether E2F-1
and -3 have overlapping function(s) in cell cycle control and tumorigenesis. In this regard,
analysis of the expression of E2F target genes in pRB--, pRB-I-;E2F-1-/- and pRB-/-;E2F-3 -/-
MEF lines might reveal differences in the spectrum of target genes deregulated in each genotypic
background. Alternatively, since mice deficient for E2F-1 and E2F-3 individually develop quite
normally (P. Humbert pers. comm. and (Field et al., 1996; Yamasaki et al., 1996) resolution of
this issue of functional specificity might also be accomplished at the organismal level by
intercrossing E2F-1-/- and E2F-3-/- animals to reveal any potential functional redundancy
between these proteins during development. Further, the generation E2F-1-/-, E2F-3-/- and E2F-
1-/-;E2F-3-/- MEFs would provide the opportunity to identify E2F target genes whose expression
is specifically regulated by E2F-1, by E2F-3, or which are only deregulated by loss of both E2F-1
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and E2F-3. In situ analysis of the expression of these genes in affected tissues might then enable
one to correlate the developmental functions of E2F-1 and E2F-3 to transcriptional effects at
specific promoters.
(2): E2F-3 deficiency rescues pRB-loss phenotypes distinct from those rescued by E2F-1
deficiency. This result would immediately suggest that E2F-1 and E2F-3 play tissue-restricted
roles in tumorigenesis, and that each is sufficient to promote this process in the absence of the
other. In the case that each protein is comparably expressed in the relevant tissues, it also suggests
that E2F-1 and E2F-3 are not functionally equivalent in their ability to promote proliferation in
vivo. Such differences might arise as a result of intrinsic properties of each protein, or from the
tissue-dependent expression of proteins that modify the activity of these transcription factors.
Interestingly, E2F-1-/- MEFs in culture are indistinguishable from wildtype MEFs in their growth
characteristics, while in contrast, E2F-3-/- MEFs in culture display a dramatically reduced
proliferative rate relative to wildtype (P.Humbert, pers. comm.). While issues of expression,
complex formation, and compensation at the molecular level have yet to be addressed in either
genetic background, this observation strongly suggests that in fibroblasts, E2F-3 is required for the
expression of genes involved in the timely execution of proliferative pathways and E2F- 1 is not.
Determining the identity of these genes may significantly advance our ability to predict the
biological outcomes associated with E2F-1 and E2F-3 activity.
(3): E2F-3 deficiency does not rescue any of the tumor phenotypes promoted by pRB
loss. This result would support a model in which E2F-3 transcriptional activity is dispensable for
tumorigenic processes in the mouse, and that E2F-1 represents the primary tumor promoting E2F
activity in pRB-/- cells. If further study of the role of E2F-3 in these tissues were to confirm its
expression and DNA-binding properties, this would strongly suggest that E2F-1 and E2F-3 are
functionally non-equivalent. Given the similar cell cycle-dependent expression patterns of these
E2Fs and their generally accepted roles as activators of E2F-dependent transcription, the different
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biological outcomes of these activities would then most likely arise due to differences in the
identity of E2F-1 and E2F-3 target genes.
D2.3 E2F-4
Molecular analysis of E2F-4 protein has led to very specific predictions regarding the role
of this protein in the transcriptional regulation of E2F-responsive genes. These data suggest that
E2F-4 functions as a necessary cofactor for pocket protein-mediated repression. Examination of
the expression patterns of this transcriptional regulator reveals that E2F-4 is the most abundant
E2F activity in all cell types yet tested, regardless of the tissue of origin. E2F-4 is therefore likely
to play an important role in regulating cell proliferation in multiple tissues by virtue of its
interactions with pRB, p107 and p130.
Genetic analysis of the function of pRB, p107 and p130 has revealed overlapping functions
for these E2F regulators during murine development (reviewed in Mulligan and Jacks, 1998).
Individually, p107 and p130 are dispensable for normal development in the 129/Sv strain.
Similarly, a reduction to heterozygosity of the dosage of the pRB gene is without developmental
effect. However, intercrossing these genotypes produces phenotypes consistent with disruption of
developmentally controlled proliferative pathways. p107-/-;p130-/- mice die neonatally, showing
disturbed bone development (Cobrinik et al., 1996). This phenotype at the cellular level is
apparently linked to chondrocyte overproliferation and differentiation defects. Similarly, the
generation of pRB+/-;p107-/- and p107+/-;p13 0-/- animals reveals phenotypes not apparent in
either of the individual genotypes (reviewed in Mulligan and Jacks, 1998). Both of these
compound mutant strains exhibit similar developmental defects: they are severely runted and are
susceptible to both embryonic and neonatal death. It is likely that the overlapping developmental
functions of pRB, p107 and p130 revealed in these crosses derives from the shared role of these
proteins as E2F regulators. However, inactivation of the pRB-specific E2Fs has yet to uncover
evidence of a developmental requirement for these proteins. In fact, as E2F-1, -2 and -3 do not
interact with p107/p 130 in vivo, the overlapping developmental functions of pRB, and especially
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p107 and p130, are likely linked to their shared role as transcriptional repressors in a DNA-binding
complex containing E2F-4.
The generation of mice carrying a targeted inactivation of the E2F-4 locus has begun to
deomonstrate the primary role of E2F-4 as a component of a transcriptional regulatory complex
with a necessary role in development. E2F-4 null animals are runted and show poor viability;
additionally, E2F-4-/- and +/- animals are recovered at reduced frequency, apparently as a result of
embryonic lethality at an undetermined developmental stage (P. Humbert, pers. comm.). This
organismal phenotype is somewhat similar to the pRB+/-;pl07-/- and pl07+/-;p13 0-/- compound
mutant phenotypes, which also display reduced recovery of mutant animals and runted adults. The
generalized similarity of these two phenotypes does not prove a common molecular defect.
However, it is possible that it reflects the common role of E2F-4, and p107/p130 as necessary
components of repressors of E2F-responsive transcription. In this regard, further analysis of the
cellular and molecular defect(s) associated with E2F-4 deficency may support our molecular
model of E2F-4 function as primarily a repressor, but not an activator, of E2F-responsive genes.
The E2F-4-/- phenotype reveals that E2F-4 protein is required for proper development,
and that it functions during this process in a manner which is not redundant with, or cannot be
compensated by, the other E2Fs. Clearly, this role is likely linked to the ability of E2F-4 to
interact with all three pocket protein family members. Unlike the case E2F-1 and pRB, our current
understanding of E2F-4 function downstream of the pocket-proteins predicts that crossing E2F-4-
deficiency into the pRB-/-, pRB+/-;pl07-/- and pl07+/-;p130-/- genotypes will fail to rescue
developmental defects or tumor progression. In contrast, our data suggest that loss of E2F-4 in
the context of these genotypes will exacerbate these defects, as it may effectively mimic loss of
additional pRB family function. While a full study of the extent to which pocket-protein growth
regulatory pathways are dependent upon E2F-4 is ongoing, the apparent requirement for this
protein in full transcriptional repression by pRB indicates that E2F-4 may also be necessary for the
tumor suppression function of this protein. If this is the case, then E2F-4 deficiency may actually
accelerate oncogenesis. However, if our model of E2F-4 function is in some way incorrect, or if
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the relative contribution of E2F-4 to repression and activation is tissue-dependent, then loss of
E2F-4 may actually rescue pocket protein-mutant phenotypes. For instance, if the chondrocyte
overproliferation defects of p107-/-;p13 0-/- mice are due to inappropriate activation of E2F target
genes by free E2F-4, the E2F-4-/- x p107 -/-;p130-/- cross may to some extent rescue this defect.
However, given the embryonic phenotypes associated with each of these genotypes, this cross
may produce more severe embryonic defects which compromise the ability to observe cellular
phenotypes at particular developmental stages. In this case, the ability to establish the extent to
which E2F-4 deficiency rescues or modifies cellular p107-/-;p]30-/- defects may be dependent
upon the generation of chimeric animals bearing cells triply mutant for E2F-4, p107, and p130. A
chimeric analysis may also be necessary to study the manner in which E2F-4 loss exacerbates or
rescues Rb mutant phenotypes. Clearly, these crosses promise to shed significant light on the role
of E2F-4 downstream of pRB, p107 and p130, and represent the ultimate test of models of E2F-4
function in the whole animal.
D3. E2F and checkpoint control
The use of genetically defined MEF lines has enabled us to demonstrate that pRB is
required for the efficient induction of G1 arrest in response to ionizing radiation. This requirement
is directly linked to changes in the phosphorylation state of the protein, which immediately
suggests that the effect of this checkpoint pathway is to maintain pRB in an underphosphorylated,
growth suppressing form. Underphosphorylated pRB is known to interact with E2F, and the
ability of pRB to induce GI arrest strongly correlates with its ability to sequester, and inhibit E2F.
In light of this, it is likely that the E2FopRB interaction represents the critical target of this
checkpoint pathway, and that arrest is imposed in part through inhibition of E2F-responsive gene
transcription.
A clear prediction of this hypothesis is that irradiation-induced arrest correlates with the
accumulation of E2FopRB transcriptional repressor complexes. Examination of the E2F DNA
binding complexes in treated and untreated populations of wildtype MEFs confirms the
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accumulation of a novel E2F activity specifically in treated cells (see Appendix). Consistent with
our model, this complex has the electrophoretic mobility characteristic of E2F*pRB complexes,
and its appearance is entirely dependent upon the status of p21CIP1. Surprisingly, this complex is
not dependent upon the status of the RB-1 gene, and antibodies which recognize murine pRB fail
to supershift the complex. Additional antibody experiments suggest that the irradiation-inducible
complex contains E2F-4 and p130, and provides yet another example of cell cycle arrest which
correlates with high levels of E2F-4*pocket protein complexes. The relevance of such a complex
to checkpoint arrest is unclear. Our genetic analysis clearly suggests that pRB is entirely epistatic
to p21 in this pathway, yet the biochemical data demonstrate that this putative E2F-4*p 130
complex is induced in a p21-dependent manner. This apparent inconsistency may reflect the
existence of two independent pathways downstream of cyclin E*cdk2, one operating through pRB
and one through p130, each of which is required for arrest. The absence of a dramatic change in
the E2F binding profile of pRB in untreated and treated cells may suggest that the relevant target of
pRB growth suppression in this response is not E2F; or that the ability of pRB to induce arrest in
this checkpoint pathway correlates with the sequestration of a small fraction of total cellular E2F.
Finally, it may be that this E2F-4*p130 complex is unrelated to the induction of arrest. In this
regard, a single attempt to examine the integrity of this checkpoint pathway in p130-/- MEFs
revealed no deficiency in the Gl arrest-response to DNA damage (G. Mulligan, pers. comm.).
We have used genetically defined MEF cells to extend the G 1 arrest checkpoint pathway
from p53 and p21, through to cdk2 and pRB. However, our biochemical methods have proven
insufficient to resolve the precise role of pRB and E2F proteins in this pathway. Clearly, the next
step is to assay the integrity of this response in MEF populations specifically deficient for different
E2F family members. Such an analysis might reveal further functional specificity between E2F
proteins in the extent to which they are required targets of a p53-dependent checkpoint pathway,
which acts through pRB to regulate a E2F-dependent G1/S transcriptional program.
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E. Where it's all going
The ultimate goal of this work is to understand the role of individual E2Fs in pathways of
pRB-mediated growth suppression. The generation of E2F-deficient mouse strains promises to
advance this effort in two distinct, yet complementary, ways. Whereas the animals will reveal the
developmental and tumorigenic roles of these proteins, the generation of MEF lines from these
animals will permit characterization of the cell biological and molecular phenotypes associated with
E2F deficiency. By a combination of these two approaches, the opportunity exists to fully
describe the consequences of E2F function, from the level of the whole organism, all the way to
the transcriptional effects of DNA binding complexes. As these sorts of models of E2F function
are improved and tested, it may become possible to ascribe specific pRB-loss phenotypes, at both
the organismal and the transcriptional levels, to the deregulated transcriptional activity of particular
E2Fs.
However, this genetic approach will bear principally upon questions of necessity, and not
of sufficiency. In this regard, improved models of E2F function may eventually permit a
fundamental test of the role of individual E2Fs in the oncogenic process: reproduction of pRB-loss
phenotypes in the context of wildtype pRB. The emerging concept that different E2Fs may fulfill
distinct transcriptional roles in the pRB pathway may eventually provide just such an opportunity.
One step towards this is the creation of mice carrying "activated" alleles of E2F-1 engineered to be
refractory to inhibition by pRB. These animals promise to reveal phenotypes specifically induced
by inappropriate activation of endogenous E2F-1. However, it is unlikely that transcriptional
activation by E2F- 1 alone is sufficient to recapitulate the full tumorigenic effect of pRB mutations.
The repressive interactions between pRB and the other relevant E2Fs will still be intact in these
animals, as will the pathways which act though these interactions to restrict progression through
G1/S. Our data suggests that these pathways in cycling cells are largely dependent upon the ability
of E2F-4 to cooperate with pRB to repress transcription during G1. Consequently, loss of E2F-4
may mimic loss of pRB so as to sufficiently deregulate these pathways and accelerate oncogenesis.
In the context of an otherwise unperturbed E2F*pRB pathway, loss of E2F-4 may have minimal
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effect upon cell cycle progression and tumorigenesis. However, a more significant issue is the
extent to which this mutation cooperates with "activating" E2F mutations to deregulate E2F-
responsive promoters in the whole animal. Such a compound genotype is predicted to have
similar effect on shared targets as does loss of pRB: simultaneous derepression, and inappropriate
activation, of responsive gene transcription. The combined effect of these E2F mutations may
therefore be sufficient to independently reproduce organismal phenotypes associated with
mutational inactivation of pRB. While the actual outcome of such a cross will not be known for
some time, the ability to replicate phenotypes associated with pRB loss by manipulation of the
activities of its downstream targets will represent a fundamental advance in our understanding of
the biological properties of the pRB*E2F interaction, and will verify the role of E2F as the primary
transcriptional effector of the cell cycle and tumorigenic properties of the p l6*cyclin D*pRB G 1/S
regulatory pathway.
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APPENDIX
A. Loss of E2F*pocket protein specificity in overexpression
Our concerns regarding the ability of overexpression-based systems to faithfully function
in vivo were confirmed by simple co-transfection of E2F-2, HA-DP-1 and p107 CMV expression
constructs into C33A cells (10tg each). Cells were labeled and subject to immunoprecipitation
using the anti-hemaglutinin (HA) monoclonal antibody, 12CA5. Precipitates were washed and
resolved by 9% SDS-PAGE. The result of this experiment clearly demonstrates that this assay
detects non-physiological complexes of E2F-2.HA-DP-1.p 107 produced by overexpression
(Appendix Fig. 1). By careful manipulation of the input amounts of overexpressed protein, this
result is reproducible in the EMSA interaction assay. I have used this autoradiograph many times
to remind myself of these pitfalls, and I think that it is as important as any other piece of published
data. Beware those who never look at endogenous protein.
B. Antibody production
Bi. Anti-human E2F antibodies
The description of the production of antibodies specific to E2F-2, -3 and -4 is described in
the Materials and Methods sections of Chapters 1 and 2. A complete summary of the known
characteristics of these antibodies may be found in the "Anti-E2F Antibodies" book in Dr. Lees'
laboratory. All of the antibodies in this section are derived from BALB-c mice.
* Symbols indicate whether or not an antibody recognizes the indicated antigen in an
overexpression assay in C33A cells. A "-" symbol indicates an antibody does not work
in that assay. The strongest antibodies in a given assay are noted with "+++"; medium
antibodies are noted with "++", and the weakest are noted with an "+".
* Overexpression used 10lgg of CMV-E2F and CMV-DP expression constructs per 10cm dish
of cells. For IPs, cells were labelled with 0.25 mCi/ml of NEN 35 S-Express Labeling
Mix for 3-4 hours. IPs were performed in ELB lysis buffer.
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* Western blot analysis of transfected protein was performed by loading -10gg total cellular
protein in a single 12cm well SDS-PAGE gel. Hybridoma supernatants were screened
by slot-blot at a 1:10 dilution.
* The comments in the "Notes" category refer to specific characteristics of individual
antibodies. Where possible, comments have been made regarding reactivity to murine
E2Fs.
* All isotypes unknown; however, all "IP+" lines must be IgG, either of subclass 2a, 2b, or 3.
* All epitopes undetermined, except for indicated anti-E2F-2 hybridomas
* Frozen stocks of all of these lines in N2(1) freezer (see nitrogen freezer log book)
B2. Anti-human DP-1 antibodies
All comments in section Al are relevant here, with the exception of:
* full-length DP-1 was used to immunize animals
* Swiss Webster mice used for anti-DP-1 antibody generation
* All clones taken through serial-dilution step (ie. NOT single-cell cloned) and frozen in N2(1)
(see nitrogen freezer book for location)
* Since clones are not pure, only "-/+" designations are used
* All clones mycoplasma-free by the BoehringerMannheim PCR assay "BM Cyclin".
C. Cyclin E- vs. Cyclin A-mediated phosphorylation of E2F-1*DP-1
While we have resolved the issue of the ability of cyclin A and cyclin B-kinase activity to
mediate site-specific phosphorylation of E2F-1 *DP-1 heterodimers, we have not published our
analysis of the differences between cyclin A and cyclin E. Partially because of a bit of a dispute in
the field, this data was withheld from publication. Like cyclin B, cyclin E does not interact stably
with E2F heterodimers. However, reports from other labs suggest that phosphorylation by cyclin
E*cdk2 actually enhances DNA binding of E2F- 1DP-1 at high levels of input kinase; this effect
was not reported for cyclin A*cdk2. The ability of cyclin E*cdk2 to produce this effect correlated
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with the presence of a novel E2F-1-derived phosphopeptide which was not produced by the
activity of cyclin A*cdk2. We also included cyclin Eocdk2 in our comparison of the ability cyclin-
dependent kinases to phosphorylate the E2F-1*DP-1 heterodimer in vitro. Like cyclin B, cyclin E
associated kinase was observed to phosphorylate this substrate 50% less efficiently than cyclin A,
based upon a normalization of kinase activity versus histone H i substrate. Significantly, our
assessment of the ability of these kinases to phosphorylate E2F-1 *DP-1 was performed in the
presence of limiting input kinase (1:10 molar ratio of cyclin*cdk:E2F*DP; see Mat. & Meth.,
Chapter 4). In this way, the experiment was intended to reveal the preferred sites of
phosphorylation, and not those which can become modified by the individual kinases. Using
these input levels, two-dimensional phosphopeptide analysis of E2F-1 *DP-1 heterodimers
incubated with either cyclin Aocdk2 or cyclin E*cdk2 failed to reveal major differences in the major
sites of phosphorylation (see Appendix Fig.2). There are, however, minor "spots" which are
differentially apparent in each of the maps. These could represent incomplete trypsin digestion, or
they could indicate minor differences in the site-preferences of cyclin A vs. cyclin E. The
physiological relevance of such in vitro differences was not investigated.
We have also taken advantage of the generation of phosphorylation site mutants in the DP-
1 cDNA (generated by R. Verona) to map the site of the "off-switch" phosphorylation in DP-1 .
We have mapped this site to serine residue 23, and show that this residue represents the only site
of DP-1 phosphorylation in vivo (Appendix Fig.5).
D. Mechanism(s) of E2F-4 localization
D1. Phosphorylation
A considerable amount of time and effort was directed towards determining the molecular
mechanisms responsible for the cell cycle-dependent localization of E2F-4. It is immediately
apparent from the examination of the timing of this process that it may be linked directly to the
accumulation of active cyclin-dependent kinases in late G 1. The ability of these kinases to
phosphorylate members of the retinoblastoma, E2F, and DP families suggests that
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phosphorylation of these proteins may trigger the disappearance of nuclear E2F-4. Examination
of the phosphorylation state of cytoplasmic and nuclear forms of endogenous E2F-4*DP-1
suggested that these forms were distinguished by a novel phosphopeptide present only in the
cytoplasmic population of DP- 1. After much work it was determined that this peptide was
actually derived from E2F-4 (a minor fraction of 3 2 p-labeled E2F-4 co-migrates with 3 2p-labeled
DP-1 in 8-10% SDS-PAGE), and that the abundance of this phosphopeptide does not correlate
with subcellular localization. However, in the course of this work, we actually learned quite a bit
about the relative abundance of DP- 1 and -2 bound to E2F-4 in each cellular compartment
(Appendix Fig.4). All three major isoforms of DP-2 were found exclusively in nuclear E2F-4*DP
complexes. Phosphopeptide mapping also suggests that a significant portion of endogenous, E2F-
4-associated DP-1 is phosphorylated on serine 23 (Appendix Fig.5). Current models suggest that
this phosphorylated E2F-4*DP- 1 heterodimer may represent a non-DNA binding form of cellular
E2F.
D2. 14-3-3 protein binding
An considerable amount of recently published work suggests that the 14-3-3 family of
cytoplasmic signaling molecules are site-specific phosphoserine binding proteins (Muslin et al.,
1996). These proteins are known to bind specifically to serine-phosphorylated forms of important
signaling molecules, like Raf and CDC25 (Muslin et al., 1996; Yaffe et al., 1997), and to be
necessary for the inhibition of the activity of these proteins. In the case of CDC25 family proteins,
this inhibition is thought to occur in large part by cytoplasmic sequestration. The 14-3-3 family is
now known to recognize a phosphoepitope which is conserved in all of its targets. This sequence
is RSxSxP, in which the fourth-position serine represents the site of regulatory phosphorylation.
Inspection of the primary amino acid sequence reveals a similar motif present in the E2F-4/5
subclass of E2Fs: KSxSxP This sequence is present within the conserved "marked-box" region
of E2F-4 and -5; the critical fourth-position residue is not present in the other E2Fs. This
observation suggested that 14-3-3 binding might directly bind to, and regulate the localization of,
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E2F-4/5. Attempts to uncover complexes containing 14-3-3 isoforms and E2F-4 were
unsuccessful (Appendix Fig.6); however, these IP-Western experiments tend to suggest that E2F-
2 binds 14-3-3 proteins in vivo. This relevance of this result is unclear, although from the
perspective of potential E2F-4 localization mechanisms, it was completely uninformative.
D3. Half-life of cytoplasmic and nuclear E2F-4 species
One possible explanation of the absence of E2F-4 protein from the nuclei of S-phase cells,
and its persistence in the cytoplasm, is that these two forms are differentially affected by
proteolytic degradation pathways. It has been reported that free E2F is more susceptible to such
destruction than are pocket-protein bound forms of E2F proteins (Hateboer et al., 1996; Hofmann
et al., 1996). The phosphorylation-triggered disruption of the E2F*pRB complex in late G1 may
then expose E2F-4 to a nuclear proteolytic process which effectively eliminates E2F-4 from this
cellular compartment. This model predicts that levels of free E2F-4 are elevated in the cytoplasm
because such a proteolytic mechanism does not operate in this subcellular compartment. To test
for differential susceptibility to proteolysis, wildtype, constitutively nuclear (NLS-E2F-4), and
constitutively cytoplasmic (NES-E2F-4) forms of E2F-4 were transfected into U20S cells and
their half-life assessed by pulse-chase 3 5 S-methionine/cysteine labeling (Fig.7). In this
experiment, free, nuclear E2F-4 was not significantly less stable than cytoplasmic E2F-4; if
anything, the cytoplasmic protein had a shorter half-life than did nuclear protein.
E. Cell cycle-dependent properties of E2F-3 protein
In the course of our analysis of the localization properties of endogenous E2F proteins in
elutriated fractions of HL-60 cells (see Chapter 3), it was observed that approximately 50% of the
total cellular E2F-3 protein undergoes an S-phase-specific modification in electrophoretic mobility
which correlates with a reduced affinity for the nuclear compartment (Appendix, Fig. 8). This
modification is specific to E2F-3, and reduces the mobility of the E2F-3 polypeptide in SDS-
PAGE. The nature of this modification was not investigated (ie. phosphatase treatment).
However, given that E2F proteins are targets of cyclinecdks in vitro and in vivo, it is likely that this
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mobility shift represents a novel phosphorylation state. Two aspects of E2F function have been
demonstrated to be regulated by site-specific phosphorylation of E2F*DP heterodimers: interaction
with pRB (Fagan et al., 1994; Peeper et al., 1995) and DNA-binding activity (Dynlacht et al.,
1994; Krek et al., 1994; Xu et al., 1994). Either mechanism may underlie the E2F-3 mobility shift
observed here.
F. An irradiation inducible E2F*pocket protein complex
Given our genetic and biochemical data regarding the role of pRB in the G1 arrest pathway
in response to DNA damage, it was logical to assume that this pathway induced the accumulation
of transcriptionally repressive E2FopRB complexes. To test this, whole cell extracts of
treated/untreated MEFs of either wildtype, p21-/- or pRB-- genotypes were subject to analysis in
gel shift assays. An irradiation inducible E2Fopocket protein complex was clearly detectable
which migrates above free E2F, but below E2Fp 107. Antibodies to E2F-4 (LLF4-2) specifically
supershift this complex; so does the Santa Cruz polyclonal rabbit antibody to p130 (sc317x),
which can cross react to p107 when added in excess (Appendix Fig.9).
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Appendix Figure 1: Interaction of E2F-2 and pRB/pl07 in transfected C33A cells
Input plasmid
CMV-pl07 
- - - +
CMV-pRB 
- - + -
CMV-HA-DP-1 + + +
CMV-E2F-2 + ++
uHA Immunoprecipitation
of 35S-labelled cells
p10 7
E2F-2
. HA-DP-1
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Appendix Fig. 2: E2F-1/DP-1 as substrates of CyclinA
and Cyclin E kinases
E2F- 1 and cyclin A-kinase E2F-1 and cyclin E-kinase
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Appendix Figure 3: "Off-switch" phosphorylation maps to
Serine 23 in E2F-1-bound DP-1
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Appendix Fig. 4: E2F-4 asscociated forms of DP proteins
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Appendix Fig. 5: Phosphopeptide analysis of DP-1 reim-
munoprecipiated from E2F-4 containing complexes in vivo
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Appendix Fig. 6: Association of endogenous E2F and 14-3-3 proteins
in the U20S cell line
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Appendix Figure 7: Half-life comparison of transfected
forms of E2F-4 in U20S cells
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Appendix Fig. 8:
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Cell cycle-dependent changes in mobility and nuclear affinity of
E2F-3 protein in HL-60 cells
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Appendix Fig.9: An irradiation-inducible E2F complex
A)
MEFs: Wildtype(WT)
Irradiation: - +
p21-/-
- +
pRB-/-
- +
E2F-pocket F
protein
Free E2F
Irradiation
. inducible
band
B)
Untreated WT Irradiated WT MEF
E2F-pocket F
protein
Free E2F
263
I .I
References
Dynlacht, B. D., Flores, O., Lees, J. A., and Harlow, E. (1994). Differential regulation of E2F transactivation by
cyclin/cdk2 complexes. Genes & Dev. 8, 1772-86.
Fagan, R., Flint, K. J., and Jones, N. (1994). Phosphorylation of E2F-1 modulates its interaction with the
retinoblastoma gene product and the adenoviral E4 19 kDa protein. Cell. 78, 799-811.
Hateboer, G., Kerkhoven, R. M., Shvarts, A., Bernards, R., and Beijersbergen, R. L. (1996). Degradation of
E2F by the ubiquitin-proteasome pathway: regulation by retinoblastoma family proteins and adenovirus
transforming proteins. Genes & Dev. 10, 2960-70.
Hofmann, F., Martelli, F., Livingston, D. M., and Wang, Z. (1996). The retinoblastoma gene product protects
E2F-1 from degradation by the ubiquitin-proteasome pathway. Genes & Dev. 10, 2949-59.
Krek, W., Ewen, M. E., Shirodkar, S., Arany, Z., Kaelin, W. G., Jr., and Livingston, D. M. (1994). Negative
regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein
kinase. Cell. 78, 161-72.
Muslin, A. J., Tanner, J. W., Allen, P. M., and Shaw, A. S. (1996). Interaction of 14-3-3 with signaling proteins
is mediated by the recognition of phosphoserine. Cell. 84, 889-97.
Peeper, D. S., Keblusek, P., Helin, K., Toebes, M., van der Eb, A. J., and Zantema, A. (1995). Phosphorylation
of a specific cdk site in E2F-1 affects its electrophoretic mobility and promotes pRB-binding in vitro.
Oncogene. 10, 39-48.
Xu, M., Sheppard, K. A., Peng, C. Y., Yee, A. S., and Piwnica-Worms, H. (1994). Cyclin A/CDK2 binds
directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. Mol. Cell. Biol. 14,
8420-31.
Yaffe, M. B., Rittinger, K., Volinia, S., Caron, P. R., Aitken, A., Leffers, H., Gamblin, S. J., Smerdon, S. J.,
and Cantley, L. C. (1997). The structural basis for 14-3-3:phosphopeptide binding specificity. Cell. 91, 961-71.
264
ACKNOWLEDGEMENTS
There are many people to whom I would like to express my gratitude and respect. Most of
all, to Jackie, who like Judy, never let me off the hook. To all my colleagues and collaborators,
who made me realize I have something to contribute. To Michelle, Raluca, Brenda, Brian, Sandra,
Pat, Cass, Elad, Riki and Scott who forvever changed my musical tastes and made lab feel like
home. To the entire Lees lab, past and present, who showed me that science should be fun. To
J.P. and Ameet, who suffered my attempts to manage them, and still got things done. And,
because nothing ever comes easy, to those lost on the way. Thank you.
"One only becomes real at the point of action"
-Chinese proverb
265
